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ABSTRACT 
Short stature can be due to several causes, including genetically transmitted 
insensitivity to the action of growth hormone (GHI). In approximately 80% of referred 
patients, no aetiology can be identified and they are classified as having idiopathic short 
stature (ISS). The overall aim of this thesis was to identify and characterise the 
molecular mechanisms of GHI and ISS. 
The genetic analysis of a large GHI population identified several novel defects in 
the GH receptor (GHR), the signal transducer and activator of transcription (STAT5b) 
and the acid-labile subunit (lGFALS) genes and a genotype/phenotype relationship 
between GHR defects and GHI severity. 
In approximately 20% of GHI patients a GHR splice mutation was present. An in 
vitro splicing assay was developed and showed to accurately identify nucleotide changes 
resulting in aberrant mRNA splicing. Among the splice mutations, was the one leading 
to the activation of a GHR pseudoexon. This defect was found to be a common cause of 
GHI and a translational approach using antisense oligonucleotides showed to effectively 
correct in vitro the aberrant GHR mRNA splicing. 
During the course of the project an algorithm for the search of alternative exons 
and pseudoexons, was developed and allowed the identification of several potential 
regions, two of which were demonstrated to be expressed in human liver cDNA. 
Identification and analysis of GHI patients with ALS deficiency caused by 
IGF ALS defects and the observation of short stature in their heterozygote parents, led us 
to hypothesise the involvement of IGF ALS in the pathogenesis of ISS. Genetic analysis 
of a large ISS population showed the presence of single heterozygous IGF ALS defects in 
9.6% of patients and in their short stature family members. 
Identification of the genetic defects responsible for growth failure can shed new 
light on the physiology of longitudinal growth and guide therapy in children with short 
stature. 
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Chapter 1 Introduction 
1 INTRODUCTION 
In the last few years the completion of the human genome project and the advances 
in genetic epidemiology have shed new light in the understanding of the genetic factors 
involved in linear growth. Height is a classical polygenic trait influenced by the 
combined action of multiple, as yet undiscovered, factors. The increasing amount of data 
provided by genome-wide association studies has identified unexpected genes and 
pathways involved in height variations (Weedon et aI., 2007, Gudbjartsson et aI., 2008, 
Lettre et aI., 2008, Weedon et aI., 2008). 
Because of the fundamental biological role of growth hormone in promoting linear 
growth, all participants in the growth hormone-IGF-I axis are strong candidates when 
searching for molecular defects causing growth failure. Nevertheless, despite this axis 
having received increasing attention in recent years, the biological role and effect of 
molecular defects occurring in its components, such as the acid-labile subunit, are still far 
from being elucidated. 
The identification and analysis of genetic abnormalities in patients with growth 
failure, not only provides invaluable information on the physiology of linear growth, but 
can also have important therapeutic implications. In fact, better understanding of the 
pathogenesis of short stature is the first step towards identifying therapeutic targets and 
the development of new medical or gene therapies, such as the antisense-based approach 
for conditions due to aberrant splicing. 
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1.1 THE GROWTH HORMONEI IGF-I AXIS 
1.1.1 Regulation of Growth hormone secretion 
Growth hormone (GH) is a key regulator of longitudinal growth and metabolism. It 
is secreted from the GH cells in the anterior pituitary gland under the regulation of two 
hypothalamic hormones: the GH releasing hormone (GHRH) and somatostatin (Fukata 
et aI., 1985, Shimon and Melmed, 1997)" Several additional neurogenic, metabolic and 
hormonal factors participate in the regulation of GH secretion, including ghrelin, 
estrogens, sleep, stress, exercise and nutrition (Schalch, 1967, Veldhuis et aI., 1991) 
(Figure 1.1). 
GH is secreted throughout life at different rates. Its secretion is low in childhood 
and increases with the onset of puberty, inducing the acceleration in growth rate 
characteristic of this developmental stage. After puberty, there is a progressive age-
dependent decline in GH secretion (Ho et aI., 1987). GH secretion is pulsatile and has a 
diurnal rhythm (Tannenbaum and Ling, 1984). Pulses of small amplitude occur 
approximately every 2 hours during the day (Hartman et aI., 1990, Iranmanesh et aI., 
1994). The highest GH peaks are observed during the slow-wave phases of sleep (stages 
III and IV) (Van Cauter et aI., 1998, Van Cauter et aI., 2004). Because of this variable 
and pulsatile secretion, a single random blood sample cannot be used for diagnostic 
purposes and, although circadian blood sampling is helpful in studying spontaneous OH 
secretion, performance of dynamic tests with stimulatory or inhibitory agents is 
mandatory in the evaluation of OH secretion (Ho, 2007). Several diagnostic tests are 
available, among which the insulin tolerance test (ITT) is considered the gold standard. 
Recent consensus guidelines have indicated a OH peak < 3 )lg/l after ITT as indicative of 
OH deficiency (Ho, 2007). 
1.1.2 Growth hormone and growth hormone binding protein (GHBP) 
The majority of circulating GH is bound to proteins. Approximately 50% of OH 
circulating in blood is bound to a high affinity protein known as the OH-binding protein 
(GHBP) (Baumann et aI., 1987), whereas 5 to 20% is bound to low-affinity proteins such 
as the alpha 2 macroglobulin (Kratzsch et aI., 1995). In humans and rabbits, OHBP is 
produced from proteolysis of the growth hormone receptor (OHR) , whereas in other 
19 
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species such as the rat and mouse, it is the result of alternative GHR splicing. In all 
species, GHBP is found in the circulation and plays an important role in modulating GH 
availability. Approximately one half of circulating GH is, in fact, bound to the GHBP in 
a 1:1 molar complex, which results in prolongation of GH half-life in the circulation 
(Schalch, 1967), but also inhibits GH binding to the GHR through different mechanisms, 
such as ligand competition with the intact GHR proteins (Mannor et al., 1991) and 
formation of a signalling-inactive GHR:GHBP complex (Ross et al., 1997). The 
GH:GHBP complex appears to be biologically inactive and protected from clearance and 
degradation (Baumann et al., 1987, Baumann, 1991). For this reason, production of an 
engineered GH:GHBP complex was recently proposed as a potential method for 
modulating GH action (Wilkinson et al., 2007). Moreover, since the GHBP derives from 
proteolysis of the growth hormone receptor, it reflects GHR tissue density and 
determination of its serum concentration can be a useful tool in the diagnostic assessment 
of patients with growth hormone resistance (Amit et al., 2000). 
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Figure 1.1 Schematic diagram of GH regulation and action. The main factors involved in 
pituitary GH secretion are indicated. GH exerts its function in part through direct action and in 
part through its main effector, IGF-I. 
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1.1.3 Growth hormone actions 
OH exerts its effects by binding to its specific and ubiquitously expressed cell 
surface receptor: the growth honnone receptor. Binding of OH to its receptor activates a 
complex intracellular signalling cascade, leading to activation of the transcription of 
numerous genes, including insulin-like growth factors I (lOF-I) and II (IOF-II). 
OH exerts its biological actions in part directly, but mostly through IOF-I, also 
known as somatomedin C, which is secreted in response to OH stimulation by the liver 
and other tissues targeted by OH, such as bone and muscle, in which IOF-I also acts as a 
paracrine/autocrine effector. IOF-I secreted by the liver circulates bound in a 150kDa 
ternary complex with two OH-dependent proteins: the IOF-binding proteins (IOFBP) -3 
or -5 and the acid-labile subunit. IOF-I not only mediates most of the actions of the GH, 
but also exerts a negative feedback on OH secretion at pituitary level. 
1.1.3.1 Skeletal and metabolic effects of the Growth Hormone 
GH has a fundamental role in skeletal maturation. During childhood, GH promotes 
longitudinal growth of bone and attainment of peak bone mass. In adult life, it promotes 
bone remodeling and maintenance of bone mass and density (Isaksson et aI., 1987, 
Ohlsson et aI., 1998, van der Eerden et aI., 2003). GH stimulates the proliferation and 
differentiation of chondrocytes and osteoblasts as well as collagen and non-collagen 
protein synthesis, both directly and through systemic and locally produced IGF-I 
(Isaksson et aI., 1982, Ho et aI., 1987, lsgaard et aI., 1988). Recently the IGFBPs were 
also found to be involved in the modulation of bone turnover (Richman et aI., 1999, Silha 
et aI., 2003, DeMambro et aI., 2008). GH deficiency in childhood is known to result in 
growth failure and short stature, whereas in adult life GH deficiency may result m 
decreased bone mass and osteoporosis (Johansson et aI., 1992, Rosen et aI., 1993). 
GH is also an anabolic honnone involved in several metabolic processes: it 
stimulates protein synthesis by increasing amino acid transport in the muscle (Kostyo et 
aI., 1959, FIorini et aI., 1996, Umpleby and Russell-Jones, 1996), promotes lipolysis of 
triglycerides and release of fatty acids from the adipose tissue and increases the number 
of LDL receptors in the liver. GH promotes gluconeogenesis and has an antagonistic 
effect to insulin. GH deficiency results in changes in body composition, characterised by 
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central obesity and decreased muscle mass. Moreover, it is associated with dyslipidemia, 
with elevated triglyceride levels, reduced high density lipoprotein cholesterol levels and 
increased low density lipoprotein levels. Moreover, it can affect carbohydrate 
metabolism, leading to insulin resistance and glucose intolerance (Rosen et aI., 1995). 
1.1.4 The Growth hormone receptor (GHR) 
The growth hormone receptor (GHR) mediates the effects of the GH on 
longitudinal growth and metabolism. The GHR is present ubiquitously, but is most 
abundantly expressed in the liver (Ballesteros et aI., 2000). 
1.1.4.1 GHR gene and protein structure 
The GHR protein is a member of the cytokine receptor family, which includes 
receptors for prolactin, erythropoietin, interferon, interleukins and numerous 
erythropoietic stimulating factors. The mature human GHR is a 620 amino-acid single-
chain transmembrane glycoprotein, of 130 kDa. It is composed of a large extracellular 
domain involved in GH binding and GHR dimerisation, a single transmembrane domain 
which anchors the receptor to the cell surface, and an intracellular domain, involved in 
GH signalling. 
The gene that encodes the human GHR is located on chromosome 5 p l4-p 12. The 
GHR coding region contains 9 exons (exons 2-10). Part of exon 2 encodes the 18 amino 
acids of the signal peptide. The remaining part of exon 2 and exons 3 to 7 encode the 
GHR extracellular domain. Exon 8 encodes the transmembrane domain and exons 9 and 
10 the intracellular domain and the 3' untranslated region (Leung et aI., 1987, Godowski 
et aI., 1989). 
The GHR is characterised by a complex 5' untranslated region that contains 
multiple alternative first non-coding exons (Pekhletsky et aI., 1992, Edens and 
Talamantes, 1998). In humans, these are clustered in two main regions of approximately 
2 kb in size, called module A and B. 
Screening of adult and foetal libraries from different tissues have demonstrated a 
heterogeneity in the 5'-untranslated region of GHR mRNA transcripts. Very little is 
known on the mechanisms regulating the transcription of these variants, which seem to be 
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under the control of different promoters. The different GHR mRNA transcripts are 
generated by the splicing of different first non-coding exons of the 5 'UTR into a common 
acceptor splice site, located 12 bases upstream of the UTG in exon 2, but all generate the 
same GHR protein .. 
In humans several 5' UTR variants (V1-V9) have been detected (Goodyer et aI., 
2001). Three variants (V2-V9-V3) are clustered in module A. These have been shown, 
together with a fourth variant (V5), to be expressed in foetal, postnatal and neoplastic 
tissues (Zogopoulos et aI., 1996, Goodyer et aI., 2001). Variants V7-V1-V4-V8 are 
clustered in module B and are expressed in postnatal liver only (Zogopoulos et aI., 1996, 
Goodyer et aI., 2001). Alteration in the expression of tissue-specific 5'UTR GHR 
variants has been postulated to affect growth. Analysis of GHR transcripts in the 
miniature bas indicus cattle, a dwarf bull similar to the human Laron dwarf, has 
demonstrated a reduced expression of the liver specific GHR mRNA transcript (Liu et aI., 
1999). 
Human GHR has one alternative gene variant that lacks exon 3 and results in the 
absence of 22 amino-acids in the extracellular domain (d3-GHR) (Pantel et aI., 2000). 
The role and biological significance of this variant is still unclear. It has been 
hypothesised that the d3-GHR might have an increased affinity for GH, but studies on 
d3-GHR patients treated with exogenous GH therapy have, so far, provided contrasting 
results (Dos Santos et aI., 2004, Binder et aI., 2006, Blum et aI., 2006, Carrascosa et aI., 
2006, Jorge et aI., 2006, Pilotta et aI., 2006). 
1.1.4.2 The 1:2 GH-GHR interaction and GHR activation 
The crystal structure of the extracellular domain (ECD) of the GHR (residues 1-
246) was resolved in 1992 and was the basis for studying its interaction with GH. The 
GHR ECD is organised in two subdomains: sub domain 1 formed by residues 1-123 and 
subdomain 2 formed by residues 128-246. The GH protein has two binding sites, 1 and 2, 
which interact mainly with GHR sub domain 1, at residues 43,44,103,104,105,106,120 
and 126,127 and with GHR subdomain 2, at residues 165,166 (de Vos et aI., 1992, 
Clackson and Wells, 1995). 
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The GHR crystal structure also revealed a 1:2 ratio of the GH-GHR complex. 
Further mutational and biophysical studies demonstrated that GH binds to its receptor 
through a sequential chain of events. Site 1 of the GH has a high affinity for GHR 
(Cunningham and Wells, 1993) and is the first to bind the GHR molecule. This is 
followed by the binding of the GH low affinity site 2 with a second GHR molecule 
(Cunningham et al., 1991, Fuh et al., 1992). (Figure 1.2) 
Extracellular {) space GHBP 
ECD ~{ domain 
TM 
domain 
IN 
domain 
Intracellular 
space 
Figure 1.2 The 1:2 GH-GHR mechanism of interaction. The GHR exists at the cell surface as 
an inactive dimer. Binding of one GH molecule to two GHRs induces a conformational rotation 
of the GHR dimer and the activation of JAK2 molecules. The GHR and the GHBP are also 
depicted. ECD, extracellular, TM, transmembrane, IN, intracellular. 
Until recently, the GHR was thought to exist as a monomer on the cell surface and 
its activation by GH was thought to occur through dimerisation of the GHR (Cunningham 
et al., 1991, Clackson and Wells, 1995). Despite previous coimmunoprecipitation studies 
having demonstrated the presence of GHR dimers in the absence of GH (Gent et al., 
2002), the presence of inactive GHR dimers at the cell surface was only recently 
definitively accepted. In 2005, it was shown that GH binding activates its receptor by 
inducing a relative rotation of the pre-existing GHR dimer (Brown et al., 2005). This 
conformational change promotes the binding of Janus tyrosine kinase 2 (JAK2) to a 
proline-rich Box 1 region located in the proximal intracellular portion of the GHR 
(Argetsinger et al., 1993) and the initiation of the intracellular signalling pathway. 
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1.1.4.3 GHR Intracellular signalling pathway 
The GHR lacks an intrinsic kinase activity and relies on recruitment of cytoplasmic 
tyrosine kinases for intracellular signalling. The JAK family members are constitutively 
associated with cytokine receptors lacking intrinsic kinase activity. The GHR mainly 
utilises JAK2, although JAK 1 and 3 activation following GH binding to GHR has also 
been reported (Carter-Su et aI., 1996, Lanning and Carter-Su, 2006). JAK2 association to 
the GHR requires the presence of the proline-rich sequence region located in the GHR 
intracellular domain and known as Box 1. Formation of the GH:GHR2 complex results in 
phosphorylation of JAK2, which, in tum, phosphorylates the tyrosines in the intracellular 
domain of the GHR. The phosphorylated JAK2 and GHR provide docking sites for 
numerous signalling molecules and activate a complex, incompletely elucidated, 
intracellular cascade with several pathways, including the signal transducers and 
activators of transcription (STATs), components of the mitogen-activated protein kinase 
(MAPKs), phosphatidyl inositol-3 kinase (PI-3), insulin-receptor substrates (IRSs) and 
small RAS-like GTPases. GHR activation has also been shown to increase intracellular 
calcium levels through JAK2-independent calcium-channel activation (Carter-Su et aI., 
1996). 
Experimental data suggest that only four of the seven known STAT proteins, 
namely STAT 1, 3 and 5a and 5b, are involved in GH signalling (Meyer et aI., 1994, 
Gronowski et aI., 1995). STAT 5b appears to be the most important in the induction of 
GH-dependent IGF-I expression. GH-induced signalling through the STAT 5 pathway 
has received increasing attention since the discovery of STAT 5b-inactivating mutations 
in GHI patients and this is discussed separately (section 1.1.4). 
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Figure 1.3 The GHR intracellular pathways. Ca++, Calcium; SOCS, suppressor of cytokine 
signalling; PI-3, phosphatidyl inositol-3 kinase; JAK2, Janus tyrosine kinase 2; IRS, insulin-
receptor substrates; ST A T5b, signal transducers and activators of transcription 5b; MAPK, 
mitogen-activated protein kinase; GAS, gamma-activated sites; GH, growth hormone; GHR, 
growth hormone receptor. 
1.1.3.4. GHR negative regulation 
The mechanisms responsible for the negative regulation of GHR signalling are still 
far from being clarified. Members of the suppressor of cytokine signalling (SOCS) family 
are known to be involved in this process. SOCS-l, -2, -3 and the cytokine-inducible SH2-
containing protein (CIS) are thought to negatively regulate GHR signalling by binding 
the phosphorylated tyrosine of the JAK2/GHR complex, thus inhibiting the apposition of 
signalling molecules, such as STAT 5b (Hansen et aI., 1999, Ram and Waxman, 1999). 
SOCS proteins may also be involved in the ubiquitination, internalization and 
degradation of the GHRlJAK2 complex (Landsman and Waxman, 2005). 
Other mechanisms involved in the down-regulation of GHR signalling include 
recruitment of protein tyrosine phosphatases (PTPs) such as the SH2 domain-containing 
26 
Chapter 1 Introduction 
protein-tyrosine phosphatase (Kim et aI., 1998) and of the ubiquitin conjugation system 
that participates in the internalization and degradation of the GHR (Govers et at, 1999, 
van Kerkhof et aI., 2000). Little is known on the mechanisms of GHR internalisation and 
degradation. In humans and rabbits the first step of this process is thought to be the 
cleavage of the GHR extracellular domain by metalloproteases, such as tumor necrosis 
factor-a converting enzyme (TACE or ADAM-17) (Zhang et aI., 2000). Using a 
mutational approach, Comte et aI. localized three ECD juxtamembranous residues 
important for TACE-induced GHR cleavage (residues 242-244) (Conte et at, 2002). 
GHR proteolysis generates a GHR remnant consisting of the transmembrane and 
intracellular domains and releases the ECD in the pericellular space. The GHR ECD 
retains its GH binding properties, is soluble and can reach the circulation, where it 
circulates known as GHBP. 
1.1.5 The Signal transducer and activator of transcription (STAT) 5b 
1.1.5.1 Gene and protein structure 
The mammalian STAT family comprises of seven proteins, namely STAT 1, 2, 3, 
4, 5a and 5b, 6. The two STAT 5 isoforms, 5a and 5b, share a 90% homology in their 
coding regions, even though encoded by two different genes located on chromosome 17 
(Lin et aI., 1996, Ambrosio et aI., 2002). All STAT family members have a similar 
structure and are organised into distinct functional domains, which include an N-terminal 
domain, a coiled-coil domain, a DNA-binding domain, a linker domain, an SH2 domain 
and a transactivation domain. The SH2 domain in the STAT structure permits: 1) docking 
of STAT to phosphorylated tyro sines on the activated receptor, 2) STAT hetero- and 
homo-dimerisation, and 3) stabilisation of the STAT-DNA interaction. The NH2 
terminus domain, the coiled-coil domain and the carboxy terminal domain are involved in 
protein-protein interaction between STATs and other regulatory elements, and in the 
interaction between adjacent STAT dimers (Ross et aI., 2007). 
1.1.5.2 Protein function 
Activation of STATs depends on the activation of JAK molecules and their 
specific receptors. STAT proteins are activated by numerous cytokines and are involved 
27 
Chapter 1 Introduction 
in the function ofT and B cells (lmada et aI., 1998, Welte et aI., 1999, Ross et aI., 2007). 
Unlike other STAT proteins, STAT 5a and 5b are also activated by GH, prolactin, EPO 
and a number of growth factors (O'Shea, 1997). 
Recruitment of STAT 5b in the GHR intracellular signalling pathway follows 
activation by the GHR:JAK2 complex. Phosphorylated tyro sines on JAK2 and GHR form 
docking sites for STAT 5b proteins, which subsequently undergo phosphorylation, 
dimerisation, disengagement from the JAK-receptor complex and translocation to the 
nucleus. There, phosphorylated STAT 5b dimers are retained and can stimulate 
transcription of several genes, including IGF -I (Davey et aI., 2001, Woelfle et aI., 2003) 
through binding to consensus recognition motifs, known as gamma-activated sites (GAS), 
located in the promoters of several genes (Darnell et aI., 1994, Boucheron et aI., 1998, 
Mitchell and John, 2005). 
Despite the strong similarity in their coding regions, STAT 5a and 5b have been 
shown to have different actions in animal models (Hennighausen and Robinson, 2008). 
The STAT 5b -/- mouse demonstrated growth failure and IGF-I deficiency. The male 
STAT 5b knockout mouse exhibited, in fact, a 30% growth reduction, wich was not 
present in the female STAT 5b -1-, suggesting a role of STAT 5b in the sexually 
dimorphic GR-induced growth in the rodent. IGF-I levels, however, were reduced by 
30% in both genders (Udy et aI., 1997). The STAT 5a deficient female animal model had 
impaired milk production in response to prolactin, resulting from a defective lobulo-
alveolar development, but no growth failure or reduced IGF-I levels (Teglund et aI., 
1998) Although no immune defects were present in the single gene knock out mouse 
model, the double knock out animal (STAT 5a/b -/- ) exhibited a severely impaired 
immune system, particularly T cell function (Teglund et aI., 1998). 
In 2003 the first human case of STAT 5b deficiency was reported in a female 
patient with growth hormone insensitivity and decreased cell-mediated immunity 
(Kofoed et aI., 2003). This finding shed new light on the importance of STAT 5b in GH-
mediated growth and IGF-I production and demonstrated the differences in the action of 
STAT 5b between the animal model and humans. Further cases of STAT 5b mutations 
and growth failure have been reported since this first case report, confirming the above 
findings. The majority of patients were females and had immunological impairment 
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(Rosenfeld et aI., 2004, Hwa et aI., 2005, Vidarsdottir et aI., 2006, Walenkamp et aI., 
2007). 
1.1.6 The Acid-labile subunit 
1.1.6.1 Gene and protein structure 
The acid-labile subunit (ALS) is encoded by the IGFALS, a single copy gene 
located on chromosome 16-p13.3. This gene, controlled by a TATA-Iess promoter (Dai 
and Baxter, 1992, Leong et aI., 1992, Boisclair et aI., 1996, Rhoads et aI., 2000) covers 
approximately 3.3 kilobases and is comprised of two exons. Exon 1 encodes the first 5 
amino acids of the signal peptide and exon 2 the remaining 22 amino acid of the signal 
peptide and the 576 amino acid of the mature protein. The transcriptional regulation of 
the IGF ALS is under GH control. A GH response element (ALSGAS 1) was identified in 
the mouse promoter (Ooi et aI., 1997, Suwanichkul et aI., 2000). Its 9-base sequence 
(TTCCTAGAA) resembles that of the y-interferon activated sequence (GAS) (Schindler 
and Darnell, 1995) and is conserved across species, including humans.. IGF ALS 
transcription is activated in response to the activation of the GH signaling pathway. 
STAT5b dimers, resulting from GH:GHR2 complex formation, translocate to the nucleus 
and activate IGF ALS transcription, most likely through ALSGAS 1 binding (Ooi et aI., 
1998). 
IGF ALS expression appears to be limited to the liver when assessed by Northern 
blot (Leong et aI., 1992, Dai and Baxter, 1994, Delhanty and Baxter, 1996), but the use of 
in-situ hybridization,identified IGF ALS expression in extrahepatic tissues such as the 
kidney, lungs, thymus, mammary gland, bone and ovary (Chin et aI., 1994). 
The ALS is a glycosylated protein of 84-86 kDa with a predicted doughnut-shape 
and belongs to the leucine-rich repeat family. Approximately 80% of the ALS structure 
is, in fact, characterised by a 18-20 leucine-rich repeat domain, which is predicted to be 
responsible for ALS interaction with other proteins, namely IGF-binding protein (IGFBP) 
-3 and -5 (Figure 1.4). ALS production increases with age until puberty, when it reaches a 
plateau and declines thereafter with the ageing process (Baxter, 1990). Although serum is 
the main source of ALS, extravascular ALS has been detected in peritoneal, synovial, 
ovarian and blister fluids and at very low levels in milk, amniotic and cerebrospinal fluids 
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(Baxter, 1990, Cwyfan Hughes et aI., 1997, Khosravi et aI., 1997, Labarta et aI., 1997). 
Its role in these compartments remains to be clarified. 
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Figure 1.4 ALS protein structure. 
1.1.6.2 ALS protein function 
The physiological role of ALS appears to be the regulation of IGF-I and II 
clearance and bioavailability at a tissue level. Almost all IGF-I and II are present in the 
circulation bound to IGFBP-3 or -5 and to the acid-labile subunit (ALS) to form ternary 
complexes (IGF/IGFBP/ALS). IGFs availability at a tissue level is limited by its ability to 
cross the endothelial barrier and reach its receptors on the cell surface. The key limiting 
factor to this process is binding of the binary complex IGF-I or -II/IGFBP-3 or -5 to ALS. 
IGFs free or bound to IGFBPs can cross the endothelium, but formation of a large ternary 
complex of l50kDa with ALS, prevents IGFs and IGFS/IGFBPs from leaving the 
circulation (Boisclair et aI., 2001) (Figure 1.5). Furthermore, binding to ALS has been 
demonstrated to increase the half-life ofIGFs from few minutes to 12-15 hours (GuIer et 
aI., 1989). Thus, ALS can be considered the principal regulator of IGFs clearance and 
bioavailability at tissue level. ALS is found in excess over IGF and IGFBP in the 
circulation, as one half of ALS is not bound into a ternary complex. 
The mechanisms by which ALS interacts with the binary complex IGFs/IGFBPs 
and is released from it, are still far from being elucidated. Mutagenesis studies on a 
conserved positively-charged amino acid sequence present on the carboxyl-terminal 
domain of IGFBP-3 and -5 found it to affect ternary complex formation (Firth et aI., 
1998, Twigg et aI., 1998). However, its counterpart on ALS has not yet been identified. 
The negative charges provided by sialic acids on the ALS have been suggested to 
influence the affmity of ALS for IGFBPs, but protein desialylation only marginally 
reduced the Ka of ALS for IGFBP-3 (Janosi et aI., 1999). 
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The importance of ALS in the regulation of circulating IGF-I levels has been 
established by human and animal studies. Homozygous IGFALS knock-out mice showed 
a 62% and 88% reduction in plasma IGF-I and IGFBP-3 levels, respectively and 
significant growth failure compared to the wild type (Ueki et aI., 2000). In children with 
homozygous IGFALS mutations and undetectable ALS serum levels, a dramatic 
reduction in serum IGF-I and IGFBP-3 levels has been documented, along with growth 
failure (Domene et aI., 2004, Hwa et aI., 2006, Domene et aI., 2007). Even more 
interesting is the documentation of reduced IGF-I and IGFBP-3 serum levels and growth 
failure in IGFALS heterozygous knock-down mice and in parents of IGFALS homozygote 
children, obligate carriers of single heterozygous IGFALS mutations (Ueki et aI., 2000, 
Hwa et aI., 2006, Domene et aI., 2007). 
IGFBP3-5 
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Figure 1.5 Interaction between IGFs and the acid-labile subunit. IGF-I and II exert their 
biological actions through interaction with receptors on the cell surface. In the circulation the 
majority of the IGFs is bound to IGFBP-3 and -5 and to the ALS. Free and IGFBP-bound IGFs 
can cross the endothelium and reach cell surface receptors. Sequestration ofIGFs into a 150kDa 
ternary complex with ALS limits trans-endothelial passage and represents a key limiting factor to 
IGFs availability. 
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1.2 GROWTH HORMONE INSENSITIVITY 
1.2.1 Definition 
Growth hormone insensitivity (GHI) is characterised by elevated serum growth 
hormone (GH) levels and reduced IGF-I serum levels, which do not increase in response 
to exogenous GH administration (Laron, 1999). GHI can be acquired or congenital. 
Acquired GHI is common in conditions such as diabetes, infectious diseases, traumas and 
surgery and represents a response to catabolic stress (Carlsson, 1996). Congenital GHI is 
a rare condition, which is caused by genetic defects causing failure of GH to exert its 
biological functions. This can be due to the presence of an inactive GH or of molecular 
defects affecting the cellular response to GH. The latter may be the result of defects in the 
GH receptor, which account for the majority of cases of congenital GHI. 
The first report of GHI of genetic origin came from Dr. Zvi Laron in 1966 (Laron 
et aI., 1966). Evidence of cellular unresponsiveness to GH in primary GHI patients was, 
nevertheless, first reported in 1984 by Laron and colleagues, who demonstrated the lack 
of binding of 1251 GH to GHRs prepared from patients' liver membranes (Eshet et aI., 
1984). The advent of modem molecular biology and the cloning and characterisation of 
human GHR (Godowski et aI., 1989) have permitted better understanding of the 
pathophysiology of GHI. 
Since 1966, more than 250 patients with primary GHI have been identified 
worldwide. GHI is, in the majority of cases, an autosomal recessive disorder and in the 
vast majority of patients a molecular defect has been identified in the GHR (Burren et aI., 
2001). There appears to be a significant geographical clustering of patients, with most 
cases having been identified in Israel and Ecuador (Berg et aI., 1994, Schaefer et aI., 
1994, Laron, 2004). At present, there is still no clear explanation for this, even though the 
presence of common ancestors is likely. It has, in fact, been demonstrated by family trees 
in reported cases that consanguinity is a major contributor to GHI propagation (Woods 
and Savage, 1996, Burren et aI., 2001). 
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1.2.2 Clinical characteristics of GHI 
GHI in its most severe fonn is known as Laron syndrome. Untreated patients have 
severe growth failure in childhood, resulting in short stature in adult life. GHI patients 
typically have low serum IGF-I, IGFBP-3 and ALS levels and are resistant to treatment 
with exogenous GH (Laron, 1999). Intrauterine growth is not markedly affected, although 
birth weight and length may be marginally subnonnaI. However, postnatal linear growth 
failure is typically seen, with a severe and rapid decline in growth velocity. If untreated, 
adult stature in GHI patients is 4 to 10 standard deviation scores (SDS) below the median 
for age and sex. Skeletal and muscular systems are also underdeveloped and osteopenia 
can be demonstrated by DEXA (Gluckman et aI., 1992, Bachrach et aI., 1998, Laron, 
1999). 
Laron patients display a characteristic mid-facial hypoplasia due to an 
underdeveloped sphenoid and mandible resulting from an impaired development of 
endochondral facial bones (Scharf and Laron, 1972). Patients with typical Laron facial 
features have a small nose with a depressed bridge and protruding foreheads. Hair is 
typically sparse with temporal and frontal recession (Burren et aI., 2001). A pubertal 
growth spurt is generally absent and puberty is delayed, even though both sexes can reach 
full sexual development with nonnal sexual and reproductive function (Laron et aI., 
1980, Savage et aI., 1993). GHI also results in metabolic abnonnalities such as fasting 
hypo glycaemia. Despite this, a state of insulin resistance has been documented, and some 
patients develop diabetes in adult life (Laron et aI., 1995). Dyslipidemia with 
hypercholesterolemia is also often present in adults. 
A minority of GHI patients have nonnal facial features and are less severely 
affected with less abnonnal growth and biochemical features. This milder fonn of GHI is 
known as non-classical GHI (Woods et aI., 1997, Burren et aI., 2001). 
1.2.3 Molecular mechanisms 
1.2.3.1 GHI and GHR defects 
The first mutation in a patient with GHI was reported in 1989 by Godowski and 
colleagues who described a homozygous deletion in the coding region of the GH binding 
33 
Chapter 1 Introduction 
domain (Godowski et aI., 1989). So far, more than 60 mutations in the GHR gene of OHI 
patients have been described (Tables 1.1 and 1.2). Almost all are recessively inherited, 
either in homozygous or compound heterozygous forms (Savage et aI., 2006). Nearly all 
reported defects in the GHR occur in the region encoding the extracellular domain of the 
receptor. Patients with such mutations have absent or extremely low OHBP and typical 
facial features of Laron syndrome (Laron and Klinger, 1994, Woods et aI., 1997). 
Molecular defects identified in the GHR range from point or gross deletions to a 
variety of point mutations, including missense, nonsense and splice mutations. The latter 
play an important role in the pathogenesis of OHI, representing approximately 20 percent 
of GHR defects identified in OHI patients. The majority of mutations causing aberrant 
OHR mRNA splicing disrupt major regulatory elements, such as the donor and acceptor 
splice sites. In two cases (defects A to G at 594 and the C to T at 723) an exonic base 
change has been shown to result in the activation of a cryptic splice site, causing an in-
frame amino acid sequence deletion and a functionless GHR. 
Among the defects causing aberrant GHR splicing is an intronic base change 
described by our group in 2001 (Metherell et aI., 2001). This point mutation leads to the 
activation of a pseudoexon sequence and the insertion of 36 new amino acid within the 
receptor extracellular domain. Potential exons (pseudoexons) are frequently found within 
introns, but are normally not included in the mature mRNA because they fail to be 
recognized by the splicing machinery (Sun and Chasin, 2000). The described mutation 
(A_I-G_I) is at the 5' donor splice site of one such pseudoexon (61J1) and leads to 
recognition of the pseudoexon and inclusion of an additional 108 bases between exons 6 
and 7. Functional studies have shown that the mutant OHR has significantly impaired cell 
surface trafficking. The signaling ability of the receptor, as judged by JAK2 and STA T5 
phosphorylation and LHRE reporter gene analysis, is reduced in proportion to the 
reduction in cell surface receptor, implying that the signaling properties of the mutant 
protein are unimpaired (Maamra et aI., 2006). 
1.2.3.1.1 GHR defects and non-classical GHI 
There are few GHI cases reported in the literature in which OHBP levels are 
normal or elevated and this is typically the result of GHR defects occurring in the 
transmembrane or intracellular domains. In 1996, Woods et ai. described a classical OHI 
patient with a homozygous point mutation (IVS8ds+ 1 G to C) in the splice donor site of 
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intron 8 resulting in the skipping of exon 8. This was the first description of a mutation 
affecting the GHR transmembrane domain. The authors suggested that the mutant GHR 
lacks the ability to be retained at the cell surface and is, thus, released from cells and 
identified in blood as GHBP (Woods et aI., 1996). In 1997, Ayling et aI. described the 
first heterozygous mutation with a dominant negative effect in the GHR intracellular 
domain. This was a mutation in the acceptor splice site of intron 8 (IVS8as-l G to C) 
resulting in the skipping of exon 9 and the production of a truncated GHR. The mutant 
GHR formed heterodimers with the wild type GHR and exerted a dominant negative 
effect on the normal protein (Ayling et aI., 1997). A second mutation (IVS9ds+ 1 G toA) 
with a similar effect was described by !ida (Iida et aI., 1998). In both cases patients had 
positive GHBP levels and normal facial features. Other homozygous mutations in the 
intracellular domain resulting in an altered GHR unable to signal have been described 
(Kaji et aI., 1997, Gastier et aI., 2000, Milward et aI., 2004). 
The pseudoexon mutation is the only example of a defect in the GHR extracellular 
domain resulting in non-classical GHI. The four GHI siblings in whom it was 
documented had, in fact, normal facial appearance and normal GHBP levels. 
1.2.3.2 GHI caused by STAT 5b defects 
In 2003, Kofoed et aI. (Kofoed et aI., 2003) reported the first molecular defect in 
the GH signalling cascade in an immune-deficient child with typical signs of classical 
GHI. This was a homozygous mutation in exon 15 of the STAT 5b gene resulting in a 
protein with a mutated SH2 domain, which could not be activated by GH thus failing to 
induce gene transcription (Fang et aI., 2006). Interestingly, the patient with severe growth 
retardation was female, suggesting a different pathogenetic mechanism to the mouse 
model, in which the STAT 5b -/- female mouse is not affected in size (Teglund et aI., 
1998)" Since then, a few other mutations in the STAT 5b gene associated with GHI and 
immunological defects in male and female patients have been described (Hwa et a!., 
2005, Vidarsdottir et aI., 2006, Walenkamp et aI., 2007). 
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1.2.3.3 GHI and ALS defects 
In 2004, Domene et ai. reported the first case of an inactivating ALS mutation. The 
defect was a guanine deletion at position 1338, resulting in a frame-shift and the 
appearance of a premature stop codon. The patient had minimal postnatal growth 
impairment and delayed puberty. Increased GH levels were accompanied by a reduction 
in IGF-I and IGFBP-3, unresponsive to stimulation by GH, and by undetectable ALS 
levels (Domene et aI., 2004). Since then, a few more cases of ALS deficiency and growth 
failure have been described (Hwa et aI., 2006, Domene et aI., 2007, Duyvenvoorde et aI., 
2008, Heath et aI., 2008). 
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TABLE 1.1 NONSENSE AND MISSENSE MUTATIONS IDENTIFIED IN THE GHR OF GHI 
PATIENTS. 
Mutations Exon Codon Nucleotide Amino Mutation Phenotype Ethnic origin 
change Acid 
chan!1;e 
Nonsense 2 -15 TGG-TAG Trp-Term W-15X LS Iraqi-Jews 
3 16 TGG-TGA Trp-Term WI6X LS German 
4 38 TGC-TGA Cys-Term C38X LS Mediterranean 
4 43 CGA-TGA Arg-Term R43X LS European, Ecuadorian 
4 65 CAG-T AG GIn-Term Q65X LS Indian 
5 80 TGG-TAG Trp-Term W80X LS German 
5 83 TCA-TAA Cys-Term C83X LS Not reported 
5 122 TGT-TGA Cys-Term CI22X ISS Not reported 
6 141 TTA-TAA Leu-Term Ll41X LS Italian 
6 157 TGG-TGA Trp-Term WI57X LS Turkish 
6 183 GAA-TAA Glu-Term El83X LS Ecuadorian, Jewish 
7 217 CGA-TGA Arg-Term R217X LS Jewish-Yemenite 
7 224 GAG-TAG Glu-Term E224X LS Not reported 
Missense 2 -18 ATG-TTG Met-Leu M-18L LS Not reported 
4 38 TGC-AGC Cys-Ser C38S LS Algerian 
4 40 TCA-TTA Ser-Leu S40L LS Turkish 
4 42 GAG-AAG Glu-Lys E42K LS Chinese 
4 44 GAG-AAG Glu-Lys E44K ISS Not reported 
4 50 TGG-CGG Trp-Arg W50R LS German 
4 65 CCA Ser-His S65H LS Chinese 
4 71 AGG-AAG Arg-Lys R71K LS Mediterranean 
5 86 TAT-GAT Tyr- Asp Y86D LS Iranian 
5 94 TGT-TCT Cys-Ser C94S LS Austrian 
5 96 TTT-TCT Phe-Ser F96S LS Mediterranean 
5 125 GTT-GCT Val-Ala Vl25A LS European 
6 131 CCA-CAA Pro-GIn P131Q LS Vietnamese 
6 144 GTC-GAC Val-Asp VI44D LS Mediterranean 
6 144 GTC-ATC Val-Ile VI44I ISS Caucasian, Cuban 
6 150 CAT-CAG Cys-Gln CI50Q LS Austrian 
6 152 GAT-CAT Asp-His Dl52H LS Indian, Pakistani 
6 152 GAT-GGT Asp-Gly Dl52G LS Taiwanese 
6 153 ATC-ACC Ile-Thr Il53T LS Caucasian 
6 154 CAA-CCA GIn-Pro QI54P LS Hispanic 
6 155 GTG-GGG Val-Gly VI55G LS Saudi Arabian 
6 161 CGC-TGC Arg-Cys Rl61C LS, ISS Middle Eastern 
6 178 TAC-TCC Tyr-Ser Y178S LS Korean 
7 208 TAT-TGT Tyr-Cys Y208C LS Swedish 
7 211 CGT-GGT Arg-Gly R211G LS Mediterranean 
7 211 CGT-CAT Arg-His R211H ISS Jewish-Iraqi 
7 222 TAT-CAT Tyr-His Y222H LS Not reported 
7 224 GAG-GAC Glu-Asp E224D ISS Not reported 
7 226 AGT-ATT Ser-Iso S2261 LS Not reported 
7 244 GAT-AAT Asp-Asn D244N LS Swedish 
10 422 (*) TGC-TTC Cys-Phe C422F LS Japanese 
10 478 GCA-ACA Ala-Thr A478T LS Not reported 
10 561 (*) CCT-ACT Pro-Thr P56lT LS Japanese 
#1 SNP lida K et al JCEM 1999; 84:4214-4219 
#2 SNP Chujo S et a1. Eur J EndocrinoI1996;134:560-2 
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1.3 IDIOPATHIC SHORT STATURE 
1.3.1 Definition and general concepts 
Idiopathic short stature (ISS) is defined as short stature of unknown aetiology and 
is, therefore, a diagnosis of exclusion. This category includes children with heights 2 
standard deviation scores (SDS) or more below the mean for age, sex and ethnic group, in 
whom no endocrine or systemic diseases are present and no known genetic causes of 
short stature or other factors compromising growth are identifiable (Bryant et aI., 2007, 
Wit et aI., 2008a). 
Short stature IS one of the most common reasons for referral to paediatric 
endocrinologists. It has been estimated that in approximately 80% of referred children no 
aetiology can be identified and are, thus, classified as ISS (Wit et aI., 2008b). The 
variability in biochemical profile and response to growth hormone (GH) treatment in ISS 
patients (Wit and Rekers-Mombarg, 2002, Leschek et aI., 2004, Hintz, 2005) suggests 
that multiple, as yet unidentified, pathological mechanisms contribute to this condition. 
Longitudinal growth is dependent on genetic and environmental factors 
(Gudbjartsson et aI., 2008, Lettre et aI., 2008, Weedon et aI., 2008). Height is normally 
distributed in the general population and, thus, SDS are used to describe height in 
children, with 2.5% of individuals having a height below 2 SDS (Wit et aI., 2008a). 
Because of the importance of the genetic background in determining linear growth, 
calculation of a child's expected height can be made by using the mean of parental centile 
heights (midparental height). A second important factor influencing final height is 
puberty onset. Estrogens, deriving from the aromatization of androgens in males, are, in 
fact, a potent stimulator of skeletal maturation and maintenance of bone mass. After birth, 
and for the first 18-24 months, linear growth shifts from a growth rate determined by 
maternal factors, to a growth rate determined by the infant's own genetic background. 
After the age of 2, however, postnatal linear growth is mainly regulated by the genetic 
background and follows the same percentile until puberty. During puberty, the increase in 
sexual steroids is a major determinant of the acceleration of growth rate, also known as 
growth spurt. This process is followed by a growth deceleration corresponding to the 
epiphyseal closure (Ho et aI., 1987, Mauras et aI., 1987). 
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The importance of a child's genetic background, reflected by hislher family height 
history, and of the child's pubertal onset has led clinicians to subclassify ISS according to 
these factors. ISS is classified as familial short stature when height is below the mean 
compared to the general population, but remains within the expected target range for the 
family (Ranke, 1996, Wit et al., 2008a). Familial short stature, in the absence of other 
diseases, is considered reassuring, thus limiting the need for diagnostic screening tests. 
However, the presence of short stature in one parent only dictates the need for more 
careful screening, since a genetic defect with a dominant effect, might be present. A 
family history of delayed puberty is also considered reassuring and does not require 
extensive diagnostic screening, as the same is likely to occur in the child with ISS (Wit et 
al., 2008a). 
1.3.2 Clinical characteristics and diagnostic screening 
ISS is a diagnosis of exclusion and, therefore, careful medical history taking, 
physical examination, biochemical and radiological tests should be performed to exclude 
the presence of chromosomal or genetic abnormalities, chronic illnesses or endocrine 
diseases responsible for the short stature (Preece et al., 1986, Wit et al., 2008a). Examples 
of systemic and endocrine causes of short stature are presented in Table 1.3. The presence 
of a normal birth size is part of the definition of ISS, and short stature children born small 
for gestational age (birth length/weight greater then 2 SDS) should not be diagnosed as 
ISS. Physical examination should exclude the presence of dysmorphic features, which 
may indicate syndromes such as the Russell-Silver syndrome, Noonan syndrome and 
Turner syndrome). Disproportionate short stature, e.g. short limbs or short limbs and 
back, are suggestive of skeletal dysplasia, such as achondroplasia (Hughes et al., 1986, 
Spranger, 1992, Wollmann et al., 1995, Wit et al., 2008a). The presence of emotional 
deprivation, psychological problems and malnutrition should also be excluded (Powell et 
al., 1967, Allen, 1994). 
Since, by definition, ISS is characterised by the absence of systemic diseases, the 
child with ISS should be asymptomatic. However, some conditions such as renal and 
gastrointestinal disease, anaemia and inflammatory diseases, may affect linear growth 
even in initial stages, when clinical signs and symptoms have yet to manifest. For this 
reason, biochemical testing, such as full blood count, electrolytes, albumin, renal function 
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tests and inflammation markers are part of the diagnostic screening of asymptomatic 
short stature children. Moreover, because of the high incidence of coeliac disease in short 
stature children, anti-tissue transglutamase antibodies or anti-endomysium antibodies are 
also commonly performed to identify patients at risk (Wit et aI., 2008a). 
TABLE 1.3 SYSTEMIC AND ENDOCRINE CAUSES OF SHORT STATURE. 
SYSTEMIC CAUSES 
• Gastrointestinal 
• 
• 
• 
Coeliac disease 
Crohn's disease 
any cause of malabsorption 
• Renal 
Chronic renal failure 
Renal tubular acidosis 
• Respiratory 
Cystic fibrosis 
Asthma 
Tubercolosis 
• Cardiovascular 
Congenital heart disease 
• Psychosocial 
Anorexia 
Emotional deprivation 
ENDOCRINE CAUSES 
• Growth hormone deficiency 
• Growth hormone insensitivity 
• Hypothyroidism 
• Cushing's syndrome 
• Pseudohypoparathyroidism 
• Hypopituitarism 
Chromosomal analysis to exclude Turner syndrome is recommended in any short 
stature female, even in the absence of a characteristic phaenotype (Gravholt, 2005, Wit et 
aI., 2008a). Thyroid function and IGF-I levels are the only endocrine tests included in the 
initial biochemical diagnostic screening (Wit et aI., 2008a). 
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The fundamental role of the GHIIGF-I axis in promoting linear growth requires that 
growth hormone deficiency or resistance are excluded for the diagnosis of ISS to be 
made. A recent ISS consensus meeting (Wit et aI., 2008a) recommended the study of GH 
secretion by means of GH stimulation test, such as the insulin tolerance test or the 
arginine test, in the presence of an IGF-I <2 SDS, or between -2 and 0 SDS associated 
with clinical signs of growth hormone deficiency. The presence of a low IGF-I and 
normal (> 6.7).lg/l) or high (>40mUl) GH response to stimulation test suggests the 
presence of GH resistance, which should be investigated further by measuring IGFBP-3, 
ALS and GHBP and performing an IGF-I generation test and, if required, DNA screening 
for GHI defects. 
Bone age assessment is recommended in the diagnostic assessment of paediatric 
short stature as it can aid in the identification of the aetiology and in the prediction of the 
final height. Skeletal age is calculated by comparing the maturity of the epiphyseal 
centres with standard radiography of the non-dominant hand and wrist (Tanner et aI., 
1983). 
1.3.3 Molecular mechanisms 
Numerous genes in the GH-IGF-I axis are known to be involved in linear growth 
(Walenkamp and Wit, 2006), and molecular investigations have identified functional 
mutations in genes coding for key proteins in patients previously labelled as having ISS 
(Ayling et aI., 1997, Metherell et aI., 2001). Defects in the Short stature HOmeoboX 
(SHOX) gene have been reported in up to 4% of cases of isolated or familial ISS 
(Rappold et aI., 2002, Huber et aI., 2006) and are the most frequent genetic defect 
identified in ISS children to date. More then 50 mutations have been reported in the 
SHOX gene and annotated in the SHOX gene mutation database (www.shox.uni-hd.de). 
SHOX defects are associated with a wide variability ofphaenotypes, seen both in patients 
with different SHOX mutations or different SHOX copy number, and in patients with the 
same SHOX defect (Schiller et aI., 2000). The phenotype can range from mild short 
stature with no additional clinical signs, to skeletal anomalies affecting long bone length 
and curvature. The latter includes disproportionate short stature (short lower legs and 
forearms, or mesomelia) and limb deformity (in Leri-Weil syndrome). A recent study on 
1608 children proposed a scoring system based on clinical signs, such as arm span/height 
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ratio and sitting heightlheight ratio, for the identification of high risk short stature 
children in whom SHOX should be screened for (Rappold et aI., 2007). 
Altered GH responsiveness has been suggested in children with proportionate mild 
short stature, normal GH levels, but reduced IGF-I. Biologically inactive GH proteins 
unable to induce GHR activation resulting from defects in the GH promoter or coding 
region have been described (Takahashi and Chihara, 1998, Millar et aI., 2003) and should 
be considered in such cases. Furthermore, single heterozygous defects in the GHR have 
been proposed as possible causes ofISS (Goddard et aI., 1995), but data are inconclusive 
as cosegregation of short stature and the heterozygous state is poor (Rosenbloom et aI., 
1994a). 
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1.4 MRNA SPLICING 
Approximately 20 percent of molecular defects causing a functionless GH receptor 
protein and thus GHI, alter the correct mRNA splicing of the GHR. Splicing is the 
mechanism by which coding exons are defined and correctly assembled to fonn the 
mature mRNA. mRNA splicing has gained increasing interest in recent years and this has 
led to the discovery that up to 50% of known deleterious mutations involve aberrant gene 
splicing. Moreover, nucleotide substitutions regarded as synonymous SNPs, have been 
reconsidered as mutations involving regulatory splicing elements. The growing interest in 
the splicing process has unveiled new potential therapeutic tools, such as the use of 
antisense oligonucleotides, to correct aberrant splicing processes. 
The majority of GHR defects causing GHI, alter GHR mRNA splicing by 
disrupting the invariant 5' or 3' splice sites, while a minority activate cryptic splice sites 
(Savage et aI., 2006). It is, however, possible that other GHR defects thought to cause an 
amino acid change or create a premature stop codon, result instead in a defective GHR 
protein by inducing aberrant mRNA splicing. mRNA analysis or in vitro splicing assays 
are, in fact, rarely perfonned to confinn the effect of mutations conventionally classified 
as nonsense or missense. 
In 2001, our group discovered the first GHR intronic mutation resulting in the 
inclusion of a pseudoexon in the mature mRNA in four boys with GHI (Metherell et a!., 
2001). This was a major breakthrough as only a few genetic diseases are known to result 
from pseudoexon activation (Akker et a!., 2007). Intronic mutations resulting III 
pseudoexon activation might be more frequent than previously thought, but can be 
extremely difficult to identify, especially if causing a frameshift and mRNA non-sense 
mediated decay. Moreover, no bioinfonnatics tools are available to detect intronic hot 
spots where a single base change may lead to pseudoexon activation. The discovery of 
the GHR pseudoexon inclusion in GHI patients is also of extreme interest because 
potentially curable with the application of new splicing therapeutic tools. 
1.4.1 Determinants of intron-exon recognition 
The coding sequence (exons) of eukaryotes is interrupted by intervening sequences 
(IVSs or introns). The splicing process removes introns from the pre-mRNA and joins 
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exons to form the mature mRNA (Lander et aI., 2001). The mechanisms driving splicing 
are still not fully understood. The pre-mRNA of a gene can be spliced in different ways 
giving rise to several different proteins. This process, called alternative splicing, is 
abundantly used in higher eukaryotes and is thought to be responsible for their functional 
diversity and complexity (Modrek et a!., 2001, Stetefeld and Ruegg, 2005, B1encowe, 
2006). About 40-60% of human genes are in fact, subjected to alternative splicing, 
compared to 22 % of C. Elegans genes (Modrek et aI., 2001). Alternative splicing is 
believed to play a fundamental role in producing structurally and functionally different 
transcripts from the same pre-mRNA in different tissues and/or developmental stages 
(Johnson et a!., 2003). 
An exon is defined by three major elements: the 5' splice site (donor) the 3' splice 
site (acceptor) and the branch point. These are short elements of 7-14 nucleotides that, in 
higher eukaryotes, can highly diverge from consensus sequences (Berget, 1995). The 
presence of additional regulatory elements, such as the polypyrimidine tract, and exonic 
or intronic enhancers and silencers is also required for the identification of an ex on and 
its inclusion in the mature mRNA (Figure 5). 
Analysis of the human genome has demonstrated that 99% of introns are flanked by 
GT and AG dinucleotides at the 5' and 3' splice site, respectively (Berget, 1995, Burset et 
a!., 2000), whereas exons are flanked in over 60% of the cases by the AICAG sequence at 
the donor site and a G at the acceptor site (Burset et a!., 2001). Two additional splicing 
elements are present within 50 nucleotides upstream of the 3' splice site. These are a 
sequence rich in pyrimidines (the polypyrimidine tract) and a 5-nucleotide sequence (the 
branch point) characterised by the consensus sequence CU(A/G)A(C/U), in which A is 
conserved in all genes (Wu et aI., 1999, Smith and Valcarcel, 2000). DNA and mRNA 
analysis has shown that constitutively spliced exons (exons that are always included in 
the mature mRNA) and alternatively spliced exons (exons expressed only in some tissues 
or developmental stages) differ in the characteristics of their splicing elements. 
Alternative exons have polypyrimidine tracts, which are less rich in pyrimidines and their 
splice sites deviate from the consensus sequences more than the constitutive exons 
(Stamm et aI., 1994, Stamm et aI., 2000). The implications of these differences between 
constitutively and alternative spliced exons are still unclear, but are thought to result in a 
less efficient recognition of the latter by the splicing machinery. Moreover, a difference 
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in exon length has been found between constitutive and alternative exons. The majority 
of exons in human genes have a length between 50 and 200 nucleotides (Lander et aI., 
2001). Alternative exons expressed in a single type of tissue have been found to be 
shorter (e.g. mean 78 ± 58 SD nucleotides for exons expressed in brain only). Although 
no explanation for this phaenomenon is yet available, the presence of a reduced number 
of regulatory elements, such as enhancers, in alternative exons, has been proposed. 
Donor Acceptor 
Splice site Branch Splice site 
point Polypyrimidine 
~ ~ tract ~ 
(A/C)AGlgt 
T 
ct (a/g) A (cit) ag lG 
+-- 20-50 bases -. 
4 Intron • 
Figure 1.6 Schematic representation of splicing elements location within the intron and 
exon. 
Exon recognition is also dependent on the environment within which the exon is 
located. Silencers and enhancers are additional elements playing a fundamental role in 
mRNA splicing (Watakabe et aI., 1993, Liu et aI., 1998, Blencowe, 2000, Cartegni et aI., 
2002). According to their function and location they are classified as exonic or intronic 
splicing enhancers or silencers. 
Enhancer sequences are positive elements within the pre-mRNA favouring exon 
inclusion. The use of algorithms to identifY redundant sequences that are less likely to 
occur by chance in a given nucleotide composition within exons have established that 
most enhancers are short, 4 to 9 nucleotides, purine- or AC-rich sequences. The majority 
of the enhancers bind to members of the serine and arginine-rich proteins (SR proteins) 
family (Blencowe, 2000, Zhang and Krainer, 2004). The SR proteins are pre-mRNA 
splicing factors belonging to a highly conserved family (Fu, 1995). They mediate the 
interaction between the pre-mRNA and the splicing machinery and are required for 
constitutive and alternative splicing (Graveley, 2000). SR proteins can recognise splicing 
enhancers and lead to the activation of suboptimal adjacent acceptor splice sites 
(Blencowe, 2000). The splicing factor 21 alternative splicing factor (SF21 ASF), the 
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U2AF, SRp55, SRp38 are among the most studied SR proteins involved in enhancers 
recognition (Wang and Burge, 2008). 
Very little is known about splicing silencers and no consensus sequence is available 
for these elements. Like enhancers, they can be located within or outside the exon. 
Silencer sequences bind to members of the heterogeneous nuclear ribonucleoprotein 
particle proteins (hnRNP protein) family (Krecic and Swanson, 1999, Spellman and 
Smith, 2006). These proteins are involved in many functions, such as gene expression 
and transcription, as well as mRNA splicing (Valcarcel and Green, 1996). In particular, 
studies have shown that hnRNP proteins are, in the majority of cases, involved in 
repressing gene splicing. Examples of this include the exclusion of donor splice sites 
following binding of the hnRNP Al to specific mRNA binding sites and the inhibition of 
acceptor splice sites resulting from the competitive and antagonising role of the hnRNP I 
for the SF21 ASF specific mRNA binding site (Lin and Patton, 1995, Singh et aI., 1995). 
These observations lead to two important considerations: first, that the same mRNA 
binding site can act as an enhancer or a silencer (Lou et aI., 1999, Shin et aI., 2004, 
Martinez-Contreras et aI., 2006) and, second that, in some cases, the tissue-specific 
variation in the ratio between SR proteins and their antagonists, such as the case 
SF2/ASF and hnRNPA1, may play an important role in the regulation of alternative 
splicing (Zahler et aI., 1993, Hanamura et aI., 1998). 
1.4.2 The Splicing machinery 
The mechanism by which an intron is excised from the pre-mRNA is a complex 
and not completely understood process. In brief, it involves the recognition of splicing 
elements by a ribonucleoprotein complex, called the spliceosome. This consists of 4 
small nuclear ribonucleoproteins (snRNPs) U1, U2, U5 and U41U6 and 50-100 non-
snRNP splicing factors (Wang and Burge, 2008). 
In vitro studies using simple minigene constructs (e.g. one intron and two exons) 
helped elucidate the steps of the splicing reaction. This begins with the recognition of the 
5 'splice site by the U1 snRNP and of the branch site by the U2 snRNP. Subsequently, the 
U41U51U6 complex binds the assembled pre-mRNA, thus initiating the splicing reaction. 
The splicing process involves a two-step enzymatic reaction (Figure 1.7). In vitro studies 
have demonstrated that the first step results in the formation of two intermediates: an 
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exon 1 and an intron-exon 2 lariat structure. The second step involves cleavage and 
removal of the intron from exon 2 and the ligation of exon 1 to exon 2 (Nilsen, 1998, 
Burge et aI., 1999, Black, 2003). 
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Fignre 1.7 Schematic representation of the pre-mRNA-spliceosome interaction dnring RNA 
splicing. 
The SR proteins are important regulators of the splicing process. Phosphorylated 
SR proteins such as SF2/ASF, have been shown to help binding of VI snRNP to the 5' 
splice site and to constitute a bridge between donor and acceptor splice sites (Wu and 
Maniatis, 1993, Xiao and Manley, 1997, Xiao and Manley, 1998). Phosphorylation ofSR 
proteins by specific kinases is thought to playa fundamental role in pre-mRNA splicing 
regulation. It has been suggested that the activation of genes coding for SR protein-
specific kinases may be involved in coordinating gene expression during development 
(Sanford and Bruzik, 1999). 
1.4.3 Bioinformatic tools and mRNA splicing 
Analysis of human genome has led to the creation of algorithms to assess the 
quality of exon splice sites by calculating a score. These scoring systems estimate the 
degree of adherence of the splice site to the consensus sequence, with higher scores 
suggesting better adherence. One of the most used scoring methods was created by 
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Shapiro and Senepathy (Shapiro and Senapathy, 1987) and allows the calculation of 
scores for acceptor, donor and branch sites. Like other in silica programs, it reliably 
predicts disruption of a splice site when one of the invariant dinucleotides at the donor or 
acceptor sites are substituted, but becomes less reliable the further the nucleotide 
substitution occurs from the splice sites. Prediction programs are even less helpful in 
cases of nucleotide substitution occurring at the splice sites of alternative exons. These 
are, in fact, already characterised by a wider diversion from the consensus sequences 
compared to constitutively exons (Stamm et al., 2000, Thanaraj and Clark, 2001). 
Although most enhancer sequences tend to be either purine- or AC-rich, studies 
have shown that they highly diverge from consensus sequences, making prediction by 
means of in silica enhancer prediction programs difficult. One of the most used 
prediction programs, the ESE finder 3.0 (http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home) uses sequence weight matrices for scoring 
candidate exonic splicing enhancers (ESE) motifs corresponding to functional consensus 
sequences of SR proteins, such as SF2/ASF, SC35, SRp55, SRp40 (Cartegni et al., 2003, 
Smith et al., 2006). Despite the evidence of good correlation between changes in 
enhancer-predicted scores and the presence of disease (Cartegni and Krainer, 2002, 
Colapietro et al., 2003) , the reliability of these in silica prediction programs has not yet 
been established and all nucleotide changes modifying an enhancer score should be tested 
in vitra. 
Algorithms for the detection of alternative exons have also been developed but are 
inaccurate due the complexity of the splicing process and the lack of understanding of the 
location and function of the majority of the regulatory splicing elements. The search for 
alternative exons relies mainly on the alignment of genomic sequences to expressed 
sequence tags (ESTs) and on cDNA derived from different tissues, developmental stages 
and diseases, available from public databases (Gelfand et al., 1999, Kan et al., 2001, 
Modrek et al., 2001). Different methods, such as micro array and differential 
hybridization techniques, have been also used, resulting in large-scale identification of 
cell and tissue specific alternative splicing events (Johnson et al., 2003, Pan et al., 2006). 
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1.4.4 Aberrant mRNA splicing 
Almost 50% of DNA point mutations responsible for human genetic diseases affect 
the efficiency of mRNA splicing leading to mutant proteins (Lopez-Bigas et aI., 2005, 
Wang and Burge, 2008). A mutation may interfere with the correct mRNA splicing by 
altering a native splice site or activating a cryptic splice site. The majority of reported 
splice mutations disrupt the native splice sites, through a base change within the donor or 
acceptor invariant dinucleotides (Krawczak: et aI., 1992). The result of these mutations is, 
in the majority of cases, exon exclusion. Rarely, this event can result in activation of a 
cryptic splice site (Treisman et aI., 1983, Wieringa et aI., 1983) or retention of an intron 
in the mature mRNA (Pequignot et aI., 2001, Zhang et aI., 2004) 
Mutations within other splicing elements, such as the polypyrimidine tract and the 
branch point, may equally contribute to genetic diseases inducing the exclusion of a 
constitutive exon or inclusion of an alternative one in the mature mRNA (De Klein et aI., 
1998, Cartegni et aI., 2002). 
In recent years, the discovery of the presence of enhancers and silencers within the 
pre-mRNA, has led to a reconsideration of the role of nucleotide changes, conventionally 
considered harmless synonymous SNPs, as potential point mutations altering regulatory 
splicing elements and consequently gene expression (Cartegni et aI., 2002, Pagani and 
Baralle, 2004). Moreover, genetic defects, conventionally classified as nonsense or 
missense mutations have been re-evaluated as possible splice defects. In this respect, the 
work by Liu et aI. (Liu et aI., 2001) has been fundamental. These authors were the first to 
acknowledge that nucleotide changes in the breast cancer susceptible gene (BRCA1), 
previously considered nonsense and missense mutations were, instead, splicing defects 
disrupting exonic enhancers. While splice sites mutations disrupt invariant dinuc1eotides 
and their effect can be easily predicted in silica, the effect of a base change within an 
enhancer or silencer is difficult to predict in silica and in vitro studies should always be 
performed. The complexity of splicing regulation and the importance of the exon-
surrounding environment, suggests that even single intronic point mutations located 
distant from an exon should be taken into consideration, since they can lead to aberrant 
splicing through the alteration of intronic regulatory elements (Buratti et aI., 2004). The 
impact and prevalence of splicing mutations outside the canonical splice sites is still far 
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from being elucidated, but has attracted increasing interest in view of the potential impact 
on numerous diseases, including cancer (Kalnina et aI., 2005, Venables, 2006). 
Another possible mechanism by which a base change can result in aberrant splicing 
is the creation of a new splice site, which competes with the native one. Rarely, a 
mutation may occur deep in the intron generating an aberrant splice site that activates a 
cryptic splice, resulting in the inclusion of a normally untranslated DNA sequence 
(pseudoexon) (Abeliovich et aI., 1992, Pagani et aI., 2002). 
1.4.5 Pseudoexons 
Introns are rich in sequences matching the consensus donor and acceptor splice 
sites. This suggests the presence in the IVSs of numerous potential exons, which are 
referred to as pseudoexons. Genome analysis has shown that pseudoexons greatly 
outnumber constitutive exons. The reasons behind non-inclusion of these pseudoexons in 
the mature mRNA are still unknown. Comparative analysis of constitutive exons versus 
pseudoexons has shown that the latter are rich in silencers, have less enhancers and 
weaker scores for splicing regulatory elements, such as donor and acceptor sites 
(Fairbrother and Chasin, 2000, Sun and Chasin, 2000, Sironi et aI., 2004, Zhang and 
Chasin, 2004). Moreover, computational analysis has suggested that intronic sequences 
surrounding the pseudoexons may form a double stranded structure, in which the 
pseudoexon is included and hidden from the spliceosome (Zhang et aI., 2005). 
In some cases, subtle changes in the pseudoexon are sufficient to activate it. A 
single base change can, in fact, create or reinforce donor sites, acceptor sites or other 
splicing regulatory sequences and lead to recognition of the pseudoexon by the splice 
machinery and its inclusion in the mature mRNA. These events are generally associated 
with a disease and examples are the splicing mutations resulting in pseudoexon inclusion 
observed in patients with GHI, cystic fibrosis, Duchenne muscular dystrophy and A TM 
among others (Akker et aI., 2007). 
1.4.6 The antisense-based approach for correction of mRNA splicing 
The increasing body of evidence demonstrating the relation between splicing 
defects and disease has led to the development of new therapeutic tools for the correction 
of aberrant splicing. Antisense oligonucleotides (ASO) are synthetic RNA molecules of 
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approximately 10-20 nucleotides, designed to be complementary to a target sequence on 
the pre-mRNA. The mechanism by which ASOs work is RNase H cleavage-independent 
and is thought to rely on the physical interference of ASOs in the apposition of 
spliceosome elements on the target pre-mRNA sequence (Kole and Sazani, 2001). This is 
in contrast with the antisense-based approach commonly utilised in the gene therapy of 
cancer, inflammation and viral diseases, which relies on hybridisation of an antisense 
oligonucleotide to a sense target sequence and the induction of the RNase H cleavage of 
the RNA:DNA hybrid (Crooke, 2001). 
An important requirement for an ASO to be effective is resistance to RNase H 
degradation. This can be achieved by designing oligonucleotides modified at the 2' 
hydroxyl group of the ribose, through 2'-0-methylation (Manoharan, 1999). 2'-0-
methyl oligonucleotides are commercially available, stable and resistant to RNase H 
degradation. Other possible modifications at the sugar, base or phosphodiester level have 
been suggested and successfully tested. Among these, is the addition of a morpholino 
ring or of an oligoglycine-like structure, such as the peptide nucleic acids (PNA), in the 
ASO backbone. These modifications have been shown to increase protection from RNase 
activity and confer better ASO delivery in in vivo studies (Stein et aI., 1997, Alter et aI., 
2006). 
Recently, the use of ASOs with a bifunctional activity has been suggested to 
improve the efficiency of aberrant splicing correction. Bifunctional ASOs consist of an 
RNA sequence complementary to the target pre-mRNA to which a non-complementary 
tail mimicking an ESE motif (Skordis et aI., 2003) or a small peptide resembling the SR 
protein RS domain (e.g. the exon-specific splicing enhancement by small chimeric 
effectors, ESSENCE) (Cartegni and Krainer, 2003) is attached. 
The use of the antisense oligonucleotide approach has been shown to be a potential 
therapeutic tool in correcting aberrant splicing. The use of ASOs complementary to pre-
mRNA splice sites, branch point or ESEs have been shown to effectively restore aberrant 
splicing in in vitro splicing assays using minigene pre-mRNA or in cell transfection 
systems. Many studies have, in fact, demonstrated that ASOs can restore exon inclusion 
or exclusion induced by splice mutations (Dominski and Kole, 1993, Sierakowska et aI., 
1996, Vacek et aI., 2003, van Deutekom and van Ommen, 2003, Hua et aI., 2007) and can 
also be a useful tool in regulating the expression of alternative protein isoforms (Khoo et 
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aI., 2007). Nevertheless, these studies have also shown a dose-dependent effect and the 
need for testing more than one, often several, ASOs to identify the most effective. 
Moreover, the use of ASOs has often resulted in unexpected and unwanted products, 
alongside the desired corrected mRNA. This has been explained by the activation of 
cryptic splice sites, which may follow the blocking of natural sites. Despite these 
potential difficulties, studies on animal models (Lu et aI., 2005, Alter et aI., 2006, 
Moulton et aI., 2007) have been promising, and preliminary trials in humans are ongoing 
(Takeshima et aI., 2006, van Deutekom et aI., 2007). 
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1.5 ORIGINAL HYPOTHESIS AND AIMS OF THE THESIS 
The overall aim of this thesis was to study the molecular mechanisms responsible 
for growth hormone insensitivity and idiopathic short stature and to combine the results 
with the current knowledge of mRNA splicing with the scope of developing new 
potential diagnostic tools and applying existing therapeutics to the endocrine field. 
The first aim of this thesis was to identify the molecular defects in a large 
population of children with growth hormone insensitivity and analyse the 
genotype/phenotype relationship. 
Molecular defects causing aberrant mRNA splicing are known to represent 
approximately 20% of GHR defects leading to GHI. Novel GHR splice defects causing a 
functionless GHR and GHI were, therefore, likely to be identified in this large 
heterogeneous GHI cohort. Nevertheless, the consequences at mRNA level of mutations 
located in splice elements other than the splice sites, are difficult to predict in silica and 
in these cases patient mRNA analysis becomes mandatory. Since obtaining patient 
samples for mRNA analysis is often difficult, another aim of this thesis was to assess the 
potential diagnostic application of an in vitro assay to study splice mutations, thus 
avoiding the need for patient mRNA analysis. The assay was based on a three-exon 
minigene system spliced in Hela nuclear extracts. A fundamental part of this project was 
the establishment of a rapid and reliable protocol for the creation of three-exon 
minigenes. The assay was tested on naturally occurring mutations identified in GHR 
splice elements of GHI patients studied in the course of this Thesis. The results of the in 
vitro assay were compared with the results obtained in silica and, where available, in vivo 
from patient mRNA analysis. 
The third aim of this thesis was to attempt a translational approach for correcting 
aberrant GHR splicing causing GHI. An antisense-based approach was used in vitro and 
in a cell system on an intronic GHR mutation resulting in the activation of a pseudoexon 
and growth hormone insensitivity. 
The last aim of this thesis was to study the effect of single heterozygote mutations 
in the IGF ALS of patients with idiopathic short stature. ALS deficiency resulting from 
homozygous or compound heterozygous IGFALS defects is an established cause of GHI. 
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The observation that parents of ALS deficient patients, obligate carners of single 
heterozygous IGF ALS defects, have mild short stature, although in the absence of 
biochemical signs of GHI, led us to speculate that single heterozygous IGF ALS defects 
may contribute to the pathogenesis of ISS. To test this hypothesis the IGF ALS was 
sequenced in a large, ethnically homogeneous, population of ISS children. 
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MATERIALS AND METHODS 
Chapter 2 Materials and Methods 
2.1 DNA PREPARATION 
2.1.1 DNA extraction from blood samples 
Three to 10ml of blood were collected in sodium EDTA tubes. DNA was extracted 
using the Nucleon Extraction and Purification kit (GE healthcare), according to the 
manufacturer's recommendations. Briefly, cell lysis was obtained by the addition of four 
times the volume of blood of a lysis buffer (Reagent A: 10mM Tris-HCl, 320M sucrose, 
5mM MgCh, 1% (v/v) Triton X-I00, pH 8.0), followed by mixing and centrifugation at 
1300g for 5 min. The pellet was resuspended by adding 2ml of resuspension buffer 
(Reagent B) and transferred to a 15ml centrifuge tube. Deproteinisation was achieved by 
adding 500~l of sodium perchlorate solution. For DNA extraction, 2ml of chloroform and 
300~l of Nucleon resin were added and the sample centrifuged at 1300g for 3 min, The 
upper phase was transferred to a clean tube, two volumes of cold absolute ethanol were 
added and mixed by inversion until the precipitate appeared. Precipitated DNA was 
hooked out using a heat-sealed Pasteur pipette and redissolved in 1 00~1 of sterile water. 
2.1.2 DNA purification from peR samples 
PCR fragments were purified using the QIAquick PCR Purification kit, (Qiagen) 
according to the manufacturer's recommendations. Briefly, 5 volumes of Buffer PBr 
(containing guanidine hydrochloride and isopropanol) were added to one volume of the 
PCR sample and the sample applied to a QIAquick spin column, which contains a silica 
membrane able to bind the DNA, and centrifuged for 1 min. The flow-through was 
discarded and 0.75ml of washing buffer (Buffer PE containing ethanol) was added to the 
column. After 1 min of centrifugation, the flow-through was discarded and the column 
centrifuged for an additional 1 min. The column was placed in a new micro centrifuge 
tube and 30~l of sterile water was added to elute the DNA. The column was centrifuged 
for 1 min and the resulting sample stored at _20DC. 
2.1.3 Visualization of DNA products on agarose gel 
DNA samples mixed with DNA loading dye (Fermentas) in a ratio 5:1 were loaded 
into the wells of an agarose gel prepared as described in section 2.5.1 and run along with 
a DNA marker (GeneRuler DNA ladder mix 0.5~g/~l, Fermentas) at a voltage ranging 
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from 100 to 200 Volts. DNA products were visualised under ultraviolet light and a 
photograph taken using the Uvidoc gel documentation system (Uvitec). 
2.1.4 DNA purification from agarose gel 
The desired DNA fragment was excised from the agarose gel under UV light using 
a sharp razor blade and subsequently purified using the QIAquick gel extraction kit 
(Qiagen) according to the manufacturer's recommendations. Briefly, the gel slice was 
inserted in an Eppendorf tube and weighed. Three volumes of buffer QG (binding and 
solubilisation buffer containing guanidine thiocyanate) were added to one volume of gel 
and incubated at 50°C for 10 min to dissolve the gel. Then, one volume of isopropanol 
was added to the sample and the sample applied to the QIAquick column, which contains 
a silica membrane able to bind DNA, and centrifuged for 1 min at 13,000 rpm to bind the 
DNA. 0.75ml of washing buffer (Buffer PE) were added to the QIAquick column and 
centrifuged for 1 min. The flow-through was discarded and the QIAquick column 
centrifuged for a further 1 min. The QIAquick column was subsequently placed into a 
clean 1.5ml microcentrifuge tube and 50~1 of sterile water were added to elute the DNA. 
The column was centrifuged for 1 min and the sample stored at -20°C. 
2.1.5 Determination of DNA concentration and purity 
DNA concentration was determined by measuring the absorbance (A) at 260 nm 
(A260) in a spectrophotometer. A 'blank' using 1~1 of the buffer in which the DNA was 
diluted was employed to zero the spectrophotometer and then the absorbance of 1 fll of 
the DNA samples was measured. 
The following relationship was used to calculate the DNA concentration: 
absorbance at 260 nm of a 50~g/ml solution of DNA is equal to 1. 
DNA purity was estimated using the ratio of the readings at 260 nm and 280 nm 
(A260/A280). Pure DNA is expected to have a A260/A280 ratio between 1.8 and 2. 
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2.2 RNA PREPARATION 
2.2.1 RNA extraction from blood 
RNA was isolated from human blood using the P AXgene blood RNA Kit and the 
P AXgene Blood RNA Tubes (PreAnalytic) according to the manufacturer's 
recommendations. All materials used for RNA extraction were RNase-free. RNA 
extraction with the P AXgene kit is based on the guanidine thiocyanate method and is 
schematically presented in Figure 2.1. 
Blood cell lysis 
... 
Sample deproteinisation 
... 
Binding of nucleic acids to the column silica-gel membrane 
... 
Washing 
... 
DNA removal by DNase treatment 
... 
Washing 
... 
Elution 
Figure 2.1 RNA purification from blood. 
The P AXgene Blood RNA Tubes contain surfactants that stabilise and preserve 
RNA from degradation, by forming an insoluble ionic complex between the nucleic acids 
and the surfactant. Briefly, the blood was collected in the P AXgene tube and incubated at 
room temperature for 48 hours to achieve complete lysis of blood cells. Subsequently the 
tube was centrifuged for 10 min at 3000 g to pellet the nucleic acids and the supernantant 
was removed. Four ml of RNase-free water was added to the pellet. The tube was 
vortexed and centrifuged for 10 min and the supernatant discarded. 350j..t1 of res us pension 
buffer (Buffer BR1) were added and the tube vortexed to dissolve the pellet. The sample 
was pipetted into a micro centrifuge tube and 300j..t1 of binding buffer (buffer BR2 
containing guanidine thiocyanate) and 40j..t1 of proteinase K added. The tube was mixed 
by vortexing and incubated for 10 min at 55°C using a shaker-incubator at 400 rpm. The 
lysate was pipetted into a P AXgene Shredder spin column and centrifuged for 3 min at 
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13,000 rpm. The supernatant was transferred to a fresh microcentrifuge tube, 350f.Ll of 
absolute ethanol was added and the contents were mixed by vortexing. 700f.Ll of sample 
was pipetted into the PAXgene RNA spin column and centrifuged for 1 min at 13,000 
rpm. This step was repeated with the remaining sample. Then, 350f.Ll of washing buffer 
(Buffer BR3 containing guanidine thiocyanate and ethanol) were pipetted into the spin 
column and centrifuged for 1 min. To digest DNA, If.LI of DNase (5xl000U Turbo 
DNase, Ambion) and 79f.LI of buffer RDD (Invitrogen) were pipetted into the spin 
column. The column was left standing on the bench for 15 min at room temperature 
before adding 350f.LI of washing buffer (Buffer BR3) and centrifuging for 1 min. The 
flow-through was discarded and 500f.LI of a second washing buffer (Buffer BR4 
containing ethanol) pipetted into the column and centrifuged for 1 min. This step was 
repeated twice. The flow-through was discarded and the spin column placed in a new 
micro centrifuge tube. To elute the RNA, 40f.LI of elution buffer (Buffer BR5) was pipetted 
onto the column and centrifuged for 1 min at 13,000 rpm and this step was repeated 
twice. (Figure 2.1) Then the eluant was incubated for 5 min at 65°C to denature the RNA 
and the sample was chilled on ice and immediately stored at -80°C. 
2.2.2 RNA extraction from cells 
Total RNA was extracted from cultured cells usmg the RNeasy mini kit 
(QIAGEN) according to the manufacturer's recommendations. Cells were harvested and 
disrupted using a guanidine thiocyanate method. The appropriate volume of lysis buffer 
(Buffer RLT: containing guanidine thiocyanate) was added to the cell culture well (350f.Ll 
of buffer RL T for less then 5x 1 06 cells). Cells were homogenised by passing the lysate 
through a 20-gauge needle attached to a sterile syringe at least 10 times. One volume of 
70% ethanol was added to homogenise the sample and 700f.LI of the sample was added to 
the RNeasy spin column and centrifuged for 15 secs at 13000 rpm. The flow-through was 
discarded and 350f.LI of washing buffer (Buffer RWI containing ethanol) were pipetted 
into the spin column and centrifuged for 1 min. To digest DNA, 1 f.LI of DNase (Turbo 
DNase, Ambion) and 79f.LI of buffer RDD (Invitrogen) were pipetted into the spin 
column. The column was left standing on the bench for 15 min at room temperature 
before adding 350f.LI of wash buffer and centrifuging for 1 min. To wash the column 
500f.LI of washing buffer (Buffer RPE containing ethanol) was added to the column and 
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the sample centrifuged for 15 secs at 13000 rpm. This step was repeated twice. To elute 
the RNA, the column was placed in a new 1.5ml collection tube and 30-50/-11 of RNase-
free water was added and the sample centrifuged for 1 min at 13000 rpm. The recovered 
RNA sample was immediately stored at -80°C. 
2.2.3 Visualisation of RNA samples 
RNA samples were mixed with RNA dye (see appendix), heated at 96°C for 5 min 
and then loaded in the wells of an agarose gel prepared as described in section 2.5.1 and 
run along with a radiolabeled DNA marker (Promega) at a voltage ranging from 100 to 
200 Volts. RNA products were visualised under ultraviolet light. 
2.2.4 RNA quantification 
RNA concentration was determined by measuring the absorbance at 260 nm (A260) 
in a spectrophotometer using RNase-free cuvettes. The spectrophotometer was zeroed 
using 1/-11 of the buffer in which the RNA was diluted and then 1/-11 of the RNA sample 
were measured. 
The following relationship was used to calculate the RNA concentration: 
absorbance at 260 nm of a 40/-1g/ml solution of single stranded RNA is equal to 1. 
RNA purity was estimated using the ratio of the readings at 260 nm and 280 nm 
(A260/A280). Pure RNA has a (A260/A280) ratio between 1.8 and 2. 
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2.3 eDNA SYNTHESIS 
2.3.1 Reverse Transcription (RT) 
Materials: 
RNasin® Ribonuclease Inhibitor (25 U/~l), Promega 
dATP, dTTP, dCTP, dGTP (l00 mM) Sigma-Aldrich 
M-MLV 5x Reaction Buffer, Promega 
Materials and Methods 
Moloney murine leukaemia virus reverse transcriptase (M-MLV RT) (200 UI~l) 
Prom ega 
• Random Primers (0.5~g/~l hexadeoxynucleotides), Promega 
All materials used for the first-strand synthesis of cDNA were RNase-free. RNA 
(2 - 2.5~g) was added to a sterile microcentrifuge tube, together with 0.5~g of random or 
a specific primer per ~g of RNA, and RNase-free water to a total volume :::; 15~1. The 
tube was heated at 70°C for 5 min to melt the secondary structure within the template and 
then immediately placed on ice to prevent secondary structure from reforming. 
The following components were thereafter added to the annealed primer/template 
in the following order: 
M-MLV 5x Reaction Buffer 
dATP 10 mM 
dCTP 10 mM 
dGTP 10 mM 
dTTP 10 mM 
RNasin® Ribonuclease Inhibitor 
M-MLVRT 
Nuclease-free water to a final volume 
5 ~1 
1.25~l 
1.25~l 
1.25~l 
1.25~l 
1 ~l 
1 ~l 
25 ~l 
The sample was mixed and incubated for 60 min at either 37°C for random primers 
or 42°C for other primers. 
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2.4 POLYMERASE CHAIN REACTION (PCR) 
The polymerase chain reaction was used to amplify genomic DNA and cDNA for 
sample preparation for sequencing analysis, genotyping, A-tailing of blunt-ended PCR 
fragments and creation of minigenes for the in vitro splicing assay. 
Materials: 
• dATP, dTTP, dCTP, dGTP (100 mM), Sigma-Aldrich 
• Taq DNA polymerase (100U, Sigma), or Phusion polymerase (100U, Finnzymes) 
• lOx Taq polymerase Buffer (Sigma) or lOx Phusion polymerase Buffer (Finnzymes) 
PCR reactions were carried out using the relevant primers pairs (sequences reported 
in Appendix 3). Standard PCR reactions were set up as follows: 
Taq polymerase (100U) 0.1~1 
10xTaq Polymerase Buffer l.S~1 
dNTP mix (10mM of each dNTP) 0.3~1 
Primer 1 (10mM) 0.3~1 
Primer 2 (10mM) 0.3~1 
DNA (10-100ng/~I) O.S~1 
Distilled H20 to a total volume IS ~l 
PCR reactions for minigene construction were set up as follows: 
Phusion polymerase 
lOx Phusion Polymerase Buffer 
dNTP mix (1 OmM of each dNTP) 
Primer 1 (SOmM) 
Primer 2 (SOmM) 
Template DNA (SO-200ng) 
Distilled H20 to a total volume 
0.2S~1 
S.O ~l 
0.2S~1 
0.2S~1 
0.2S~1 
O.S ~l 
2S.0 ~l 
The final volume of the PCR mix amplified by Taq polymerase was typically 
lS~l, unless otherwise specified. The final volume of the PCR mix amplified by proof 
reading polymerase for minigene construction was typically 2S ~l. Final MgCb 
concentration was typically 1.SmM. 
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Primer design 
Oligonucleotide primers were designed from the published genomic DNA database 
(www.ensembl.org). Each primer was designed to have, when possible a GC content of 
40-60%, and a CG rich terminal dinucleotide to improve annealing. Pairs of primers were 
designed to have similar melting temperatures. To avoid primer-primer annealing care 
was taken to avoid the presence of complementary sequences between primers pair. 
Radiolabelling of peR reaction 
PCR reactions were radiolabelled by adding 0.05 ).lCi of a)2p dCTP (9.25 MBq, 
Perkin-Elmer, Wellesley, MA) to the reaction. 
Thermocycling conditions 
Cycling conditions were as follows: 
One denaturing cycle of 2 min at 95°C (if Taq Polymerase was used) or 98°C (if 
Phusion Polymerase was used), followed by 25-35 cycles of steps 1 to 3: 
1) denaturation for 30 sec at 95°C (Taq Polymerase) or 98°C (Phusion Polymerase), 
2) annealing temperature (optimised according to primers) for 30 sec, 
3) extension at noc for 30 sec, 
and a final cycle of 5 min at noc. 
PCR reactions were optimised by varying the annealing temperature by 2-5 0c. 
2.4.1 A-tailing reaction for blunt-ended peR fragments 
PCR reactions were set up as follows and had a final volume of25).l1 : 
Purified PCR product (50-200 ng) 
dATP (10 mM) 
Taq DNA Polymerase 
10x Reaction Buffer 
deionized H20 
10 ).ll 
1 ).ll 
0.2).l1 
2.5).l1 
11.3 ).ll 
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Cycling conditions: 1 cycle at 95°C for 30 sec, 2 cycle of: 95°C for 30 sec, 55°C 
for 30 sec and 72°C for 30 sec, 1 cycle at 72°C for 2 min. 
2.4.2 Sequencing 
Direct sequencing of PCR products was performed using the ABI Prism Big Dye 
Sequencing kit and the ABI3700 automated DNAIRNA Sequencer (Applied Biosystems), 
an automated capillary gel electrophoresis system available at the Genome Centre of the 
William Harvey Research Institute. Data were collected with the Data Collection 
Software 2.0 and results analysed with the BioEdit Sequence analysis software version 7. 
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2.5 ELECTROPHORESIS 
2.5.1 Agarose gel for nucleic acid visualisation 
Agarose gels, ranging in concentration from 1 to 2% were prepared according to 
the size of the DNA fragments to be visualized. To make a 1 % gel, 19 of agarose (Sigma) 
was mixed with 100ml of 0.5xTAE (National Diagnostic) and heated in the microwave 
until the gel dissolved. After cooling to approximately 60°C, 1111 of ethidium bromide 
(5.25mg/ml in H20, Sigma) was added to the gel,mixed and poured into a gel 
electrophoresis cast and combs inserted to obtain wells. Once set, the gel was placed in a 
gel tank filled with 0.5xTAE buffer. 
2.5.2 Preparation of denaturing polyacrylamide gels for splicing assays 
Materials: 
All reagents were from Sequagel Ultrapure, National Diagnostics 
• Concentrate: 237.5g acrylamide, 12.5g methylene bisacrylamide and 7.5M urea in a 
deionized aqueous solution; 
• Diluent: 7.5M urea in deionized water; 
• Buffer: 0.89M Tris-Borate-20mM EDTA buffer pH 8.3 (lOx TBE) and 7.5M urea. 
According to the required percentage of polyacrylamide gel, the following reagents 
were used: 
- to obtain an 8% gel: 10ml of buffer, 32ml of concentrate and 58ml of diluent to 
make a total of 100ml solution, 
- to obtain a 4% polyacrylamide gel: 10ml of buffer, 16ml of concentrate and 
74ml of diluent to make a total of 100ml solution. 
Immediately before use, 4111 of TEMED (n,n,n',n'-tetramethylenediamine, Sigma) 
and 100111 of 10% Ammonium persulphate (Sigma) were added to 10ml of the above 
solutions and mixed thoroughly by inversion. The mixture was then poured into a 20cm x 
20cm x 2mm supporting glass gel plate and a comb inserted. The gel was left to set at 
room temperature for at least 1 hour. 
66 
Chapter 2 Materials and Methods 
2.5.3 Preparation of denaturing polyacrylamide gels for genotyping 
Materials 
• 5% GENE-PAGE plus 6M Urea (Acrylamides 5%, Urea 6M, Tris 0.089M, Boric 
Acid 0.089M, EDTA 0.002M, Amresco), 
• TEMED ((n,n,n',n'-tetramethylenediamine, Sigma) 
• 1 0% Ammonium Persulphate (Sigma) 
• 10xTBE (composition in Appendix) 
Polyacrylamide gels were prepared as follows: 36cm gel plates were cleaned with 
tap water, rinsed with copious amounts of deionised water and left to air dry. Plates were 
assembled with 0.2mm teflon spacers and clamped into a gel frame. To make up a 5% 
gel, 25ml of the 5% GENE-PAGE plus 6M Urea were used. 15111 ofTEMED and 150111 
of 10% ammonium persulphate (10% APS) were added immediately before pouring the 
gel. Gels were left to set at room temperature for at least 2 hours then pre-run at 900 Volt 
for 20 min. To make up a 8% polyacrylamide gel, 4ml of 30% polyacrylamide gel were 
mixed with 1.5ml of 1xTBE and 9.5ml of deionised water. 5.25111 ofTEMED and 240111 
of 10% ammonium persulphate were added, the gel mixed and immediately poured into 
clean glass gel plates. A comb was inserted and the gel was left to set for at least 1 hour. 
Gels were pre-run for 20 min at 900 Volt. 
2.5.4 Preparation of non-denaturing polyacrylamide gels 
Materials 
• 30% (w/v) acrylamide/methylene bisacrylamide solution (37.5:1 ratio, National 
Diagostics) 
• TEMED (n,n,n',n'-tetramethylenediamine, Sigma) 
• 10% Ammonium Persulphate (Sigma) 
• 10xTBE (composition in Appendix) 
To make up a 8% polyacrylamide gel, 3.99ml of 30% acrylamide solution were 
mixed with 1.5ml of 1xTBE and 9.51ml of deionised water. 5.25111 ofTEMED and 240111 
of 10% ammonium persulphate were added immediately before pouring the gel into 
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cleaned supporting gel glasses. A comb inserted and the gel was left to set for at least 1 
hours. Gels were pre-run for 20 min at 700 Volt. 
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2.6 CLONING OF PCR PRODUCTS 
The pGEM T -easy vector system was used for cloning in bacteria cell lines. The 
pcDNA 3.1 vector, characterised by a cytomegalovirus (CMV) promoter was chosen for 
transfection of eukaryotic mammalian cell lines. 
2.6.1 Preparation of Ligation reactions 
Ligations were set up using the pGEM T-easy Vector System (Promega) or 
pcDNA 3.1 expression vector (Invitrogen). The following reagents were added into a 
0.5m1 tube in the following order: 
Standard Reaction Positive 
control 
2x rapid ligation buffer 5111 5111 
Vector pGEM-T easy (50 ng/1l1), or 
Xll1 Xll1 
pcDNA3.1 (100 ng/1l1) 
PCRproduct x III 
Control insert DNA (4 ng/1l1) 2111 
T4 DNA ligase (3 Weiss units/ill) 1 III 1 III 
Deionised water to make a final volume 10 III 10111 
The amount ofPCR product (ng) to add was calculated using the formula: 
(ng of vector x kb insert size) / kb vector size x insert:vector molar ratio 
The ratio insert/vector was typically 2: 1 for the pGEM T -easy and 1:4 for the 
pcDNA 3.1 vector. Reactions were mixed by pipetting and incubated for 2 hours at room 
temperature. 
Ligation reactions were optimised by: 
a) varying the insert/vector ratio (e.g. 1: 1 and 3: 1); 
b) incubating the ligation reactions overnight at 4°C. 
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2.6.2 Preparation of Ampicillin culture plates 
Materials: 
• Agar (Sigma) 
• LB broth (Sigma) 
• Ampicillin (Sigma) 
• IPTG (isopropyl-beta-D-thiogalactopyranoside) [Promega] 
• X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) [Promega] 
7g of Agar were added to 8g of LB broth and made up to 400ml with deionised 
water and autoclaved. After cooling to 50°C, 4ml of 10mg/ml ampicillin was added per 
400ml of LB agar and then poured in 85mm petri dishes using a sterile field created by a 
lit bunsen burner. Once hardened 100/-11 ofIPTG (200 mM) and 50/-11 of X-gal (50 mg/m!) 
were added to each plate and smoothed over the surface using a sterile spreader. 
2.6.3 Transformation 
Materials: 
• Competent cells JMI09 High Efficiency (Promega) 
• SOC medium (Invitrogen) 
Competent cells were removed from -70°C storage and placed in an ice bath to 
thaw. The tube containing the ligation was centrifuged. Two /-11 of reaction and 50/-11 of 
competent cells were added to a sterile 1.5ml microcentrifuge tube and left on ice for 20 
min. The cells were heat-shocked for 50 sec in a water bath at exactly 42°C and then 
immediately returned on ice for 2 min. 950/-11 of SOC medium was added to each tube 
and reactions were incubated for 1.5 hours at 37°C with shaking (150 rpm). 100/-11 of each 
transformation culture were plated onto duplicate LB/ampicillinlIPTGIX-Gal plates by 
smoothing over the surface with a sterile spreader. Plates were incubated overnight (16-
18 hours) at 37°C. 
2.6.4 Colony selection 
The pGEM-T easy vector contains a multiple cloning region within the alpha-
peptide coding region for the enzyme beta-galactosidase. Bacteria with a functional beta-
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galactosidase enzyme convert substrates such as X-gal, to a blue product and appear as 
blue colonies. Insertion of the PCR product disrupts the beta galactosidase sequence and 
bacteria appear as white colonies. The plates were checked after overnight incubation and 
white colonies were picked using sterile pipette tips. Individual colonies were cultured 
overnight in 5ml LB Broth medium (composition in Appendix 2) containing ampicillin 
(final concentration 100Ilg/ml). 
2.6.5 Isolation of Plasmid DNA 
The 5ml cell cultures were pelleted by centrifugation for 10 min at 1300 g and the 
supernatant discarded. Minipreparation of plasmid DNA was obtained using the Qiagen 
plasmid mini kit (Qiagen) that uses the modified alkaline lysis method of Birnboim and 
Doly (Sambrook et aI., 1989). Briefly, pelleted bacterial cells were resuspended in 250111 
of resuspension buffer (Buffer PI: 50 mM TrisCI [pH 8.0], 10mM EDTA, IOOllg/ml 
RNase A) and 250111 of lysis buffer (Buffer P2: 200 mM NaOH, 1% SDS) and mixed. 
The lysate was neutralised and adjusted to high-salt binding conditions by the addition of 
350111 of neutralising buffer (Buffer N3, contains guanidine hydrochloride and acetic 
acid). The tube was then centrifuged for 10 min to precipitate proteins. The supernatant 
containing the plasmid DNA, was applied to the QIAprep silica membrane spin column 
and centrifuged for 30 sec at 13000rpm. The flow through was discarded, and the spin 
column washed by adding 0.5ml of buffer PB (wash buffer PB contains guanidine 
hydrochloride and isopropanol) and centrifuged for 60 sec. The flow-through was 
discarded and 0.75ml of buffer PE (buffer PE contains 99% ethanol) was added to the 
column and centrifuged for 60 sec. The flow through was discarded and the column was 
centrifuged for an additional 1 min to remove any remaining wash buffer. The DNA was 
eluted using 50111 of sterile distilled water and stored at -80C. 
2.6.6 Sub cloning 
Parent (pGEM T -easy vector) and destination (pcDNA 3.1 vector) expressIOn 
vectors were checked for the presence of common restriction sites in their multiple 
cloning sites (Figure 2.2). The insert product was released from the parent vector using a 
single digestion, purified and ligated into the destination vector and the ligation reaction 
transformed into competent bacterial cells. Transformed cells were screened for the 
presence of the insert by direct sequencing. 
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Restriction digestion 
Materials and Methods 
NheI 
Pme I 
AfflI 
Hind III 
Asp7BI 
Kpn I 
BamHI 
BstX I 
EcoRI 
pGEM-T easy vector Spe I 
EcoRI 
Not I 
Bst Z I 
Pst I 
pcDNA3.1 vector 
Sal I 
Nde I 
Sac I 
BstX I 
Nsi I 
\tSP6 
Figure 2.2 pGEM T -easy and pcDNA 3.1 vector maps. 
Restriction enzymes EcoR1 (Promega) or Notl (Promega) were selected for single 
digestion of parental vector and used with Buffer D (Promega). Standard digestion 
reactions were set up as follows: 
DNA (1-2/lg) x/ll 
Restriction enzyme (10 U) 1/l1 
lOx buffer 2/l1 
Deionised water to a final volume 20/l1 
Digestion reactions were incubated overnight at 37°C in order to maXImIse 
digestion of parental vector. To avoid self-recircularisation of vectors that had been cut 
with only one restriction enzyme, a dephosphorylation step was performed. 1/l1 of calf 
alkaline phosphatase (lU//l1, Promega) was added and the reaction was incubated at 37°C 
for 1 hour. Reactions were subsequently run on a 1 % agarose gel. The band 
corresponding to the released insert product size was cut from the gel and purified by 
standard DNA purification from gel as described in section 2.1.4. Purified insert was 
ligated in pcDNA 3.1 vector by standard ligation reaction as described in section 2.6.1. 
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2.7 SITE-DIRECTED MUTAGENESIS 
Site-directed mutagenesis was performed according to the principles of the 
Stratagene QuikChange ® kit. 
Materials: 
• Pfu Turbo DNA polymerase (2.5 U/J1,I), 
• 10x reaction buffer 
• Dpn I restriction enzyme (10 U/J1,I) 
• dNTP mix (Promega) 
• specific primers 
Two mutagenic primers, complementary to opposite strands of the target sequence 
in the insert, were designed (see appendix). The desired base change was located in the 
middle of the primer with 10-15 bases of unaltered sequence on either side. The primers 
were designed to have a melting temperature of 78°C and a GC content of at least 40 %. 
The reaction was set up as follows: 
dsDNA template (recommended dsDNA concentration ranging from 5 to 50 ng) 1-5 J1,1 
lOx reaction buffer 5 J1,1 
oligonucleotide primer 1 (100 ng/J1,l) 1.25J1,1 
oligonucleotide primer 2 (100 ng/J1,l) 
dNTPs mix 
and distilled water to a final volume of 50J1,1. 
1 J1,1 of Pfu Turbo DNA polymerase (2.5 U/J1,I) was then added. 
Cycling parameters were: 
Segment 
1 
2 
Cycles 
1 
12-18 
55°C 1 min 
68°C 1 minlKb of plasmid length 
Temperature Time 
30 sec 
30 sec 
1.25J1,1 
J1,1 
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The number of cycles in segment 2 was dependent upon the type of mutational 
change required, as described below: 
Type of mutation 
Point mutations 
Single amino acid change 
Multiple amino acid deletions or insertions 
Number of cycles 
12 
16 
18 
The reaction was then placed on ice for 2 min to cool. 1 III of Dpn I restriction 
enzyme (10 VillI) was added and the reaction was centrifuged for 1 min before being 
incubated at 37°C for 1 hour to digest the parental supercoiled dsDNA. llli of Dpn 1-
treated reaction was transformed into JM 1 09 High Efficiency Competent cells. 
Transformation was carried out according to the method previously described in section 
2.6.3. 
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2.8 IN VITRO SPLICING ASSAY 
2.8.1 DNA constructs for the in vitro splicing assay 
No well characterised protocol was available for the creation of the three-exon 
minigenes and several optimisations were performed, as described below. The three-exon 
minigene constructs were generated by inserting the GHR exon of interest and its 
flanking introns in a well characterised splicing reporter derived from the Adenovirus 
Major Late first (L1) and second (L2) leader exons (Adml-par, a gift from Prof Chew, 
genomic sequence reported in Appendix 7). The L1 and L2 exons were amplified by PCR 
using specific primers (sequences reported in Appendix 3: 10.3.4). The GHR ex on of 
interest was amplified by PCR using specific forward and reverse primers (sequences 
reported in Appendix 3: 10.3.4) of approximately 30 bases designed to have a 10 base 
overlap with L1 and L2 sequences, respectively. The GHR exon PCR fragments were 
inserted in between Adml-par exons L1 and L2 by two rounds of overlap-extension 
proof-reading PCR (Ho et aI., 1989), using specific primers. The fusion of the exons 
relies on the annealing of the overlapping ends of the two PCR products that will then 
function as primers for the 3' extension of the complementary strand 
Optimisation of overlap extension peR 
PCR reactions for overlap extension were optimised by: 
a) varying the annealing temperature of identical PCR reactions by 5°C in the range 
35°C - 55°C, 
b) varying the concentrations of the PCR products for the second PCR round, 
c) varying the number of exons included in the reaction; either 
including all three exons in a one-step reaction, or 
annealing the GHR exon to exon L1 and the resulting product to L2 in a two-step 
reaction, 
d) varying the order of exon annealing, either 
step!: GHR exon and L1, step 2: GHRexon/L1 and L2, or 
step 1 : GHR exon and L2, step 2: GHRexonIL2 and L1, 
e) varying primer concentrations. 
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The second round of overlap PCR always generated non-specific products along 
with the desired one. PCR products of the correct size were excised from the agarose gel, 
purified and sequenced. PCR products were modified using the A-tailing procedure, as 
described below, before being cloned into pGEM T -easy vector, as described in section 
2.4.1. 
2.8.2 RNA extraction from denaturing polyacrylamide gels 
The desired 32P-labelled RNA fragment was excised from the denaturing 
polyacrylamide gel (prepared as described in section 2.5.2) using a sharp razor blade. To 
identify the band of interest, fluorescent markers were apposed on the gel prior to 
autoradiography. RNA bands were excised from the gel and incubated overnight with 
400).tl of elution buffer (0.5M Sodium acetate pH 5.2, ImM EDTA, 0.2% SDS). The 
eluate was transferred to a fresh tube. To optimise the recovery of RNA, 10 mg/m! of 
glycogen was added to the sample before washing with Iml of 100% ethanol. The 
reaction was centrifuged for 15 min and the supernatant removed. Iml of 70% ethanol 
was added to the pellet and the reaction centrifuged for 15 min. RNA was redissolved in 
10111 of DE Pc treated H20 and stored at -20°C. 
2.8.3 In vitro transcription 
DNA minigene PCR products were transcribed into mRNA and labelled with a 
radioactive isotope by the incorporation of a)2p labeled GTP (9.25 MBq, Perkin-Elmer, 
Wellesley, MA) using the following protocol: 
DNA 1111 
lOx Transcription Buffer (Ambion) 1111 
NTPs (ATP,CTP,UTP 5mM, Prom ega) 1111 
RNA CAP (New England Biolabs) 1111 
T7 RNA Polymerase Plus 20U/lll (Ambion) 1111 
32p_GTP Xlll (corresponding to 10 llCi) 
RNAse free water to a final volume of 10111. 
Reactions were incubated at 37°C for 1 hour. Ten III of RNA loading dye 
(composition in Appendix 2) was added to each sample. Reactions were denatured at 
98°C for 5 min and then run on a 4% polyacrylamide gel for 45 min. 
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2.8.4 Standard in vitro Splicing Reaction 
Materials: 
• 25xATP/CP mixture: 12.5mM ATP (Promega), 0.5M creatine phosphate 
(Calbiochem) 
• MgCh (80 mM) 
• 
• 
13% Polyvinyl alcohol (PVA) (Sigma) 
0.4 M Hepes-KOH, pH 7.3 (Sigma) 
• Buffer D (20mM Hepes-KOH (pH 8.0), 100 mM KCI, 0.2 mM EDTA, 20% 
glycerol, 0.5 mM PMSF, 1 mM DTT). 
• HeLa Nuclear extracts (Cilbiotech) 
A splicing master mix was set on ice as follows: 
25xATP/CP 0.5 ~l 
MgCl2 (80 mM) 0.5 ~l 
13%PVA 2.5 ~l 
Hepes (0.4 M) 0.625~l 
RNA (10 fmol) x ~l 
Buffer D 3.5 ~l 
Nuclear extracts 4 ~l 
RNAse free water to a final volume of 12.5~l 
Reactions were incubated at 30°C from 20 min to 120 min and control reactions 
were set up and incubated on ice for the same time. 
Deproteinisation, precipitation and visualisation of mRNA splicing products 
At the end of the incubation time 200~1 of stop solution (3M Sodium acetate pH 
5.2, 10% SDS, 25~g/ml tRNA, dH20 to a final volume of 50~1) and 200~1 of Tris-
saturated Phenol (Invitrogen) were added to each reaction for deproteinisation. Samples 
were vortexed for 2 min and then centrifuged for 10 min. The aqueous phase containing 
the RNA was transferred into a fresh tube with 470~l of 100% ethanol, vortexed, kept on 
ice for 5 min and then centrifuged for 15 min to pellet the RNA. The supernatant was 
carefully removed and discarded without disturbing the pellet. The pellet was then 
washed using 470~1 of 70% ethanol. The sample was vortexed, kept on ice for 5 min and 
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then centrifuged for 15 min to pellet the RNA. The supernatant was carefully removed 
and discarded without disturbing the pellet and 3.5111 of RNA loading dye mixture added. 
Reactions were denatured for 5 min at 98°C and then loaded into the wells of a 4% 
denaturing polyacrylamide gel prepared as described in section 2.5.2. The gel was run for 
approximately 2 hours at 950 V in lxTBE buffer (Sigma) before autoradiography. 
2.8.5 Autoradiography 
Autoradiography was used to obtain images of polyacrylamide gels resulting from 
in vitro splicing assays. Films, placed on wet polyacrylamide gels wrapped in Saran wrap 
were put inside a sealed cassette and exposed at -80°C for 3-16 hours depending upon 
the strength of the signal. Films were then developed using an automated developing 
system (Compact X4, Xograph Imaging System, UK). 
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2.9 SIZE EXCLUSION CHROMATOGRAPHY 
• 
• 
• 
• 
Materials 
IGF-I (10 I1g, Invitrogen) 
Disuccinimidyl suberate (Sigma Aldrich) 
1M Tris HCI (Sigma) 
Buffer A (composition reported in Appendix 2) 
2.9.1 Iodination ofIGF-I 
Materials and Methods 
IGF-I iodination was carried out by Dr R Edwards at the NETRIA laboratories of 
St Bartholomew's Hospital using a standard chloramine T iodination procedure. 
2.9.2 The HiPrep 16/60 Sephacryl S-200HR column 
The HiPrep 16/60 Sephacryl S-200HR column (Amersham Biosciences, GE 
Healthcare, USA), a prepacked gel filtration column (column volume 120ml), was used 
for the size exclusion chromatography assay. The column was equilibrated for first-time 
use with 60m1 of distilled water and run at a flow rate of O.Smllmin. 240ml of buffer A 
(composition in Appendix 2) was then run at a flow rate of 1mllmin. After each run the 
column was regenerated using 120ml of buffer A run at a flow rate ofO.8mllmin. 
Protein separation and peak distribution on the HiPrep 16/60 Sephacryl S-200HR 
column was first assessed by running the following proteins of known molecular weight: 
bovine IgG (1S0 kDa), albumin from bovine serum (66 kDa), carbonic anhydrase from 
bovine erythrocytes (29 kDa) and aprotinin from bovine lung (6.S kDa). 1.Smg of each 
protein was added to SOOml of buffer A and the solution run on the Sephacryl column at a 
flow rate of 1 m1l1 Omin. The elution of the standard proteins was measured by reading the 
1ml fractions at 280nM using a spectrophotometer. 
2.9.3 Size Exclusion chromatography assay 
Samples were fractioned on a HiPrep 16/60 Sephacryl S-200HR column. Serum 
samples (100111) were incubated overnight at 22°C with 3.Sx106 counts per minute of 1251_ 
labeled IGF-I and buffer A to a final volume of SOOI11. Reactions were then cross-linked 
with SmM disuccinimidyl suberate (Sigma Aldrich). After 30min incubation at 22°C, the 
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cross-linking reaction was stopped by the addition of 1M Tris HCI. The reactions were 
loaded into the column and run overnight at a flow rate of 1ml per 10 min. One ml 
fractions were collected and the amount of 125I-labeled IGF-I in each fraction assessed by 
using a gamma counter. 
Calculation of1251 1GF-1 incorporation in the ternary complex 
Incorporation of 125I-labeled IGF-I in the ternary complex was calculated according 
to the following formula: 
(sum of iodine counts per minute in the ternary complex / total iodine count per 
minute) xl 00 
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2.10 SPLICING PREDICTION PROGRAMS 
Splicing prediction programs that are freely available on the web were used for the 
in silica analysis of nucleotide changes occurring in the DNA of patients with OBI or ISS 
and to create an algorithm to search for GHR alternative exons. 
Nucleotide changes occurring at donor or acceptor splice sites, within exons or at 
the branch point were studied using the Alex Dong Li's splice site finder 
(http://violin.genet.sickkids.on.ca/~ali/),anin silica prediction program that calculates the 
scores of donor, acceptor and branch sequences using an algorithm based on that created by 
Shapiro and Senapathy (Shapiro and Senapathy, 1987). 
To search for the alteration/creation of exonic enhancers the ESE finder 3.0 
(http://rulai.cshI.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home)wasutilised.This 
uses sequence weight matrices for scoring candidate ESE motifs corresponding to 
functional consensus sequences of SR proteins, such as SF2/ASF, SC35, SRp55, SRp40 
(Cartegni et aI., 2003, Smith et aI., 2006). 
No valid prediction programs for silencers are currently available. 
The scores threshold used to predict the occurrence of a splicing event by the in 
silica programs, were those set up by default by the authors, unless otherwise specified. 
81 
Chapter 2 Materials and Methods 
2.11 STATISTICAL ANALYSIS 
Statistical analyses were performed using R version 2.6.2 (R Development Core 
Team, 2008, R Foundation for Statistical Computing, Vienna, Austria). Numerical 
variables were expressed as median (range), with the exception of 1251 IGF-I 
incorporation in the ternary complex which was expressed as mean ± standard deviation. 
Categorical variables were expressed as number (percent). Comparison between 
continuous variables was performed using Wilcoxon's rank sum test. Comparison 
between categorical variables was performed using Fisher's exact test. A two-sided p-
value <0.05 was considered indicative of statistical significance. 
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CHAPTER 3 
GENETIC CHARACTERISATION OF PRIMARY GHI 
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3.1 BACKGROUND 
Primary or genetic growth hormone insensitivity (GHI) is a rare condition, 
phenotypically resembling GH deficiency, but differing from it through high levels of 
circulating GH. It is caused by genetic defects of the GH-IGF-1 axis and has to be 
differentiated from secondary or acquired GHI, in which conditions such as malnutrition, 
liver disease and catabolic illness result in GH resistance (Laron et aI., 1993, Laron, 
1999). 
In its most severe form, pnmary GHI is known as classical GHI or Laron 
syndrome. Intrauterine growth is not affected, although birth weight and length may be 
marginally subnormal. However, postnatal linear growth failure is typically observed, 
with a severe and rapid decline in growth velocity. If untreated, adult stature is 4-10 
standard deviation scores (SDS) below the mean for age and sex (Gluckman et aI., 1992). 
The cardinal biochemical features of GHI are normal or increased GH levels associated 
with low IGF-I, IGFBP-3 and ALS levels. Patients are resistant to treatment with 
exogenous GH and fail to generate GH-dependent proteins during the IGF-I generation 
test. Patients with classical Laron syndrome display a characteristic mid-facial hypoplasia 
due to underdeveloped sphenoid and mandible. The nose is small, with depressed bridge 
and the forehead is protruding. Hair is sparse with temporal and frontal recession. GHBP 
levels are typically low or undetectable (Laron, 1999, Laron, 2004). 
Primary GHI can present in a less severe form known as non-classical GHI. 
Patients present with normal facial appearance and less impaired longitudinal growth. 
GHBP levels are typically normal or high (Woods and Savage, 1996). 
The first report of GHI of genetic origin came from Dr Zvi Laron in 1966 (Laron et 
aI., 1966) with the demonstration of a lack of binding of GH to GHRs obtained from liver 
membranes of GHI patients. Since then, more than 250 patients with primary GHI have 
been identified worldwide. GHI is generally transmitted as an autosomal recessive 
disorder and is usually observed in populations with high consanguinity. Almost all GHI 
patients in whom a molecular defect has been identified have a mutation in the GHR 
(Woods et aI., 1997). 
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Figure 3.1 GH signalling and ternary complex formation. Proteins of the GH-IGF-I axis, in 
which the presence of a genetic defect results in GHI, are indicated with a red cross. 
The vast majority of GHR defects are recessively inherited either in homozygous or 
compound heterozygous forms and range from exon deletions to a variety of point 
mutations including missense, nonsense, splice and frameshift mutations. Nearly all 
reported molecular defects in the GHR occur in the region encoding the extracellular 
domain of the receptor and result in classical Laron syndrome. Many of these molecular 
defects have a common pathogenetic mechanism, resulting in either total absence of the 
GHR or presence of a defective receptor, which lacks GH-binding capacity, hence the 
low or absent circulating GHBP levels (David et al., 2005). 
Mutations in the GHR regions coding for the transmembrane and intracellular 
domain are less frequent. Patients with such defects have non-classical GHI. Their GHBP 
levels are normal or high, reflecting the presence of an intact extracellular GHR domain. 
Two such defects in the intracellular GHR domain located at the splice sites of exon 9 are 
of particular interest because they are the only example of GHR defects with a dominant 
negative effect (Ayling et al., 1997, Iida et al., 1998). The truncated mutant GHR 
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resulting from these mutations can form a heterodimer with the wild type GHR inhibiting 
the effect of the normal GHR protein (lida et aI., 1999). 
In addition to the GHR, another two defective genes in the GH-IGF-I axis, namely 
STAT5b and IGFALS, have been involved in the pathogenesis of GHI (Figure 3.1). In 
2003 Kofoed et ai. reported the first STAT5b defect. The mutation led to a mutant protein 
that could not be activated by GH, thus failing to activate gene transcription (Kofoed et 
aI., 2003). The patient had all the signs of classical GHI, with the addition of 
immunodeficiency, consistent with a non-functional STAT5b protein. In 2004 Domene' 
et ai. reported the first IGFALS defect resulting in a frameshift and the appearance of a 
premature stop codon. The patient had a biochemical profile suggestive of severe GHI 
despite a mild short stature. Delayed puberty was also reported (Domene et aI., 2004). 
To date, more then 60 different mutations have been found in the GHR. 
Nevertheless, identification of novel defects and their characterisation can bring new 
insight into the physiology of this protein. Moreover, the relationship between different 
GHR mutations and the severity of GHI, as well as the relation between defects in 
different genes and the severity of GHI remains unclear. 
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3.2 HYPOTHESIS AND AIMS 
The aim of this study was: 1) to perform a genetic analysis of a large population of 
patients with primary GHI from different ethnic backgrounds; 2) to define a relationship 
between GHR defects and the GHI phenotype by pooling data from the GHI cohort 
presented in this study, data from another large genetically heterogeneous population 
reported in the European Pharmacia and Upjohn Treatment Study Group published by 
Woods et al. in 1997 and data from the two studies on GHR dominant negative 
mutations; 3) to analyse the auxological and biochemical data from GHI patients with 
IGF ALS defects identified in this study and compare their phenotype to that arising from 
GHR defects. 
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3.3 STUDY POPULATION 
The majority of patients included in this study were recruited as part of an 
international collaboration led by Dr Cecilia Camacho-Hubner at St. Bartholomew 
Hospital London, UK, to study the effect of the recombinant IGF-I1IGFBP-3 compound 
(rhIGF-I/rhIGFBP-3, Insmed Incorporated, NASDAQ:INSM) on children with primary 
growth hormone insensitivity. Patients followed in the Paediatric Endocrine Unit at the 
Royal London Hospital, London, UK were also included in the study. 
Patients in this study were growth hormone insensitive, defined as severe postnatal 
short stature associated with normal or high GH levels and low basal IGF-I levels failing 
to rise in response to administration of exogenous GH. Exclusion criteria were the 
presence of chronic illnesses or endocrine diseases possibly leading to acquired growth 
hormone insensitivity. 
Informed consent was obtained from all patients and their parents. Ethical approval 
was obtained by individual centres recruiting patients. Height and weight were measured 
using standard anthropometric techniques (Cameron, 2002) and were converted into SDS. 
Pubertal status was assessed according to the criteria of Tanner (Marshall and Tanner, 
1969, Marshall and Tanner, 1970). Boys were considered prepubertal if genitalia were 
stage I and testicular volume was <4 ml (Zachmann et aI., 1974). Girls were prepubertal 
if breast development was stage 1 (Marshall and Tanner, 1969). 
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3.4 MATERIALS AND METHODS 
3.4.1 PCR and sequencing 
Genomic DNA was extracted from peripheral blood leucocytes. GHR coding 
exons, including the pseudoexon 6'¥, and their intronic boundaries were amplified by 
polymerase chain reaction (PCR) using specific primers (primer sequences reported in 
Appendix 3: 10.3.1). Cycling conditions were 95"C for 5 min (1 cycle); 95"C for 30 secs, 
55°C for 30 secs and noc for 30 secs (30 cycles); and noc for 5 min. 
IGF ALS coding exons and their intronic boundaries were amplified by PCR using 
specific primers (sequences reproted in Appendix 3: 10.3.3). Cycling conditions were 
95°C for 5 min (1 cycle); 95°C for 30 secs, 63°C for 30 secs and noc for 30 secs (35 
cycles); and noc for 5 min. 
STAT5b genetic analysis was performed by Dr V. Hwa in the Department of 
Paediatrics, Oregon Health and Science University, Portland, Oregon, US. 
PCR products were visualised on 1 % agarose gel and sequenced using the ABI 
Prism Big Dye Sequencing kit and an ABI 3700 automated DNA sequencer (Applied 
Biosystems), in accordance with the manufacturer's instructions. 
3.4.2 RNA extraction and RT-PCR 
RNA was extracted from patients' leucocytes using the PAXgene blood RNA Kit 
as described in Materials and Methods (section 2.2.1) and used for cDNA synthesis. The 
standard RT-PCR technique was used to amplify cDNA using specific primer pairs 
(sequences reported in Appendix). To improve the specificity and sensitivity of the PCR 
technique, the GHR was amplified using a hem i-nested PCR technique. Briefly, l/ll from 
the first PCR reaction was used in a second 12.5/l1 PCR reaction and amplified with a 
second set of primers, one of which corresponded to the primer used in the first PCR 
reaction, and the second primer annealed within the first round PCR product. PCR 
products were visualised on 1 % agarose gel and sequenced. 
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3.4.3 Genotyping 
Genotyping was performed using two types of genetic marker: dinucleotide repeats 
and single nucleotide polymorphisms (SNPs). 
Dinucleotide repeats 
Dinucleotide repeats occur throughout the genome and can co segregate with a 
nearby gene of interest. Different numbers of repeats can be identified by PCR across the 
region as they result in PCR fragments of different lengths whose size can be resolved by 
polyacrylamide gel electrophoresis. The dinucleotide markers were selected on the basis 
of their proximity to the GHR locus. Characteristics of dinucleotide repeat markers 
utilised in this study are according to Ensembl database (www.ensembl.org) and are 
reported in Table 3.1. Their position relative to the GHR locus is presented in Figure 3.2. 
TABLE 3.1 CHARACTERISTICS OF DINUCLEOTIDE REPEAT MARKERS UTILIZED IN TillS 
STUDY 
Marker Heterozygosity No.of Alleles Distance to Size ofPCR 
index GHR(Mb) product (bp) 
DSs2021 0.S7 4 -4.6 113-119 
DSs2022 0.73 9 -2.S 220-240 
DSs430 0.67 8 -1.0 2S6-270 
DSs2082 O.SS 4 -0.4 186-200 
DSs2087 0.76 6 +1.8 248-260 
D5s474 0.63 6 +12.5 87-97 
Figure 3.2 Dinucleotide repeat markers position relative to the GHR locus. 
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Dinucleotide repeat markers were amplified from genomic DNA by PCR using 
specific pairs of primers ( sequences reported in Appendix 3: 10.3.8) one of each pair was 
labelled at its 5' end with a fluorescent moiety. PCR products were denatured and 
electrophoresed as follows: 
0.5)11 of each sample was mixed with 0.5)11 of loading dye (Applied Biosystem) and 
0.25)11 of a size marker (GeneScan 500 ROX, Applied Biosystems), incubated at 95°C for 
2 min to denature the DNA and immediately chilled on ice. Samples were then loaded 
into the wells of a 5% denaturating polyacrylamide gel (prepared as described in section 
2.5.3) and electrophoresed for 2 hours at 2.5 kV. Results were analyzed using Genescan 
and Genotyper software (Perkin Elmer Applied Biosystems, UK). If the PCR had failed 
or the results were not interpretable, the PCR was repeated and the sample rerun. 
Single Nucleotide Polymorphisms (SNPs) 
Single Nucleotide Polymorphisms (SNPs) are single base variations that occur 
throughout the genome. Different patterns of SNPs in and around a gene can be used to 
create genotypes in a similar manner to microsatellite markers. Analysis of six SNPs in 
intron 9 of the GHR has identified 6 haplotypes (Amselem et aI., 1989) and they are 
presented in Appendix 6. In this study we utilised these SNPs to establish the genotypes 
for GHI patients with identical mutations. PCR reactions were set up using specific 
primers (sequences reported in Appendix 3:10.3.1) to amplify the GHR intron 9. PCR 
products were checked by running on an agarose gel and analysed by direct sequencing. 
3.4.4 Size exclusion chromatography 
Samples were fractioned on a HiPrep 16/60 Sephacryl S-200HR column according 
to the protocol described in Materials and Methods (section 2.9.3). Briefly, serum sample 
(100)11) was incubated overnight at 22°C with 3.5xl06 counts per minute of 125I-labeled 
IGF-I and was then cross-linked with 5mM disuccinimidyl suberate (Sigma Aldrich). 
After 30 min, the reaction was stopped by adding 1M Tris HCl. Five hundred microliters 
were loaded onto the column and one-milliliter fractions were collected and counted. 
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3.4.5 Biochemical assessment 
Serum IGF-I, IGFBP-3, ALS and GHBP were measured from venous blood 
samples, using enzyme-linked immunosorbent assays (ELISA kit; Diagnostic System 
Laboratories, Inc. Webster, TX, USA), by Dr F. Miraki-Moud in the laboratories of Dr C. 
Camacho-Hubner at Barts and the London. 
For IGF-I, assay sensitivity was 0.03ng/ml. The intra- and inter-assay coefficients 
of variation were 8.6% and 6.8% for mean serum concentrations of 104 and 90ng/ml, 
respectively. For IGFBP-3, assay sensitivity was 0.04ng/ml. Mean intra- and inter-assay 
coefficients of variation were 7.2% and 8.3%, respectively. For ALS, assay sensitivity 
was 0.7ng/ml and inter-assay coefficient of variation was 8%. For GHBP the assay 
sensitivity was 1.69pmoIll. The inter-assay coefficient of variation was 8.4%. 
Normal values for IGF-I, IGFBP-3 and ALS were obtained from Diagnostic 
System Laboratories and used to calculate SDS. Since IGF-I and IGFBP-3 are not 
normally distributed, values were converted to their normal logarithm. For the purpose of 
the analysis, undetectable values were arbitrarily substituted for the values immediately 
below the assay sensitivity (e.g. undetectable IGF-I levels were considered = 0.02ng/ml). 
3.4.6 Statistical analysis 
Statistical analyses were performed using R version 2.6.2 (R Development Core 
Team, 2008, R Foundation for Statistical Computing, Vienna, Austria). Numerical 
variables were expressed as median (range). Comparison between continuous variables 
was performed using the Student's t-test. A two-sided p-value <0.05 was considered 
indicative of statistical significance. Bonferroni adjustment was performed to reduce the 
likelihood of type I error. 
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3.5 RESULTS 
3.5.1 Auxological and biochemical characteristics of the GHI population 
Fifty three patients (27 females, 26 males) were included in the study. Median age 
was 8 years (range 0.5 to 21 years) and median height SDS was -6.00 (-2.45 to -9.36). 
Median IGF-I SDS was -6.36 (-0.05 to -17.67) and median IGFBP-3 SDS was -8.35 (-
0.49 to -24.61). 
3.5.2 Genetic analysis 
All GHI patients were initially screened for the presence of mutations in the GHR, 
since defects in this gene are the most common cause of congenital GHI. After exclusion 
of mutations in GHR coding exons, pseudoexon 6'¥ and their intronlexon boundaries by 
direct sequencing, genetic screening was performed according to the following flowchart: 
Low 
GHBP levels 
\ 
GHR 
cDNA analysis 
Sequencing of GHR 
Undetectable High GHBP levels 
GHBP levels GHBP levels in the normal range 
/ 1 
Immunological 
problems 
Sequencing of 
STAT5b 
Sequencing of 
IGFALS 
Direct sequencing of the GHR led to the identification of 15 different genetic 
defects in 38 out of 53 GHI patients (Table 3.2). Among the identified mutations, two 
93 
Chapter 3 Genetic characterisation ofprimary GHI 
nonsense (C48X and Q216X), one missense (L229P) and 2 splice mutations (IVS7 as-6 T 
to A and IVS9 ds+2 C to T) were novel (Figure 3.3) and their characterisation is 
presented in this Chapter. 
IVS2 ds+1 G to A 
Amino acid -1 8 
GHR 
2 
++ 
Signa 
peptid 
I 
e 
3 
IVS6 ds+1 G to A 
IVS6 ds+792 G to A 
fF, 
29 72 130 189 
.... 
Extracellular 
domain 
I 
I V12SA I 
I R43X I 
IVS7 as-6 T to A 
IVS8 ds-I G to C 
++ 
Transme mbrane 
in doma 
L229P l 
G223G 1 
Q216X I 
Intracellular 
domain 
IVS9 ds+2 T to C 
Figure 3.3 Mutations identified in the GHR of the GHI population. Novel defects are 
highlighted in orange boxes. 
In 15 patients, no defects in the GHR were found. Six out of 15 patients (patients 
39-44, Table 3.2) had normal GHBP levels. In two sisters with immunological problems 
(patients 39 and 40, Table 3.2), a novel STAT5b defect (del G at 1680) was found in 
collaboration with the Dept of Paediatrics, Portland, Oregon, US. Five novel IGFALS 
defects were found in 4 unrelated patients (patients 41-44, Table 3.2). The clinical details 
of these patients and characterisation of the STAT5b and IGFALS defects are presented 
later in this Chapter. 
Four out of the 15 patients with no defects in the GHR coding region (patients 45-
48, Table 3.2) had undetectable GHBP levels indicative of a deleterious defect in the 
GHR. In one of these (patient 45, Table 3.2) a single heterozygous GHR deleterious 
splice defect (C to T at mRNA position 723 leading to the activation of a cryptic splice 
site in exon 7, also known as G223G) was found . The same heterozygous defect was 
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identified in his mother who had normal stature. Even though this patient is likely to be a 
GHR compound heterozygote, DNA and cDNA analysis did not reveal a second 
mutation. 
Five out of the 15 patients with no defects in the GHR coding region (patients 49-
53, Table 3.2) had low GHBP levels (range 41-135 pmolll) suggesting the presence of a 
deleterious GHR defect. All patients were of the same origin (Kuwait) and belonged to 4 
families, two of which were known to be related. A novel homozygous A to C base 
change in IVS2 ds+4 was found in all subjects. Their parents were heterozygous for this 
defect. cDNA analysis revealed no GHR products. The occurrence of aberrant splicing 
from the IVS2 ds+4 base change was studied with the in vitro splicing assay, the results 
of which are presented in Chapter 4. No aberrant splicing was demonstrated and this base 
change is likely to be a novel SNP. 
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TABLE 3.2 CLINICAL CHARACTERISTICS AND GENETIC DEFECTS OF THE GHI 
POPULATION. 
Patients with 
a genetic diagnosis 
Patients without 
a genetic diagnosis 
Patient Sex Age Ht SDS Pubertal Gene Mutation 
(yrs) stage 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
19 
20 
M 15.9 -4.86 
F 8. 1 -6.78 
F 9.0 -9.28 
F 18.2 -5.55 
M 11.6 -8.57 
F 7.2 -8.45 
F 5.6 -9.00 
M 13.5 -7.55 
F 3.7 -7. 15 
F 11.5 -7.88 
F 8.3 -8. 10 
F 7.9 -8.78 
M 6.2 -6.13 
M 7.2 -8.91 
F 16.9 
M 13.7 
M 2.4 
-6.89 
-9.36 
-7.68 
M 14.3 -8.36 
F 0.7 < -4.00 
M 9.1 -4.06 
21 M 5.1 -5.04 
22 F 2.0 -6.72 
23 F 6.4 -6.00 
24 M 21.0 -5.00 
25 M 6.0 -3.40 
26 M 11.0 -4.60 
27 F 7.0 -3.30 
28 F 13.0 -3.50 
29 F 8.0 -5.97 
30 F 7.0 -4.98 
31 M 8.4 -8.74 
32 F 2.2 -4.46 
33 M 5.8 -7.66 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
M 1.5 
M 10.4 
F 12.4 
F 7.2 
F 12.0 
-6.00 
-7.13 
-4.57 
-7.11 
-4.30 
F 4.0 -5.58 
F 2.2 -5.8 1 
M 13.4 -3.20 
M 10.6 
M 12.9 
M 11.9 
-2.82 
-2.45 
-2.66 
45 M 1.8 -6.93 
46 M 0.5 -4.92 
47 M 3.8 -7.82 
48 F 9.7 -5.44 
49 
50 
51 
52 
53 
F n.a. < -4 .00 
F n.a. < -4.00 
M n.a. < -4.00 
M n.a. < -4.00 
M n.a. < -4.00 
IV 
IV 
I 
IV 
I 
V 
I 
II 
IV 
I 
I 
II 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
GHR 
STAT5b 
STAT5b 
IGFALS 
rvS2 ds+l G to A 
IVS2 ds+1 G to A 
S40L 
S40L 
S40L 
S40L 
S40L 
S40L 
S40L 
R43X 
R43X 
R43X 
R43X 
R43X 
R43X 
R43X 
C48X 
C48X 
Q65X 
V125A 
VI25A 
RI61C 
IVS6 ds+ 1 G to A 
IVS6 ds+ 792 A to G 
IVS6 ds+792 A to G 
IVS6 ds+792 A to G 
IVS6 ds+ 792 A to G 
IVS6 ds+792 A to G 
IVS6 ds+792 A to G 
IVS6 ds+792 A to G 
Q216X 
G223G 
L229P 
rvS7 as-6 T to A 
IVS8 ds- l G to C 
IVS8 ds-l G to C 
IVS8 ds-I G to C 
IVS9 ds+2 T to C 
G del at 1680 
G del at 1680 
P73L 
IG F ALS L134Q and A ins at 546 
IGFALS D440N 
IGFALS T ins at 1490 
GHR 
n.k. 
n.k. 
n.k. 
n.k. 
n.k. 
n.k. 
n.k. 
n.k. 
G223G 
n.a. 
n.a . 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
Homozygosity 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
no 
yes 
yes 
yes 
no 
yes 
yes 
no 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
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3.5.3 Identification and characterisation of novel GHR defects 
Five of the 15 defects identified in the GHR of these GHI patients were novel. 
Their characterisation, as well as the clinical details of the patients in whom these defects 
were identified, are presented below. 
3.5.3.1 Mutation C48X 
This mutation was identified in 2 Argentinean brothers of 2 and 14 years with 
severe GHI, from a consanguineous marriage (patients 17 and 18, Table 3.2). They 
presented with short stature (-7.68 and -8.36 SDS for age and sex, respectively) and 
typical Laron facial features. They both had low IGF-I levels [undetectable (normal range 
per age and sex 20-158ng/ml) and 9ng/ml (n.r. l09-1471ng/ml), respectively], low 
IGFBP-3 levels [O.4mg/l (n.r. 1.2-3.7mg/l) and O.6mg/l (n.r. 1.3-9.7 mg/ml), respectively] 
and undetectable ALS levels. GHBP levels were also undetectable. Sequencing of the 
GHR gene revealed the presence of a homozygous base change from C to A in exon 4 at 
position 197, in both patients (Figure 3.4). 
s * H S C H 
-- ----
TCATGACAC TCATGCCAC 
! ! 
II. , 
'\ ·\ t \ 
Patient Control 
Figure 3.4 Chromatograms showing partial DNA and amino acid sequences from patients 
with the GHR C48X mutation and a normal control. The position of the C to A base change is 
indicated by the arrow. The stop codon is depicted with an asterisk. 
This mutation leads to the creation of a premature stop codon at residue 48 (C48X). 
The resulting GHR protein is truncated prematurely and lacks most of the extracellular, 
transmembrane and intracellular domains. 
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3.5.3.2 Mutation Q216X 
This mutation was identified in a Turkish 8-year-old patient with severe GHI from 
a consanguineous marriage (Patient 31 in Table 3.2). He presented with short stature (-
8.74 SDS for age and sex) and typical Laron facial features . He had low IGF-I levels 
[5.1ng/ml (n.r. 77-374ng/rnl)], low IGFBP-3 levels [O.3mg/1 (n.r. 2.3-5.1ng/rnl)] and 
undetectable ALS levels (n.r. 24.1 -11.1mgll). GHBP levels were undetectable. 
Sequencing of the GHR gene demonstrated a homozygous base change from C to T in 
exon 7 at position 699 (Figure 3.5). 
K * R K E R 
AAACAACGA 
! ! 
IN 
f 
I . j 
Patient Control 
Figure 3.5 Chromatograms showing partial DNA and amino acid sequences for the patient 
with the GHR Q216X mutation and a normal control. The position of the C to T base change 
is indicated by the arrow. The stop codon is depicted with an asterisk. 
This mutation, like the previous one, creates a premature stop codon at residue 216 
(Q216X) leading to a prematurely truncated GHR protein, which lacks the last 48 
residues of the extracellular domain and all of the transmembrane and intracellular 
domains. 
3.5.3.3 Mutation L229P 
This mutation was identified in 5.8-year-old Pakistani patient with severe GHI 
(patient 33, Table 3.2), who was the product of a consanguineous marriage. He presented 
with severe short stature (-7.66 SDS for age and sex) and typical Laron facial features. 
He had undetectable IGF-I levels (n.r. 37-257ng/ml), low IGFBP-3 levels [O.2mg/l (n.r. 
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1.8-3.9ng/ml)] and low ALS levels [0.3mg/l (n.r. 8.8-21.1mg/l)] GHBP levels were 
undetectable. Sequencing of the GHR gene revealed the presence of a homozygous base 
change from T to C in exon 7 at position 739 (Figure 3.6). 
v P Y V L Y 
GTGCCCTAT GTGCTCTAT 
~ ~ 
Patient Control 
Figure 3.6 Chromatograms showing partial DNA and amino acid sequences for the patient 
with the GHR L229P mutation and a normal control. The position of the T to C base change 
is indicated by the arrow. 
This base change results in a leucine to proline change at residue 229 (L229P). 
Leucine and proline have similar properties (they are neutral, non-polar amino acids), but 
different chemical structures. Leucine has a hydrophobic aliphatic side chain, which 
favours formation of c.:.-helices, whereas proline has a cyclic structure that does not. 
Because of these chemical differences, a leucine to proline substitution is likely to induce 
a change in the GHR protein structure leading to a non-functional receptor. 
3.5.3.4 Mutation IVS7 as-6 T to A 
This mutation was identified in a 1.5-year-old patient with severe GHI from a 
consanguineous marriage (Patient 34 in Table 3.2). He presented with severe short stature 
(-6.00 SDS for age and sex) and typical Laron facial features. He had low IGF-I levels 
[4ng/ml (n.r. 8-141ng/rnl)] and low IGFBP-3 levels [0.35mg/l (n.r. 1.1 -3.8mg/rnl)]. 
Sequencing of the GHR gene revealed the presence of homozygous T to A base 
change at the acceptor splice site of intron 7, position - 6. In both parents, the same 
mutation was present in heterozygosity (Figure 3.7). 
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IVS7 IEx8 IVS7 lEx8 IVS7 IEx8 
GTGATTCAGATTT GTG TTCAGATTT GTGTTTCAGATTT 
! ! ! 
'I 
t\ '\ i\ '! I 
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, /' I I , , 
/\ 'II I \ I ,. 
II 
\ I \ : I 
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Patient Parents Control 
Figure 3.7 GHR polypyrimidine tract mutation IVS7 as-6 T to A. Chromatograms showing 
partial DNA sequences for the patient, his parents and the normal control are presented. The 
position of the mutation i;; indicated by the arrows. 
This base change is localised in the polypyrimidine tract of intron 7 and is thought 
to alter the correct splicing of the GHR pre-mRNA. Its deleterious effect was studied and 
confirmed in vitro and results are presented in Chapter 4 of this Thesis. 
3.5.3.5 Mutation IVS9 ds+2 T to C 
This mutation was identified in heterozygosity in a 12-year-old Spanish patient 
from non-consanguineous marriage (patient 38, Table 3.2). She presented with short 
stature (-4.30 SDS for age and sex) and normal facial features. She had low IGF-I levels 
[43ng/ml (n.r. 126-1188ng/ml)], low IGFBP-3 levels [0.87mg/l (n.r. 2.0-9.3ng/ml)] and 
low ALS levels [7.4mg/l (n.r. 14-29mg/l)]. GHBP levels were extremely high [35634 
pmolll (normal adult range 534-5785pmolll)]. 
Sequencing of the GHR revealed the presence of a T to C base change, on one 
allele, at the donor splice site of intron 9, position +2. No other mutations were detected 
in the GHR exons and their flanking introns. Further investigation revealed the presence 
of short stature in another two family members, namely the patient's mother and maternal 
grandfather. Sequencing of the GHR revealed the presence of the same single 
heterozygous mutation, identified in the patient, in both family members (Figure 3.8). 
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Ex9 IVS9 Ex9 I IVS9 Ex9 I IVS9 
TCAAGG AACTAA TCAAGG AACTAA TCAAGGTAACTAA 
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Figure 3.8 GHR mutation IVS9 ds+2 T to C. Chromatograms showing partial sequences from 
the patient, her mother and a normal control. The position of the mutation is indicated by the 
arrow. 
This mutation abolishes the donor splice site of exon 9 and is likely to cause its 
skipping. RNA was extracted from peripheral leukocytes from the patient and a normal 
control and eDNA was synthesised. A first round of RT-PCR was performed using 
primers from exon 2 (primer 2FiGHRm, sequence reported in Appendix 3) to exon 10 
(6RGHRm) and from ex on 6 (6FGHRm) to exon 10 (lOR3GHRm). These products were 
heminested using primers from ex on 2 (2FfGHRm) to 6 (9RGHRm) and from exon 6 
(6FGHRm) to 10 (6RGHRm) or from exon 8 (8FGHRm) to 10 (lOR3GHRm), 
respectively. Results are shown in Figure 3.9. 
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Figure 3.9 RT-PCR products from patient with the GHR IVS9 ds+2 T to C mutation. Panel 
A: RT-PCR products using primers from exon 6 to 10. The expected product size is 474 bp. Panel 
B: RT-PCR products using primers from exon 8 to 10. The expected product size is 187 bp. Panel 
C: a larger sample (20/-lI) of the RT-PCR product presented in panel B better demonstrates the 
presence of two products (187 bp and 117 bp). Panel D, RT -PCR products using primers from 
exon 2 to 6. Expected product size (452 bp). C, normal control; Pt, patient; N, negative control. 
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cDNA amplification using primers from exon 2 to 6 resulted in a product of the 
expected size from both patient and normal control. The heminested RT-PCR product 
using primers from exon 6 to 10 produced a band of the expected size (474 bp) from the 
normal control and a single smaller band (404 bp) from the patient, consistent with the 
skipping of exon 9 (70bp). Since no product from the patient's normal allele was 
detected, a different set of primers (from exon 8 to 10), which produce a shorter product, 
was used. cDNA amplification produced a band of the expected size (187 bp) alongside a 
smaller band of 117 bp. A single band of the expected size (187 bp) was obtained from 
the normal control. All RT-PCR products were gel extracted and sequenced, 
demonstrating the absence of ex on 9 in the bands of 404 bp and 117 bp, with exon 8 
splicing into exon 10 (Figure 3.10). 
Patient TTATTATCTT TGGAATATTT GGGCTAACAG TGATGCTATT TGTATTCTTA 
Control TTATTATCTT TGGAATATTT GGGCTAACAG TGATGCTATT TGTATTCTTA 
Patient TTTTCTAAAC AGCAAAG----- --.----------------- --------.---------- -------------------
Control TTTTCTAAAC AGCAAAGGAT TAAAATGCTG ATTCTGCCCC CAGTTCCAGT 
Patient -.---------------- --------------------- -----.------------- --------------GAA GGAAAATTAG 
Control TCCAAAGA TT AAAGGAATCG ATCCAGA TCT CCTCAAGGAA GGAAAA TT AG 
Patient AGGAGGTGAA CACAATCTTA GCCA TTCATG ATAGCT A T AA ACCCGAA TTC 
Control AGGAGGTGAA CACAATCTTA GCCATTCATG ATAGCTATAA ACCCGAATTC 
Figure 3.10 Partial cDNA sequences from the patient GHR IVS9 ds+2 T to C mutation and 
a control showing the skipping of exon 9. 
Wt GHR mRNA I Exon 7 I Exon 8 I Exon 9 I Exon 10 I 
GHR Genomic DNA Exon 7 8 Exon 8 8:tiS Exon 10 I 
MutGHRmRNA Exon 7 Exon 8 I Exon 10 I 
Exon 8 Exon 9 
,'I ~~-------------
WtGHR ITA TITTCT AAA CAG CAAAGGAIT AAAATGCTG AIT CTG 
Leu Phe Ser Lys Gin Gin Arg IJe Lys Met Leu IJe Leu 
Exon 8 Exon 10 -----------------.IJ.-~~-----------
MutGHR ITA ITTTCT AAA CAG CAAAGGAAG GAA AAT TAG AGG AGG 
Leu Phe Ser Lys Gin Gin Arg Lys Glu Asn End --- ---
Figure 3.11 The GHR IVS9 ds+2 T to C mutation. On the left, normal and aberrant splicing is 
indicated. Mutation position is indicated by the asterisk. On the right, wild type (Wt GHR) and 
mutant (Mut GHR) GHR DNA sequences and translated products are shown. The splice junctions 
between exons are also indicated. 
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Skipping of exon 9 results in a frame shift, the appearance of three new amino acids 
and a premature stop codon (Figure 3.11). The resulting GHR protein is truncated 
prematurely and lacks 98% of the intracellular domain. 
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3.5.3.6 The Turkish cohort 
Twenty one GHI patients in this study were from Turkey. One (patient 31, Table 
3.2) was homozygous for the novel GHR Q216X mutation already described and one 
(patient 43, Table 3.2) for a novellGFALS defect, presented later in this Chapter. In three 
patients with undetectable GHBP levels (patients 46-48, Table 3.2), no GHR mutation 
has yet been found. 
The remaining 16 GHI patients were homozygous for one of the following 
deleterious mutations: R43X (7 patients), S40L (7 patients) or IVS2 ds+ 1 G to A (2 
patients). All mutations have already been reported as causes of GHI (Amselem et a!., 
1991, Sobrier et al., 1997). Patients presented with severe short stature (ranging from -
5.50 SDS to -9.30 SDS for age and sex) and typical Laron facial features. Biochemically, 
they all had high basal GH levels and low IGF-I, IGFBP-3 and ALS levels. GHBP levels 
were undetectable in all patients. Unfortunately, no data on the geographic location or the 
presence of a relationship among these patients, were available. In an attempt to identify 
a founder effect, microsatellite markers spanning 17Mb around the GHR locus, were used 
and the polymorphic site in GHR intron 9 was studied. Analysis of GHR intron 9 showed 
the presence of frame I in patients with mutations S40L and R43X (14 subjects) and of 
frame II in patients with the IVS2 mutation (2 subjects). Results for microsatellite marker 
analysis showed the same haplotype in 6 out of 7 patients with the R43X mutation, being 
identical 5.6Mb upstream of the GHR. The remaining patient shared 1Mb homology 
upstream the GHR locus with the other 6 patients. In the S40L group, all 7 patients were 
identical 12.5Mb downstream of the GHR locus. The same was true for the 2 patients 
with the IVS2 mutation, but for a different genotype (figure 3.12). These data suggest the 
presence of a common ancestor for patients with the same mutation. 
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Figure 3.12 Genotype analysis of the Turkish cohort. The genotypes of patients with mutation 
S40L (panel A), R43X (panel B) and IVS2 ds+ 1 G to A (panel C) are indicated. M, marker. 
Numbers indicate the length(s) of the PCR amplification products from each microsatellite 
markerPCR. 
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3.5.4 Identification and characterisation of a novel STAT5b defect 
Two sisters (patients 39 and 40 in Table 3.2) from a consanguineous family from 
Kuwait, were among the GHI patients with normal GHBP levels and no mutations in the 
GHR coding exons. Analysis of GHR common SNPs in these two patients and their 
parents revealed the presence of different haplotypes in the two siblings, thus excluding a 
defective GHR as the cause of GHI 
Both sisters had facial features resembling those of classical Laron syndrome 
(Figure 3.13) and severe GHI (Table 3.3). Patient A was 3.9-year-old, her height was -
5.58 SDS and she had juvenile idiopathic arthritis. Patient B was 2. 19-year-old, her 
height was -5.81 SDS and she suffered from recurrent pulmonary infections. Both 
parents were of normal stature. The presence of a defective STAT5b was hypothesised. 
The DNA samples of the two children were analysed in collaboration with the 
Department of Paediatrics, Oregon Health and Sciences University, Portland, Oregon, 
US, revealing the presence of a novel homozygous Guanine deletion at the junction exon 
l3-intron l3 (l680de1G) of STAT5b. This mutation is likely to cause a frameshift and a 
premature stop codon 16 amino acids downstream. 
TABLE 3.3 CLINICAL CHARACTERISTICS OF THE TWO CHILDREN WITH STAT5B 
DEFECTS. 
Patient Sex Pubertal Age Height IGF-I IGFBP-3 ALS 
stage SDS ng/ml mg/L mg/L 
A F I 3.99 -5.58 und 0.7 0.4 
n.r. 20-170 1.2-4.1 9.7-21.8 
B F I 2.19 -5.81 und 0.8 0.8 
n.r. 20-158 1.2-3.7 8.0-19.5 
und = undetectable levels. n.r., normal ranges for age and sex. 
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Figure 3.13 Front and side views of two sisters with STAT5B defect. Top: patient A, bottom 
patient B. 
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3.5.5 Identification and characterisation of novel IGFALS defects 
Four GHI children had no mutations in the GHR coding exons and their GHBP 
levels were within the normal range. They belonged to four unrelated families of different 
ethnic origin. Their height SDS ranged from -2.45 to -3.20 SDS and all had normal facial 
features. Biochemically, they all had severe GHI, as demonstrated by the low levels of 
GH -dependent proteins. 
Sequencing of the IGFALS identified 5 novel defects which are presented in Figure 
3.14. 
ALS 
protein 
v P G v L G 
Control Patient 
Signal peptide 
~
N term 
Q L R 
L D L L N L ALP A F A 
CTCAACCTG GCA TTGCCC GCA TTTGCC 
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Control Patient Control Patient 
D440N T ins at 1490 
LCR domain 
C term 
Q LlQ R S L A S LlL A1G 
CAGCNGCGC AGCCTGGCG 
l .. 
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Figure 3.14 ALS protein structure and location of the novel IGFALS defects. 
Chromatograms showing partial DNA sequences from patients and normal control are also 
presented. The position of the base changes is indicated by the arrows. LCR, leucine-rich repeat 
domain. 
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3.5.5.1 Homozygous defect P73L 
Patient A (patient 41, Table 3.2) was a 13.4-year-old boy. At the time of evaluation, 
his height was -3.20 SDS. His medical history and physical examination were otherwise 
unremarkable. His bone age was 12.5 years and he was pubertal stage II. His hormonal 
profile is presented in Table 3.4. His father and mother were consanguineous and had 
mild short stature (height SDS -1.10 and -2.20 SDS, respectively). 
Sequencing analysis revealed the presence of a homozygous base change from C to 
T at position 218 resulting in a missense mutation with proline to leucine substitution 
(P73L) (Figure 3.14). Size exclusion chromatography did not detect the peaks 
corresponding to the ternary and binary complexes (Figure 3.15). The P73L mutation is 
localised in the leucine-rich repeat domain. Because of the different chemical properties 
of these two amino acids, the proline to leucine change is predicted to alter the secondary 
structure of the ALS protein. 
3.5.5.2 Compound heterozygous defects L134Q and A insertion at 546 
Patient B (patient 42, Table 3.2) was a 10.6 year-old boy. At the time of evaluation 
his height was -2.82 SDS, whereas the rest of his medical history and physical 
examination were unremarkable. He was pubertal stage I and had a bone age of 6.5 years. 
His hormonal profile is presented in Table 3.4. His mother and father were non-
consanguineous and had mild short stature (-1.98 and -1.67 SDS, respectively). 
Sequencing analysis revealed the presence of a heterozygous base change from T to 
A at position 401 causing a leucine to glutamine substitution (L134Q) and a heterozygous 
insertion of an adenine at position 546 (Figure 3.14). No peaks corresponding to the 
ternary and binary complexes were detected by means of size exclusion chromatography 
(Figure 3.15). The L 134Q mutation is localised in the leucine-rich repeat domain and is 
likely to cause a change in the secondary structure of the ALS protein, whereas the A 
insertion at 546 causes a frameshift and the appearance of a premature stop codon. 
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Figure 3.15 Results of size exclusion chromatography for two patients with IGFALS 
defects. Peaks corresponding to ternary complex IGF-I/IGFBP-3/ALS (150kDa), binary complex 
IGF-I/IGFBP-3 (50-40 kDa) and IGF-I (7.5 kDa) are indicated by the arrows. 
3.5.5.3 Homozygous defect D440N 
Patient C (Patient 43 in Table 3.2) was a 12.9 year-old boy of Turkish origin. At the 
time of evaluation his height was -2.45 SDS, whereas the rest of his medical history and 
physical examination were unremarkable. His bone age was 10.0 years and he was 
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pubertal stage 1. His hormonal profile is presented in Table 3.4. His mother and father 
were consanguineous and had mild short stature (-2.80 and -2.00 SDS, respectively). 
Sequencing analysis revealed the presence of a homozygous base change from G to 
A at position 1318 causing an Aspartic acid to Asparagine substitution (D440N) (Figure 
3.14). This amino acid change lies within the leucine-rich repeat domain. Since the ALS 
structure has not yet been resolved, it is difficult to predict the consequence of this 
mutation at protein level. Nevertheless, the presence of an asparagine is predicted to 
create a novel N-glycosylation site in the ALS protein. 
3.5.5.4 Homozygous T insertion at position 1490 
Patient D (patient 44, Table 3.2) was a 11.9 year-old boy of Kurdish origin. At the 
time of evaluation his height was -2.66 SDS. His bone age was 9.6 years at 10.5 years of 
chronological age and he was pubertal stage 1. His hormonal profile is presented in Table 
3.4. His mother and father were consanguineous and had mild short stature (-3.4 and -2.3 
SDS, respectively). 
Sequencing analysis revealed the presence of a homozygous T insertion at position 
1490 (Figure 3.14). This mutation is predicted to cause a frame shift and the appearance 
of a premature stop codon. 
TABLE 3.4 CLINICAL CHARACTERISTICS OF THE 4 PATIENTS WITH IGFALS DEFECTS. 
Patient Sex Pubertal Age Height GH levels O.lU/ml) IGF-I level IGFBP-3 level ALS level 
stage SDS after provocation test ng/ml (SDS) ng/ml (SDS) mg/L 
A M II 13.4 -3.2 185 40 (-3.06) 400 (-9.51) und 
B M 10.6 -2.82 115 33 (-2.20) 200 (-9.59) und 
C M 12.9 -2.45 159 28 (-3.32) 200 (-11.20) und 
D M 11.9 -2.66 118 48 (-1.38) 900 (-5.31) und 
und, undetectable; SDS, standard deviation score. 
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3.5.6 Predictors of genomic defects in primary GHI 
Data from the GHI population analysed in this study were pooled with data from 
another large genetically heterogeneous population reported in the European Pharmacia 
and Upjohn treatment study group published by Woods et al in 1997 (Woods et aI., 
1997)] and data from two studies on GHR dominant negative mutations: G to C at IVS8 
as-l and G to A at IVS9 ds+ 1 (Ayling et aI., 1997, Iida et aI., 1998). GHR defects were 
divided into missense, nonsense, splice mutations, mutations with a dominant negative 
effect and the pseudoexon 6\{! mutation. Because of its peculiarity, the latter was 
considered separately from the other splice mutations. As all data belonged to patients 
with homozygous GHR defects, data from the compound heterozygote (V144DIR43X) 
patient reported by Woods et aI. were excluded from the analysis. 
Data on a total of 74 GHI subjects were analysed. GHI patients with dominant 
negative GHR mutations were significantly (P<O.05) taller than patients with GHI caused 
by GHR splice, nonsense and missense mutations. Moreover, patients with GHI caused 
by the pseudoexon 6\{! mutation were significantly (P<O.05) taller than patients with GHI 
caused by nonsense and missense GHR mutations (Figure 3.16, on the left on panel A). 
IGF-I levels were available for 45 patients. Patients with GHI caused by missense 
mutations had significantly (P<O.05) lower IGF-I SDS values compared to patients with 
GHI caused by pseudoexon 6\{!, splice and dominant negative mutations. Moreover, 
patients with GHI caused by the pseudoexon 6\{! mutation had significantly (P<O.05) 
higher IGF-I SDS values than patients with GHI caused by nonsense and missense GHR 
mutations (Figure 3.16, on the right in panel A). 
Patients with GHI caused by IGFALS defects were compared to patients with GHI 
caused by GHR mutations. Patients with GHI due to ALS deficiency were significantly 
(P<O.05) taller than patients with GHI caused by splice, nonsense and missense mutations 
(Figure 3.16, on the left in panel B). Moreover, they had significantly (P<O.05) higher 
IGF-I SDS values compared to patients with GHI caused by GHR nonsense and missense 
mutations (Figure 3.16, on the right in panel B). 
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Figure 3.16 Predictors of genomic defects in primary GHI. Panel A: box plots for height and 
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(on the right) for the 6 groups are also presented. 
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3.6 DISCUSSION 
The population studied in this thesis represents one of the largest series of 
ethnically heterogeneous patients with GHI. Genetic characterisation identified several 
novel defects in the GHR and in other genes of the GH-IGFI axis, namely STAT5b and 
IGFALS. Analysis of the clinical data of the four patients with IGFALS defects, 
representing four of out of the 9 families known worldwide with ALS deficiency, allowed 
a better understanding of the novel emerging GHI phenotype associated with IGFALS 
defects. Moreover, the analysis of the genetic and clinical data of the entire GHI cohort, 
in combination with published data on additional GHI patients, allowed establishment of 
a relationship between GHI severity and the causative genetic defect, as well as between 
GHI severity and GHR type of mutation. 
n. of patients with genetic defects 
total n. of mutations identified 
n. of novel mutation identified 
GHR defects and GHI 
GHR STAT5b IGFALS 
38 
15 
5 
2 
1 
1 
4 
5 
5 
Growth failure in the presence of IGF-I deficiency and normal or high GH levels 
can be due either to the presence of a defective GH (Besson et aI., 2005) or to the 
inability of cells to respond to GH (Kofoed et aI., 2003, David et aI., 2005). Failure to 
generate IGF-I in response to exogenous GH administration, points to the latter as the 
pathogenetic mechanism responsible for primary GHI. GH exerts its biological actions 
through binding to its receptor and any mutation leading to absence or a non-functional 
GHR, result in GHI. GHR mutations represent the most common cause of primary GHI 
and were present in 72% of GHI patients in this study. Five GHR defects were novel, 
including the first mutation in this gene to be identified in a polypyrimidine tract (see 
Chapter 4). A novel dominant negative mutation in the GHR intracellular region was also 
identified, possibly sharing the same pathogenetic mechanism to the other heterozygous 
mutations reported by Ayling and Iida (Ayling et aI., 1997, Iida et aI., 1998, Iida et aI., 
1999). 
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As expected, most of the GHR defects identified in this study were in the exons 
coding for the extracellular domain and resulted in the classical Laron phenotype, 
whereas defects in exons coding for the intracellular domain were rare and associated 
with non-classical GHI. 
A wide phenotypic variability was found among subjects with different GHR 
defects, as demonstrated by the wide range of height SDS within patients with different 
mutations, as well as within patients with the same mutation. This finding supports the 
important role of environmental and individual genetic factors in determining height 
(Rosenbloom et aI., 1994b). Nevertheless, when data from the cohort of patients analysed 
in this thesis were pooled with data from previously reported cases, a clear genotype-
phenotype relationship was found between the severity of GHI type and the type of GHR 
defect. Patients with dominant negative mutations and the pseudoexon 6\f' mutation had a 
significantly less severe phenotype compared to GHI subjects with nonsense, missense 
and splice mutations. The milder phenotype in subjects with dominant negative mutations 
could be explained by the three possible combinations of GHR dimerisation which can 
occur in these patients. A similar scenario can be hypothesised in subjects with the 
pseudoexon mutation 6\f'. Although the pseudoexon defect causes GHI in homozygosity, 
the presence of the wild type GHR transcript has been documented in these patients 
(Metherell et aI., 2001). For yet unknown reasons, a splice mutation may not always be 
100% efficient in causing aberrant splicing and coexistence of normal and mutant 
transcripts may occur. Therefore, in patients with the pseudoexon mutation 6\f' the wt/wt 
GHR dimer can be present alongside the non-functional wt/mt heterodimer and the non-
functional mt/mt homodimer. 
The presence of different ratios of mutant to wild type receptor can also explain the 
occurrence of different phenotypes within patients with the same splice mutation. 
Although all the dominant negative defects identified in the GHR have the same effect at 
the protein level - the same prematurely truncated protein - they generate different 
phenotypes. While the patient reported in this study and her affected family member, as 
well as the proband and mother reported by Ayling et aI., had normal facial features 
(Ayling et aI., 1997), the three GHI subjects reported by lida et al. had classical Laron 
facial features (midfacial hypoplasia and prominent forehead) (lida et a!., 1998). 
Different phenotypes are known to occur when the genetic defect causes aberrant splicing 
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(Zhu et aI., 1997, Lemahieu et aI., 1999). This phenomenon has been described among 
the Ecuadorian GHI subjects with the E180 splice mutation (Rosenbloom and Guevara-
Aguirre, 1998, Rosenbloom et aI., 1999) but perhaps it has its maximum expression in 
GHI patients with the GHR pseudoexon 6'¥ mutations, as described in Chapter 5. 
STAT5b and IGFALS defects and GHI 
At the time this study started, only one case of GHI due to a STAT5b defect 
(Kofoed et aI., 2003) and one case ofGHI due to aIGFALS defect (Domene et aI., 2004) 
had been reported. The genetic analysis presented in this study allowed the identification 
of the second case of GHI due to a STAT5b defect. The analysis of genetic and clinical 
data from two GHI siblings with no mutations in the GHR and normal GHBP levels, led 
. us to hypothesise a STAT5b defect, which was identified and reported in 2005 (Hwa et 
aI., 2005), thanks to the collaboration with the group led by Dr Rosenfeld at the Oregon 
Health and Science University. 
The description of the first case of short stature in a child with inactivation of the 
IGFALS (Domene et aI., 2004) prompted us to consider the role of this protein in the 
genesis of GHI in four children with normal GHBP levels, mild growth failure and no 
defect in the GHR coding region. Five novel IGF ALS defects in four unrelated patients 
were thus identified. Disappointingly, two of these patients were simultaneously studied 
elsewhere and their genetic analysis published independently from our results (Hwa et aI., 
2006, van Duyvenvoorde et aI., 2008). Nevertheless, the four patients reported in this 
study represent the largest series of unrelated patients with IGF ALS defects and analysis 
of their clinical data allowed observations on the novel emerging GHI phenotype 
associated with an inactive ALS protein. 
All novel IGF ALS mutations identified in this study resulted in undetectable ALS 
serum levels. Their deleterious effect was demonstrated either by western immunoblot 
analysis from other groups (Hwa et aI., 2006, van Duyvenvoorde et aI., 2008) or by size 
exclusion chromatography in this study. No ternary complex formation was, in fact, 
demonstrated from the serum samples of two ALS deficient patients. Moreover, in these 
patients, serum samples did not support the formation of the binary complex either. This 
is in discordance with what was previously shown for other IGFALS defects (Domene et 
aI., 2004), but not surprising considering the practically null serum IGFBP-3 levels. 
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Circulating IGFBP-3 and IGF-I have a short half life when free or bound together in the 
relatively unstable binary complex IGF-I/ IGFBP-3. Binding to the ALS protein stabilises 
the complex increasing their half lives (GuIer et aI., 1989). 
ALS deficiency due to inactivating IGFALS mutations resulted in a phenotype 
resembling growth hormone resistance. All patients in this study, as well as those 
reported in the literature (Domene et aI., 2004, Domene et aI., 2007, Heath et aI., 2008) 
had normal or high GH levels, almost undetectable GH dependent proteins and no 
response to IGF-I generation test. Nevertheless, GHI patients with IGFALS defects had a 
milder phenotype, similar, in height SDS and IGF-I levels to that caused by GHR 
pseudoexon 6'P and dominant negative mutations and significantly less severe compared 
to that caused by GHR missense, nonsense or splice mutations. Interestingly, parents of 
ALS deficient patients, obligate single heterozygous carriers of the mutations, also had 
short stature, but to a lesser degree than their homozygous children. This suggests that 
single heterozygous IGFALS defects might be sufficient to affect final height. 
An increased GH response to stimulation test was present in the four cases reported 
in this study, as well as in almost all reported cases. Patients with ALS deficiency have 
been shown to have a reduction in total as well as free circulating IGF-I (Hwa et aI., 
2006). It is widely accepted that free IGF-I is biologically active and its reduction, even 
minimal, may be sufficient to trigger an increased GH release from the pituitary and 
affect metabolism at tissue level. Moreover, the increased IGF-I clearance associated 
with ALS deficiency might explain the absence or mild response to rhGH observed in 
these patients (Domene et aI., 2004). 
Delayed puberty has been postulated to be part of the ALS deficiency phenotype 
(Domene et aI., 2004, Domene et aI., 2007). Three out of four patients were prepubertal 
at the time of this study. Nevertheless, a normal puberty was present in the one post-
pubertal child in this series and was documented in another patient by a follow-up study 
(Hwa et aI., 2006). This finding suggests that delayed puberty may be due to the 
individual genetic background rather than to IGFALS defects. It is possible, however, that 
ALS deficiency results in a profound alteration in IGF-I availability, with consequences 
at central and local level, which could influence normal pubertal development in 
individuals with a predisposing genetic background. 
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All subjects with IGFALS defects were male, and the same is true for the majority 
of reported cases. This observation is, at the moment, difficult to explain. However, it is 
possible that, for social reasons, the presence of short stature attracts more attention when 
the subject is a boy rather then a girl. 
Limitation and future work 
In 9 out of 53 patients, no mutations responsible for GHI have been identified yet. 
The presence of low or undetectable GHBP levels suggests that the defect lies within the 
GHR. Since no defects were found in its coding region, it is possible that a novel intronic 
or promoter GHR defect may be the cause of GHI in these patients. In six cases, analysis 
of cDNA extracted from leucocytes resulted in no GHR products. Since this could be due 
to the presence of a low amount of GHR mRNA in these cells, mRNA extraction from 
fibroblasts is part of future work. 
The use of the Student's t-test (or non-parametric equivalent, such as Wilcoxon 
rank sum test) for the establishment of a genotype-phenotype relationship may be 
inappropriate in a population of partially related subjects, as it does not account for 
familial clustering. However, because of the severe phenotype, affected members of the 
same family are often referred together, making identification of a single index case 
arbitrary. Moreover, since consanguinity plays a fundamental role in the propagation of 
GHI, even if one index case per family could be identified, index cases with the same 
mutation, would likely be related, albeit belonging to different families. Furthermore, 
exclusion of affected family members would result in loss of information in an already 
small population. As GHI is a very rare disorder, application of multilevel analysis would 
be grossly inefficient. 
118 
Chapter 4 An in vitro splicing assay to study GHR splice mutations 
CHAPTER 4 
AN IN VITRO SPLICING ASSAY TO STUDY GHR SPLICE 
MUTATIONS 
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4.1 BACKGROUND 
Approximately 20% of GHR defects resulting in GHI are splice mutations (David 
et aI., 2005). Aberrant mRNA splicing is a common cause of genetic diseases with almost 
1 in 2 disease-causing nucleotide changes disrupting a splicing element. Advances in 
splicing physiology have, in fact, led to reconsideration of nucleotide changes 
conventionally classified as harmless SNPs or missense/nonsense defects as potential 
mutations causing aberrant splicing, (Wang and Burge, 2008). The lack of a 
comprehensive understanding of the splicing regulatory elements, in combination with 
the complexity of the splicing process, makes it difficult to predict the consequences of a 
nucleotide change on mRNA splicing by using in silica prediction programs. These 
programs are fairly reliable when used to predict the effects of nucleotide changes 
occurring at the invariant donor and acceptor dinucleotide sequences, but become less 
efficient as nucleotide changes occur further away from the consensus splice site or in 
different splicing elements, such as the polypyrimidine tract (Thanaraj and Clark, 2001). 
In these cases, analysis of RNA extracted from patients' leucocytes or fibroblasts 
becomes mandatory for establishing the diagnosis. This, however, requires either blood 
sampling or a skin biopsy. Both techniques are invasive and may be difficult to perform 
in infants and children, particularly those with reduced body size, such as GHI patients. 
Analysis of RNA extracted from mammalian cells transfected with minigenes containing 
the mutation of interest has been used as an alternative to the analysis of patient mRNA 
(Cooper, 2005). 
The in vitro splicing assay is a technique widely used to study the physiology of 
splicing and of its regulatory elements, but is not employed to study the consequences of 
naturally occurring mutations. It is based on the use of minigenes in a splicing reaction 
with nuclear extracts from cells, such as the HeLa (Anderson and Moore, 1997, Jurica 
and Moore, 2002). In 2001, the in vitro splicing assay was used to study the 
consequences of a GHR intronic defect (Metherell et aI., 2001). Its results accurately 
predicted those by in vivo mRNA analysis. These findings were the the basis for this 
project. 
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4.2 ORIGINAL HYPOTHESIS AND AIMS 
The aim of this project was to establish the diagnostic value of an in vitro splicing 
assay, based on a three-exon minigene system spliced in HeLa nuclear extracts, in 
assessing the consequences of genetic defects on mRNA splicing. In particular, the study 
aimed to 1) establish a rapid and reliable protocol for the creation of three-exon 
minigenes; 2) analyse in silica all GHR defects detected in the GHI study population, 
including nucleotide changes conventionally considered SNPs or missense and nonsense 
mutations; 3) study in vitro all nucleotide changes predicted in silica to cause aberrant 
splicing and those occurring in splice regulatory elements, but not predicted in silica; 4) 
compare the results obtained in vitro to those obtained in silica and in vivo from patient 
mRNA analysis. 
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4.3 MATERIALS AND METHODS 
4.3.1 PCR and overlap-extension PCR 
Wild type mini genes were created usmg PCR and overlap extension PCR 
techniques. The wild type GHR exon of interest was amplified from genomic DNA and 
L1 and L2 exons from Adml-par, a well-characterised splice reporter (sequence reported 
in Appendix 10.3 .4), using a proof-reading polymerase. The three exons L1, GHRexon 
and L2, were joined together to form the wild type minigenes using the overlap extension 
PCR technique (Figure 4.1), as described in the Materials and Methods section 2.9.1. 
30 bps I 30 bps I 
~ ~ GHRX 
.. .. 
I-------l I-------l 
10 bps 10 bps 
Figure 4.1 The three-exon minigene constructs. The GHR exon of interest (GHR X) and Adml-
par exons Ll and L2 were amplified by peR using specific forward and reverse primers (depicted 
in green) of approximately 30 bases (bps) designed to have a 10 bases overlap. 
The splice reporter Adml-par (L1 -L2) was amplified by conventional PCR using 
specific primers (for exon L1: primers T7-L1 and Admlpar-int51AS; for exon L2: 
primers Admlpar-int51S and L2A; primer sequences reported in Appendix 3:10.3.4) and 
used as positive control for the splicing reaction. The PCR products were run on a 1 % 
agarose gel and those corresponding in size to the three-exon minigene, cut and purified 
by PCR gel extraction. The identity of the PCR product was confirmed by direct 
sequencing on the ABI 3700 Sequencer. 
4.3.2 A-tailing and Cloning 
Blunt-ended PCR reactions generated by Phusion polymerase (100U, Finnzymes) 
were A-tailed and cloned in the pGEM T-easy vector system (a T-vector cloning system). 
White colonies containing the insert were screened by PCR and direct sequencing. 
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4.3.3 Site-directed mutagenesis 
The mutant minigenes were obtained from the corresponding wild types by site-
directed mutagenesis as described in the Material and Methods section 2.7, using specific 
primers (sequences reported in Appendix 3: 10.3.5). 
4.3.4 In vitro transcription and RNA purification 
Wild type and mutant DNA minigenes and Adml-par were transcribed into mRNA 
in the presence of a32P_GTP (10/lCi). After 1 hour incubation at 3rC, reactions were 
mixed with RNA dye, heated at 9SoC for 5 min and then run on a 4% polyacrylamide gel 
for 45 min at 9S0 Volts. Fluorescent markers were attached on the gel that was exposed 
overnight at -SO°C and then subjected to autoradiography. The fluorescent-labelled gel 
image was used to excise the RNA bands from the gel. The RNA was extracted from the 
gel bands and stored at -20°C or used for the in vitro splicing assay. 
4.3.5 In vitro splicing assay 
5'-capped radiolabeled mRNA mlmgenes were incubated in 12.5/ll splicing 
reaction mixture with 4/l1 of HeLa nuclear extracts (CilBiotech) at 30°C for 60 minutes. 
Controlled reactions were incubated on ice for the same time. At the end of the 
incubation, reactions were deproteinised and precipitated according to the protocol 
described in the Materials and Methods section 2.9.4, mixed with RNA loading dye, 
heated at 98°C for 5 min and run on a S% denaturing polyacrylamide gel for 1 hour and 
45 min at 9S0 Volt, before autoradiography. 
All results were repeated at least three times. Magnesium concentration titration 
curves (final concentration ranging from 40 to SOmM) were also performed to optimise 
splicing conditions. 
4.3.6 RNA extraction from denaturing polyacrylamide gels and RT -peR 
The bands of interest, corresponding in size to correctly spliced or aberrant 
products, were excised from the gel and retro-transcribed into DNA as described in 
Material and Methods (section 2.S.3). This was amplified by PCR using specific primers 
and analysed by direct sequencing on the ABI 3700 DNA Sequencer. 
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4.3.7 Splicing prediction programs 
The Alex Dong Li's splice site finder (http://violin.genet.sickkids.on.ca/~ali/) was used 
to calculate the splice site score of wild type and mutant sequences. 
4.3.8 RNA extraction from blood and RT-PCR 
RNA was isolated from human blood using the P AXgene blood RNA Kit and the 
PAXgene Blood RNA Tubes (PreAnalytic) according to the manufacturer's 
recommendations. First-strand synthesis of cDNA was obtained by reverse transcription 
of RNA and amplified in a 12.5).l1 PCR reaction using specific primers (sequences 
reported in Appendix 10.3.2). To strength the specificity and sensitivity of the PCR 
technique GHR cDNA was then amplified using a heminested PCR technique. PCR 
products were electrophoresed on an agarose gel. In the presence of multiple bands for 
the same PCR product, these were cut from the gel, DNA purified from the gel and 
sequenced on the ABI 3700 Sequencer. 
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4.4 RESULTS 
4.4.1 GHR nucleotide changes 
All novel and previously identified defects and SNPs identified in the GHR during 
the course of the genetic study of the GHI population described in Chapter 3 of this 
Thesis, were analysed. Of these, nine were splice defects, seven were missense or 
nonsense defects and four SNPs (Table 4.1). The splice defects were located as follows: 
four nucleotide changes were within natural donor splice sites (G to A at IVS2 ds+ 1, G to 
A at IVS6 ds+ 1, G to C at IVS8 ds-l and T to C at IVS9 ds+ 2), two base changes 
downstream to the natural donor splice site of ex on 2 (A to C and A to G at IVS2 ds+4) 
and one upstream the acceptor splice site of intron 7, in the polypyrimidine tract (T to A 
at IVS7 as-6). Moreover, two nucleotide changes, one located deeply within intron 6 (A 
to G at pseudoexon 6'¥ ds-l) and one located deeply within exon 7 (C to T at exon 7 ds-
62, also known as G223G) were also present. Both defects are known to create novel 
splice sites resulting in aberrant splicing. 
4.4.2 In silico prediction scores 
All sixteen novel and previously described GHR defects and the four SNPs were 
analysed in silica and results are presented in Table 4.1. The four base changes occurring 
within natural splice sites (G to A at IVS2 ds+ 1, G to A at IVS6 ds+ 1, G to C at IVS8 ds-
1 and T to C at IVS9 ds+2) caused a reduction of the splice site prediction score, ranging 
from 12.15% to 30.80%, compared to the corresponding wild type. The two base changes 
occurring downstream of the donor splice site (A to C and A to G at IVS2 ds+4) and 
within the polypyrimidine tract (T to A at IVS7 as-6) caused a <10% reduction in the 
splice site score compared to the wild type (9.46%, 8.96% and 3.24%, respectively). The 
splice mutations known to create novel donor sites (A to G at 6'¥ ds-l and C to T G223G 
within exon 7) resulted in an increase in the donor site prediction score of 13.33% and 
40.48%, respectively. 
Among the nonsense and missense defects, the C to T base change located within 
exon 4, conventionally known to produce the nonsense mutation R43X, resulted in a 
51.34% increase in the score for a novel donor splice site located 87 bases upstream to 
the natural exon 4 donor site. The A to C base change conventionally known to result in 
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the R48X, however, resulted in a <5% score reduction for a potential acceptor splice site 
(cryptic splice site) within exon 4. 
Two exonic base changes, SNPs rs6179 (GI86G) and rs6176 (S491S), resulted in a 
58% increase in the score for novel donor splice sites. The remaining 5 exonic base 
changes conventionally known to result in missense or nonsense mutations and the 
remaining two SNPs, did not produce scores suggestive of the creation of a novel splice 
site. The natural splice site scores for exon 4 and 7 were also calculated: exon 4 donor 
site 74.73, exon 4 acceptor site 92.00, exon 7 donor site 79.15, and ex on 7 acceptor site 
84.55. 
TABLE 4.1 IN SILIca RESULTS. 
Mutation exonl Mutation Wt score Mt score Variation Splice element 
type intron (mRNA position) (%) 
Missense/ exon4 S40L (C to T at 173) 0.00 
Nonsense exon4 R43X (C to T at 181) 52.26 79.09 51.34 novel donor 
exon4 C48X C to A at 198) 79.85 77.78 -2.59 cryptic acceptor 
exon 5 V125A (T to C at 428) 0.00 
exon 6 R161C (C to T at 535) 0.00 
exon 7 Q216X (C to Tat 699) 0.00 
exon 7 L229P (T to C at 740) 0.00 
Splice intron 2 IVS2 ds+ 1 0 to A 93.03 66.2 -28.84 donor 
intron 2 IVS2 ds+4 A to C 93.03 84.23 -9.46 donor 
intron 2 IVS2 ds+4 A to 0 93.03 84.69 -8.96 donor 
intron 6 IVS6 ds+l 0 to A 91.96 65.13 -29.18 donor 
6'I' 6'I' ds+ 1 A to 0 79.36 89.94 13.33 novel donor 
intron 7 IVS7 ac-6 T to A 85.57 82.8 -3.24 acceptor 
exon 7 exon 7 ds-63 (C to T at 723) 66.3 93.14 40.48 novel donor 
intron 8 IVS8 ds-l 0 to C 90.71 79.69 -12.15 donor 
intron 9 IVS9 ds+2 T to C 87 60.2 -30.80 donor 
SNPs exon 6 01860 (A to 0 at 601) 45.69 72.53 58.74 novel donor 
exon 10 S491S (C to T at 1516) 46.11 72.95 58.21 novel donor 
exon 10 1544L (A to C at 1673) 0.00 
exon 10 P579T (A to C at 1778) 0.00 
Wt score, score for the wild type sequence; Mt score, score for the mutant sequence; 6'I', 
pseudoexon sequence; "-", no splice site identified. 
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4.4.3 Predicted consequences at mRNA and protein level according to the in 
silico prediction program 
According to the in silica data, twelve nucleotide changes create or abolish splice 
sites, thus inducing aberrant splicing of the GRR mRNA. Seven nucleotide changes, 
IVS2 ds+ 1 G to A, IVS2 ds+4 A to G, IVS2 ds+4 A to C, IVS6 ds+ 1 G to A, IVS7 as-6 T 
to A, IVS8 ds-l G to C and IVS9 ds+2 T to C, would result in exon skipping. The exon 4 
mutation, conventionally known as R43X (T to C position 181 in the GRR mRNA) 
creates an alternative, preferred donor site (mutant score 79.09 vs wild type 74.73) and 
should result in the preferential use of the novel splice site with premature truncation of 
exon 4, a frameshift and a premature stop codon in the GRR mRNA. The exon 7 defect 
creates an alternative, preferred donor site within exon 7 (mutant score 93.14 vs wild 
type 79.15) and would result in the premature truncation of exon 7, the lack of 63 bases 
from the mature mRNA, no frameshift and a GRR protein lacking 21 amino acids. The 
nucleotide change in intron 6 (pseudoexon 6'¥ ds-l A to G) increases the donor score for 
the pseudoexon and should result in the inclusion, in-frame, of the pseudoexon sequence 
in the mRNA and in a GRR protein with 36 additional amino acids. 
4.4.4 In vitro splicing assay results 
All those defects that were predicted to cause aberrant splicing were tested with the 
in vitro splicing assay. Five base changes [IVS2 ds+ 1 G to A, IVS6 ds+ 1 G to A, IVS9 
ds+2 T to C and the two SNPs rs6179 (GI86G) and rs6176 (S491S)] were not studied in 
vitro during the course of this project and are part of future work. 
4.4.4.1 Defects in regulatory splicing elements: nucleotide changes IVS7 as-6 T to A 
and IVS8 ds-1 G to C 
The wild type minigene Ll-GRRexon8-L2 and the corresponding mutants were 
created to study the nucleotide changes IVS7 as-6 T to A, located in the polypyrimidine 
tract before exon 8 and the IVS8 ds-l G to C, located at the donor splice site of exon 8. 
After 1 hour under standard splicing conditions, the wild type minigene produced a band 
of 277 bases corresponding to the three-exon-correctly-spliced product (Ll-exon8-L2 
mRNA) whose identity was confirmed by direct sequencing. Such a band was absent in 
both mutant minigenes. Both mutations resulted, instead, in the skipping of the mutation-
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harbouring exons (GHR exon 8 in both cases) and in the appearance of a product 186 
bases long, corresponding to exons Ll and L2 joined together, as confirmed by direct 
sequencing (Figure 4.2). 
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Admlpar wt Mut 
o 60 0 60 0 60 
-
622 
~ 562bp - 527 
-
404 
D---CJ 300 bp 
307 
c:::::.=I 277 bp 
242 
D- 217 
190 
~ J86bp 1180 
160 
147 
G 
A GCAA , G r A GG r 
~ I L1 I GHR 8 I L2 I 
___ -"L' __ _ 
Exon 8 IVS 8 I L1 L2 
IVS7 ac-6 T to A 
Admlpar Wt Mut 
060060060 
~ 562 bp 527 
Wild-type 
Pre-rnRNA 
Mutant 
404 
D---CJ 300 bp 
c:::::.=I 277 bp 
307 
D-
242 
238 
~ 186 bp 217 
190 
!I 80 
160 
I LI I GHR 8 I L2 I TGT . TTCAGATT 
II ' 
~II;I\ "' I' ,lllill,,'1 
,1,1 '\ .. r \ 
I LI L2 I IVS7 1~8 
Figure 4.2 GHR mutations IVS8 ds-l G to C and IVS7 ac-6 T to A. Top panels: in vitro 
splicing assay results. Bands corresponding to correct and aberrant spliced products are indicated 
by the arrows. Bands sizes are also indicated. Bottom panels: schematic representation of the 
splicing events for the wild type and mutant minigenes. Mutation location is indicated by an 
asterisk. Partial genomic sequences from patients DNA are also presented. 
4.4.4.2 Defects downstream of the splice site: nucleotide changes IVS2 ds+4 A to G 
and IVS2 ds+4 A to C 
The wild type minigene LI-GHRexon2-L2 and the corresponding mutants were 
created to study nucleotide changes IVS2 ds+4 A to G and IVS2 ds+4 A to C, both 
located downstream of the donor splice site of exon 2. After 1 hour under standard 
splicing conditions, the wild type minigene produced a band of 264 bases corresponding 
to the three-exon-correctly-spliced product (Ll-exon2-L2 mRNA) whose identity was 
128 
Chapter 4 An in vitro splicing assay to study GHR splice mutations 
confirmed by direct sequencing. Such a band was also detected in both mutant minigenes, 
indicating neither nucleotide change caused aberrant splicing (Figure 4.3). 
IVS2 ds+4 A to G and A to C 
Admlpar Wt Mut A / G Mut A / C 
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Figure 4.3 GHR IVS2 ds+4 A to G and A to C nucleotide changes. On the left: in vitro 
splicing assay results. Bands corresponding to correct and aberrant spliced products are indicated 
by the arrows. Bands sizes are also indicated. On the right: schematic representation of the 
splicing events for the wild type and mutant minigenes. Mutation location is indicated by the 
asterisk. Partial genomic sequence from patient DNA is also presented. 
4.4.4.3 Exonic defects: nucleotide changes ex 7 ds-62 C to T and ex 4 (R43X) C to T 
The wild type minigene LI -GHRexon7-L2 and the corresponding mutant were 
created to study the nucleotide change ex7 ds-62 C to T located deeply within exon 7 of 
the GHR, which was predicted to create a novel donor splice site 63 bases upstream the 
natural one (score for mutant =93.14 vs score for wild type = 79.15). After 1 hour under 
standard splicing conditions, the wild type mini gene produced a band of 352 bases 
corresponding to the three-exon correctly spliced product (Ll -exon7-L2 mRNA) , the 
identity of which was confirmed by direct sequencing. A band of smaller size (289 bases) 
was, instead, produced by the splicing of the mutant mini gene (Figure 4.4, left panel). 
Direct sequencing showed the presence of a product lacking the last 63 bases of ex on 7. 
A band of similar size was produced by the wild type minigene. Direct sequencing of this 
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product showed it was an intermediate of the reaction, formed by exon L 1, its intronic 
boundary and part of exon L2. GHR exon 7 was not present in this mRNA product. 
The wild type minigene L1-GHRexon4-L2 and the corresponding mutant, were 
created to study the nucleotide change located deeply within exon 4 of the GHR 
conventionally known as R43X, predicted in silica to create a novel donor splice site 
preferred to the natural site (mutant score 79.09 versus wild type 74.73). After 1 hour 
under standard splicing conditions, both wild type and mutant minigenes produced a band 
of 316 bases, corresponding to the three-exon-correctly-spliced product (L1-exon4-L2 
mRNA) , the identity of which was confirmed by direct sequencing (Figure 4.4, right 
panel). 
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Figure 4.4 GHR mutations exon 7 ds-62 C to T and exon 4 R43X. Top panels: in vitro splicing 
assay results. Bands corresponding to correctly and aberrantly spliced products are indicated by 
arrows. Bands sizes are also indicated. Bottom panels: schematic representation of the splicing 
events for the wild type and mutant minigenes. Mutation position is indicated by the asterisk. 
Partial genomic sequences from patients DNA are also presented. 
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4.4.4.4 The pseudoexon defect: 6'1' ds-l A to G 
The wild type mini gene L1-GHR6,¥-L2 and the corresponding mutant were created 
to study the nucleotide change 6'¥ ds-1 A to G, located deeply in intron 6 and predicted 
to create a novel donor splice site resulting in the insertion of the pseudoexon sequence in 
the mature GHR mRNA. After 1 hour under standard splicing conditions, the wild type 
minigene produced only a band of 186 bp corresponding to exons Ll and L2 joined 
together. The mutant minigene produced a band of 294 bases corresponding to the three-
exon product L1 -GHR6,¥-L2 (Figure 4.5), as confirmed by direct sequencing. 
6'1' ds -l A to G 
Admlpar Wt Mut 
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c:::::.::::::J 294 bp 
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c::::r::::J 186 bp 217 2011190 Mutant IGHR 6'1' I I L1 L2 180 
Figure 4.5 GHR pseudoexon mutation 6'1' ds-l A to G. Left panel: in vitro splicing assay 
results. The bands corresponding to correctly and aberrant spliced products are indicated by the 
arrows. Bands sizes are also indicated. Right panel: schematic representation of the splicing 
events for the wild type and mutant minigenes. Mutation position is indicated by the asterisk. 
Partial genomic sequences from patient DNA is also presented. 
4.4.5 In vivo results and patients' data 
mRNA extracted from patient leucocytes was available for the analysis of 
nucleotide changes IVS2 ds+4 A to C and IVS9 ds+2 C to T. In vivo results for mutations 
IVS8 ds- l G to C, ex 7 ds-62 C to T and 6'¥ ds-1 A to G (pseudoexon mutation) were 
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available from previously published papers. Patient mRNA for analysis of mutations 
IVS2 ds+4 A to G, IVS7 as-6 T to A and R43X was not available. In vivo results showed 
skipping of the mutation-harbouring exons in the GHR mRNA of patients with nucleotide 
changes occurring at the invariant splice site sequences (IVS8 ds-l G to C and IVS9 ds+2 
C to T). mRNA analysis for mutations exon 7 ds-62 C to T and 6'¥ ds-l A to G, revealed 
the absence of the last 63 bases of exon 7 and the activation and insertion of the 
pseudoexon sequence in the GHR mRNA, respectively. No product corresponding to the 
GHR mRNA was detected in patients with the IVS2 ds+4 A to C. The 6'¥ ds-l A to G 
resulted in activation of the pseudoexon and inclusion of 108 additional nucleotides in the 
patient's GHR mRNA. 
DNA analysis of GHI patients revealed that no additional nonsense or missense 
mutations were present in patients carrying the above nucleotide changes, except for the 
patient carrying the IVS2 ds+4 A to G base change, in whom a deleterious GHR 
homozygous defects (R161 C) was found. 
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4.5 DISCUSSION 
This study showed that the in vitro splicing assay can accurately identify nucleotide 
changes resulting in aberrant gene splicing. The assay was particularly helpful in cases of 
defects occurring outside the invariant nucleotides of the splice sites, for which the in 
silico prediction programs gave ambiguous results. 
Base change 
IVS2 ds+4 A to G 
IVS2 ds+4 A to C 
Exon 4 C to T R43X 
Pseudoexon 6'I' ds-l A to G 
IVS7as-6 T to A 
Exon 7 ds-62 C to T 
IVS8 ds-l G to C 
n.a., not available 
In silico results 
(score wild type vs mutant) 
93.03 vs 84.69 
93.03 vs 84.23 
52.26 vs 79.09 
79.36 vs 89.94 
85.57 vs 82.80 
66.30 vs 93.14 
90.71 vs 79.69 
In vitro splicing results 
No effect on exon 2 splicing 
No effect on exon 2 splicing 
No effect on exon 4 splicing 
Pseudoexon insertion 
Skipping of exon 8 
63 bases missing 
Skipping of exon 8 
In vivo results 
SNP 
n.a. 
R43X 
Pseudoexon insertion 
n.a. 
63 bases missing 
Skipping of exon 8 
The in vitro splicing assay for defects within the invariant splice site sequence 
Splice mutations are approximately 50% of DNA point mutations responsible for 
human genetic diseases. In the majority of cases, they affect the efficiency of mRNA 
splicing leading to mutant proteins, by abolishing a native splice site through a base 
change located within the invariant nucleotides of the donor or acceptor sites (Krawczak 
et al., 1992), and less frequently by altering other splicing elements, such as the 
polypyrimidine tract and the branch point (Li et al., 1998, Groussin et al., 2006). The aim 
of this study was to establish the diagnostic value of an in vitro assay, based on a three-
exon minigene system spliced in HeLa nuclear extracts, to assess the consequences of 
genetic defects on mRNA splicing. All novel and previously identified nucleotide 
changes detected in the GHR of the GHI population were analysed in silico and those 
suspected of inducing aberrant splicing where studied in vitro, prioritising those 
occurring outside the splice sites. Splice sites are, in fact, characterised by invariant 
nucleotide sequences, with introns being flanked in 99% of cases by GT and AG 
dinucleotides at the 5' and 3' splice site, respectively (Berget, 1995, Burset et al., 2000) 
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and exons by the AICAG sequence at the donor site and G at the acceptor site in over 
60% of the cases (Burset et aI., 2001). Therefore, any base change occurring at these 
positions can be easily and efficiently predicted to cause aberrant splicing. As expected, 
the use of the in vitro assay to test the base change disrupting the invariate nucleotides at 
the splice site (nucleotide change G to C at IVS8 ds-l) resulted in the skipping of the 
mutation-harbouring exon, thus confirming the in silica prediction and in vivo data 
(Woods et aI., 1996). 
The in vitro splicing assay for defects outside the invariant splice site sequence 
The potential diagnostic application of the in vitro assay became evident in cases 
where the nucleotide change, either exonic or intronic, occurred outside the splice site 
consensus sequences. In this study, three defects were located either upstream of the 
acceptor (IVS7 as-6 T to A) or downstream of the donor splice site (IVS2 ds+4 A to C 
and IVS2 ds+4 A to G). The in silica analysis showed a modest score reduction (less than 
10%) compared to wild type for all three nucleotide changes. In particular, the IVS7 as-6 
T to A, located within the polypyrimidine tract, resulted in the smallest score reduction 
among the three, with only 3% reduction compared to the wild type, which would not 
have indicated this defect as the cause of GHI. The in vitro assay, however, showed clear 
skipping of the mutation-harbouring exon from the mRNA. Mutations in the 
polypyrimidine tract are rare and this is the first of its kind to be identified in the GHR. 
Although in vivo analysis to further confirm the occurrence of aberrant splicing is needed 
and is part of future work, it has to be noted that, due to nonsense mediated decay 
(NMD), no patient's GHR mRNA may be present. 
The two nucleotide changes downstream of the donor splice site of exon 2 (IVS2 
ds+4 A to C and IVS2 ds+4 A to G) resulted in a near-l 0% score reduction, suggesting 
the possible occurrence of aberrant splicing. Nevertheless, in both cases the in vitro assay 
showed correct inclusion of the GHR ex on in the mRNA. No in vivo data are available 
for the IVS2 ds+4 A to C change, while the A to G change at the same position can be 
considered a rare SNP since it was found in a GHI patient homozygous for the 
deleterious R161C GHR defect (Amselem et aI., 1993). Although no splicing regulatory 
element has yet been identified downstream of the donor splice site, the in vitro assay is 
important in patients in whom no other defects in the coding region are found and mRNA 
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analysis shows no product for the GHR mRNA, such as the patient carrying the IVS2 
ds+4 A to C. 
The discordant results between the in silica and in vitro data underline an important 
and yet well-known, limitation of the in silica prediction programs. There is, in fact, no 
rule to define the percent of change from the wild type which indicates the occurrence of 
aberrant splicing. Moreover, prediction programs become less efficient the further away 
the base change is located from the invariant splice site sequence. As a consequence, 
false negative or positive predictions can be easily made, as in the case of nucleotide 
changes IVS7 as-6 T to A and IVS2 ds+4 A to C or G. 
The in vitro splicing assay for defects predicted to create novel splice sites 
Five base changes resulted in a splice site score increase compare to the wild type. 
In four of these cases the increase was greater then 40%, suggesting the creation of novel 
splice sites. Among these cases was a base change conventionally classified as a 
nonsense mutation (C to T within exon 4, R43X). According to the in silica analysis, this 
base change creates a novel donor site stronger than the natural one (mutant donor site 
score 79.09 vs 74.73), which could result in its preferential use over the natural site. 
Nevertheless, the in vitro assay showed no difference in the splicing of the mutant 
minigene compared to the wild type. Unfortunately, no mRNA analysis was available. In 
cases like this, in which the nucleotide change is thought to create a nonsense mutation, 
mRNA analysis is generally not performed. Therefore, it is not possible to know whether 
the base change produces a mutant protein through a nonsense mutation or a splicing 
defect. In this particular case, the result at a protein level would have been the same - a 
prematurely truncated protein - but in other cases, a splice defect may result in a partially 
functional protein rather than a truncated non-functional one. 
The C to T base change within exon 7 is an example of how the conventional 
classification of a defect could be misleading. This nucleotide change would normally be 
thought to result in the harmless synonymous SNP G223G whereas it has been proven at 
an mRNA level to be a splice defect, resulting in a mutant GHR protein (Baumbach et aI., 
1997). The in vitro assay proved to be accurate in demonstrating the occurrence of 
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aberrant splicing by showing the preferential use of the novel splice site over the natural 
one. 
The nucleotide change A to G at 6'1' ds-l (pseudoexon mutation) located deeply in 
intron 6 was studied in this laboratory in 2001 (Metherell et aI., 2001) and proved in vivo 
and with the in vitro assay to result in the activation of a pseudoexon and the insertion in-
frame of a new amino acid sequence. The encouraging results obtained in 200 1 with the 
in vitro splicing assay on the pseudoexon mutation, were the basis for this project, which 
aimed at establishing a quick and reliable protocol for the creation of minigenes and at 
testing different mutations, thus making the assay a valid alternative to patient mRNA 
analysis. The recreation of the pseudoexon minigene LI-GHR6'1'-L2 confirmed previous 
findings but, more importantly, demonstrated the superiority of the in vitro assay over the 
in silica predictions. 
Limitations 
A limitation of this study is the small number of mutations studied and in vivo 
results available. Although, the three-exon minigene system spliced in nuclear extract is a 
widely used technique for studying regulatory splicing elements, it should not be 
forgotten that it is an in vitro system, and tissue specific differences may occur. Thus, the 
study of additional mutations, especially outside the invariant splice sites sequences in 
the GHR and other genes, and in vivo analysis is necessary for assessing further the 
accuracy of this system. 
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CHAPTER 5 
THE GHR PSEUDOEXON 6'1': FROM DIAGNOSIS TO 
THERAPY 
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5.1 BACKGROUND 
In 2001, Metherell et aI. described a novel GHR intronic point mutation located 
between exons 6 and 7 (base change A to G). This was positioned at the donor splice site 
of a pseudoexon (6'¥), which is normally not recognised by the splice machinery. Introns 
are rich in pseudoexons, which are not included in the mature mRNA for reasons which 
still remain unclear (Sun and Chasin, 2000). In the case of the GHR pseudoexon 6'¥, 
Akker et aI. demonstrated the presence of multiple sequences within the pseudoexon 6'1', 
which can bind the heterogeneous nuclear ribonucleoprotein particle E 1 protein (hnRNP 
El) and the Ul snRNP in the pre-spliceosomal complex and silence the pseudoexon 6,¥. 
Moreover, the authors showed that a combination of the 5' splice site and the splicing 
silencing elements, is required for pseudoexon 6'¥ silencing (Akker et aI., 2007). 
In some cases, subtle changes in the pseudoexons are sufficient to lead to their 
activation and the GHR 6'¥ A to G defect is an example of such a case. This mutation 
leads to the recognition of the pseudoexon sequence and the inclusion of 108 additional 
nucleotides between exons 6 and 7 in the GHR mRNA. The result of this mutation is the 
production of an abnormal GHR protein with 36 additional amino acids in its 
extracellular domain (Metherell et aI., 2001) (Figure 5.1). 
GHR 
Mutant GHR 
protein 
Wild type GHR 
protein 
12'iI31:4\'5.1·6t~%§l¥~a 7 \' 8 19\ 10 
I I~I I 
Extracellular TM Intracellular 
domain domain domain 
12131,'i){!llsl.i6 f71 8 191 10 
I I~\ \ 
Extracellular TM Intracellular 
domain domain domain 
Figure 5.1 The GHR pseudoexon 6'1' mutation. The A to G base change at the donor splice site 
of the pseudoexon leads to aberrant GRR splicing and the inclusion of 36 new amino acids in the 
GRR protein. TM, transmembrane domain. 
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Functional studies demonstrated that the mutant protein maintains its signaling 
properties, but has impaired cell surface trafficking (Maamra et aI., 2006). 
There is now a significant amount of literature demonstrating the relationship 
between splice defects and diseases. This has led to the development of new therapeutic 
tools, such as antisense oligonucleotides (ASOs), aimed at correcting aberrant splicing. 
ASOs are synthetic RNA molecules of approximately 10-20 nucleotides, designed to be 
complementary to a target sequence on the pre-mRNA. ASOs complementary to pre-
mRNA splice sites, branch points or ESEs are effective in restoring aberrant splicing in 
vitro and in cell transfection systems and can restore ex on inclusion or exclusion induced 
by splice mutations (Dominski and Kole, 1993, Sierakowska et aI., 1996, Vacek et aI., 
2003, van Deutekom and van Ommen, 2003, Hua et aI., 2007). The mechanism of action 
of ASOs is RNase H cleavage-independent. ASOs are thought to act by physically 
interfering with the apposition of spliceosome elements on the target pre-mRNA 
sequence (Kole and Sazani, 2001). The ASO approach has been used in vitro and in vivo 
to correct aberrant splicing defects leading to neuro-muscular diseases, with promising 
results and human trials are currently under way (Takeshima et aI., 2006, van Deutekom 
et aI., 2007). 
Although mutations occumng in the GHR extracellular domain, such as the 
pseudoexon, are generally associated with typical GHI, also known as classical Laron 
syndrome, the four siblings in whom the pseudoexon defect was originally found, had 
non-classical GHI, with normal facial features and a mild degree of GHI (Bjamason et 
aI., 2002). The genetic study of GHI presented in Chapter 3 of this Thesis has now 
identified seven novel patients from 5 apparently unrelated families with the same 
pseudoexon 6'¥ defect. 
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5.2 HYPOTHESIS AND AIMS 
The aim of this project was to define the relation between genotype and phenotype 
in patients with the pseudoexon 6'f' mutation, by analysing auxological, biochemical, 
genetic and haplotype data from all known patients with severe short stature and GHI 
caused by the GHR 6'f' ds-l A to G defect. Moreover, this project aimed to correct the 
aberrant splicing caused by this mutation by use of RNA antisense oligonucleotides in an 
in vitro splicing assay and in a cell transfection system. 
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5.3 POPULATION 
Eleven patients with the GHR 6'P ds-1 A to G (pseudoexon mutation) were studied. 
Four of these patients were the cohort reported in 2001. The remaining seven patients 
were part of the GHI study population presented in Chapter 3 of this thesis. Informed 
consent was obtained from all patients and their parents. Ethical approval was obtained 
by individual centres recruiting patients. 
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5.4 MATERIALS AND METHODS 
5.4.1 Genotyping 
Dinucleotide repeat markers spanning 17.10Mb around the GHR locus on 
chromosome 5 and SNPs present in the GHR intron 9 and presented in Chapter 3 of this 
Thesis (section 3.4.3), were used for the genotype analysis of GHI patients with the 
pseudoexon mutation IVS 6'1' ds-l A to G. Briefly, repeat markers were amplified from 
genomic DNA by PCR using specific primers (sequences reported in Appendix 3:10.3.8), 
denatured and electrophoresed. Results were analysed using Genescan and Genotyper 
software (Perkin Elmer Applied Biosystems, UK). For the analysis of the complex 
polymorphic GHR intronic region, intron 9 was amplified using specific primers 
(sequences reported in Appendix 3:10.3.1). PCR samples were visualised on a 1% 
agarose gel and analysed by direct sequencing on the ABI 3700 Sequencer. Haplotypes 
were indicated by Roman numerals according to the classification proposed by Amselem 
et aI. (Amselem et aI., 1989), and reported in Appendix 6. 
5.4.2 PCR and sequencing 
The wild type mini gene Ll-GHR6'1'-L2 was created usmg PCR and overlap-
extension PCR techniques as previously decsribed. The splice reporter Adml-par (Ll-L2) 
was also amplified by conventional PCR and used as a positive control for the splicing 
reaction. The PCR products were run on a 1 % agarose gel and those corresponding in 
size to the three-exon minigene, cut and purified by PCR gel extraction. The identity of 
the PCR product was confirmed by direct sequencing on the ABI 3700 Sequencer. 
5.4.3 A-tailing and Cloning 
Blunt-ended PCR reactions generated by the proof-reading polymerase were A-
tailed and cloned in the pGEM T-easy vector system. White colonies containing the 
inserts were picked and cultured. Minipreparation of plasmid DNA was obtained using 
the Qiagen plasmid mini kit (Qiagen). The presence of the insert was assessed by direct 
sequencmg. 
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5.4.4 Site-directed mutagenesis for the creation of mutant minigenes 
The mutant GHR minigene was obtained by site-directed mutagenesis usmg 
specific primers (sequences reported in Appendix 3: 10.3.5) and the wild type minigene 
as a template. 
5.4.5 In vitro transcription and RNA purification 
Wild type and mutant DNA minigenes and Adml-par were transcribed into mRNA 
in the presence a32P_GTP (lO/-lCi). After 1 hour incubation at 37°C, reactions were mixed 
with RNA loading dye, heated at 98°C for 5 min and then run on a 4% polyacrylamide 
gel for 45 minutes at 980 Volts. Fluorescent markers were attached on the gel that was 
exposed overnight at -80°C and then subjected to autoradiography. The fluorescent-
labelled gel image was used to excise the RNA bands from the gel. The RNA was 
extracted from the gel bands and stored at -20°C or used for the in vitro splicing assay. 
5.4.6 Antisense oligonucleotides (ASOs) 
Three 18-mer 2'O-methyl oligoribonucleosides complementary to the donor, 
acceptor and branch site of the GHR pseudoexon were designed and synthesised 
(Dharmacon). Their sequences are reported in Appendix 3:10.3.6. ASOs were tested at 
different concentrations (ranging from OnM to 250nM) in the in vitro splicing assay and 
in a cell transfection system. 
5.4.7 In vitro Splicing assay and ASOs 
ASOs (final concentration ranging from OnM to 250nM) were incubated at 30°C 
for 5 minutes with a 12.5/-l1 splice reaction mixture prepared as described in Materials and 
Methods section 2.9.4, but without the addition of the RNA minigene. At the end of the 
incubation, 10fmol RNA was added and the reaction was incubated at 30°C for an 
additional hour. Control reactions were kept on ice for the same time. 
To optimise ASOs efficiency the following modifications to the protocol were 
tested: 
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a) ASOs were first incubated at 30°C for 5 minutes with RNA and at the end of the 
incubation the complex was added to the splicing master mix and incubated for an 
additional hour, or 
b) ASOs and RNA added together to the master mix and incubated at 30°C without 
any pre-incubation step. 
At the end of the incubation, reactions were deproteinised, precipitated, mixed with 
RNA dye, heated at 98°C for 5 minutes and run on an 8% denaturing polyacrylamide gel 
for 1 hour and 45 minutes at 980 Volt, before autoradiography. The bands of interest, 
corresponding in size to correctly spliced or aberrant products, were excised from the gel 
and retro-transcribed into cDNA. This was amplified by PCR (RT-PCR) using specific 
primers for Adml-par exon Ll and exon L2 (sequences reported in Appendix 3:10.3.4) 
and products analysed by direct sequencing on the ABI 3700 DNA Sequencer. 
5.4.8 Sub cloning of minigenes in pcDNA 3.1 
Wild type and mutant minigenes Ll-GHR6,¥-L2 were subcloned from the bacterial 
pGEM T -easy vector into the mammalian pcDNA 3.1 vector. The insert product was 
released from the parent vector and ligated into the destination vector according to the 
protocol described in Materials and Methods section 2.6.6. The ligation reaction was 
transformed into competent bacterial cells and the identity and correct orientation of the 
pcDNA3.1 Ll-GHR6,¥-L2 plasmid insert was assessed by direct sequencing on the ABI 
3700 Sequencer. 
5.4.9 Cell culture and transfection of ASOs 
HEK293 cells (a gift from Dr P Chapple) were maintened in Dulbecco's minimum 
essential medium (DMEM, Sigma-Aldrich) with 10% fetal bovine serum (FBS, Sigma-
Aldrich) at 37°C under 5% CO2 and split when confluent. Before transfection, HEK 293 
cells were seeded in 12-well plates. Cells were transiently transfected when 
approximately 50% confluent, with the mutant pcDNA3.1 Ll-GHR6'¥-L2 plasmid 
(50ng) and different concentrations of ASOs (final concentration ranging from to OnM to 
250nM) using Lipofectamine 2000 (Invitrogen) and the following protocol: 
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a) for each transfection 2.64/-L1 of Lipofectamine 2000 was added to 107.36/-L1 of 
Optimem (Invitrogen) in a 1.5ml tube and left to incubate at room temperature for 5 
minutes; 
b) the ASOs-plasmid-Lipofectamine 2000 complex was made as follows: according 
to the desired ASOs final concentration, x/-Ll of one or more 100/-LM stock ASOs, were 
placed in 1.5ml autoclaved tube with l/-Ll of plasmid (50ng) and x/-Ll ofOptimem to a final 
volume of 100/-L1. In the negative control ASOs were omitted; 
c) 100/-Ll of the Lipofectamine200010ptimem was added to the 
ASOs/plasmidiLipofectamine 2000 reaction and the complex left at room temperature for 
20 minutes; 
d) the complex (200/-Ll) and Iml of cell media were added to each well of a 12-well 
plate to give a final volume of 1.2ml per well. 
Cells were incubated for 48 hours at 37°C before harvesting. 
5.4.10 RNA extraction and RT-PCR 
Forty eight hours after transfection, cells were harvested, RNA extracted and reverse 
transcribed into cDNA. cDNA was amplified in the presence of 0.5/-LCurie of 32p dCTP 
in a 12.5/-Ll PCR reaction with Taq polymerase (Sigma) and specific primers for L1 and 
L2 (sequences reported in Appendix 3: 10.3.4). PCR products were electrophoresed on an 
8% non-denaturating polyacrylamide gel (prepared as decribed in Materials and Methods 
section 2.5.4) prior to autoradiography and phosphoimaging. 
5.4.11 Phospho imaging 
Quantification of phospholabeled alternative splicing products was performed using 
the PhosphorImager and ImageQuant software (GE Healtcare) available at the Centre of 
Molecular Oncology at the William Harvey Research Institute. The percentage of 
alternative splicing was calculated as isoform/total of all isoforms. 
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5.4.12 Biochemical assessment 
Serum IGF-I, IGFBP-3, ALS and GHBP were measured from venous blood 
samples, using an enzyme-linked immunosorbent assay (ELISA kit; Diagnostic System 
Laboratories, Inc. Webster, TX, USA) by Dr F. Miraki-Moud in the laboratories of Dr C. 
Camacho-Hubner at Barts and the London .. 
5.4.13 Statistical analysis 
Results are presented as mean ± standard deviation from at least three separate 
experiments. 
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5.5 RESULTS 
5.5.1 Clinical characteristics of patients with the IVS 6'1' mutation 
The 11 patients with the pseudoexon mutation had normal GHBP levels but 
differing degrees of GH insensitivity, as demonstrated by the wide range of growth 
failure and serum IGF, IGFBP-3 and ALS levels. Biochemical and auxological data for 
all 11 patients are shown in Table 5.1. 
TABLE 5.1 AUXOLOGICAL AND BIOCHEMICAL DATA FOR THE 11 PATIENTS WITH THE 
GHR PSEUDOEXON MUTATION. 
Family Family Age (yrs) at Sex Tanner Height GH (mUll) IGF-I (ng/ml) Facial 
member assessment Stage (SDS) Basal (Peak) [NR] features 
A 10 M -4.4 16.7 (55.2) I 23* normal 
[38-318J 
2 14 M -5.6 12.0 (203) 21* normal 
[39-537) 
3 10 M -3.9 52.4 (270) 20* normal 
[38-318) 
4 14 M II -3.3 14.3 (86.7) 29* normal 
[39-537] 
5 7 F -5.0 (21.3) 32* normal 
[64-406) 
B 8 F -6.0 (>100.0) I [64~4:61 typical LS I 
C 21 M V -5.0 1.8 149 typical LS 
[49-550] 
D 6 M -3.4 NA 36* typical LS 
[64-406] 
2 11 M II -4.6 NA 132 typical LS 
[38-318) 
E 7 F -3.3 18.0 (60.0) 53* normal 
[64-406) 
2 13 F IV -3.5 25.0 (80.0) 113 normal 
[39-537) 
Patients AI-A4 were the four boys with non-classical GHI described in 200l. 
Patient A5's genetic diagnosis was established as part of the genetic analysis of the GHI 
population presented in this thesis. She was a member of the same highly consanguineous 
Pakistani family as patients AI-A4. Her height was -5.0 SDS and, similar to other 
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affected members of this family, she had normal facial features and a biochemically mild 
GHI phenotype. 
Patient B 1 was an 8-year-old female. Her grandparents were cousins of Pakistani 
origin. Her height was -6.0 SDS. She had a younger sibling with growth retardation and 
elevated GH levels (DNA not available for analysis). She had typical LS facial features, 
with a prominent forehead and mid-facial hypoplasia. Biochemically, she had severe GHI 
as demonstrated by the almost undetectable levels of GH-dependent proteins (IGF-I, 
IGFBP-3 and ALS). 
Patient C 1 was the 21-year-old son of two first-degree cousins of Palestinian-Arab 
origin. His height was -5.0 SDS. He had two other siblings with short stature (DNA not 
available for analysis). They all had typical LS facial features. Biochemically, he had a 
mild GHI phenotype. His IGF-I and IGFBP-3 values were normal. 
Patients D 1 and D2 were from a consanguineous Pakistani marriage. D 1 was a 6-
year-old male with a height SDS -3.4 and low IGF-I, IGFBP-3 and ALS levels. His 
brother, D2, age 11, height SDS -4.6, also had low ALS levels but normal IGF-I and 
IGFBP-3 levels reflecting his pubertal status. Both children had typical LS facial features. 
Patients EI and E2 were sisters from a consanguineous Pakistani family. They had 
similar height SDS scores of -3.3 and -3.5, respectively. Both displayed a normal facial 
phenotype, but EI had subnormal IGF-I and IGFBP-3 levels, whereas her sister's values 
were normal for her age, again reflecting her pubertal status. 
5.5.2 Genotype analysis of patients with the IVS 6'1' mutation 
Analysis of a 17.1 OMb region on chromosome 5 surrounding the GHR locus, 
revealed the same genotype in affected members of three apparently unrelated families 
(A, B and C), suggesting a common ancestor. A recombination event downstream of the 
GHR locus, between markers D5S2087 and D5S474, had occurred in family B. Families 
D and E were not known to be related, but had the same haplotype being identical by 
descent upstream of the GHR and homozygous both at the GHR locus and downstream. 
The analysis of the single nucleotide polymorphisms in intron 9 of the GHR and of 
marker D5S2087 demonstrated the same genotype in all families (Figure 5.2) over a 
conserved region of at least 1.8Mb, suggestive of a common ancestor. 
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Figure 5.2 Family pedigrees and genotype analysis. Affected family members are shown in 
black, possibly affected in grey. In family A, the five cousins had identical genotypes. In family 
D, the brothers had identical genotypes and in family E the sisters had identical genotypes. The 
genotypes of the affected members of each family are indicated below the family trees in boxes. 
All families had an identical genotype at the GHR locus and marker D5S2087, as shown in bold. 
5.5.3 Correction of aberrant splicing caused by the IVS 6'P mutation: effect of 
ASOs in the in vitro splicing assay 
Three 2'O-methyl RNA ASOs were targeted to the donor (ASO 5') and acceptor 
(ASO 3') splice sites and branch point (ASO br) of the mutant pseudoexon sequence 
(Figure 5.3). Their ability to restore correct splicing was tested using the in vitro splicing 
assay and the LI-GHR6,¥-L2 mutant minigene. 
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Figure 5.3 Diagram of the LI-GHR6'P-L2 mutant minigene and the ASO position within 
the minigene. The position of splice elements is also indicated. Mutation position is indicated by 
the arrow. 
Each ASO was initially tested at a 250nM concentration. ASO 3' induced 
pseudoexon skipping from the mRNA, as demonstrated by the absence of the 294 bases 
band corresponding to the Ll-GHR6'1'-L2 mRNA and the appearance of the 186 bases 
band corresponding to exon Ll and L2 joined together (Ll-L2 mRNA). ASO' 5' 
produced a modest pseudoexon skipping, whereas ASO br had practically no effect 
(Figure 5.4). 
To assess whether targeting two splice elements is more effective than targeting a 
single element, two ASOs, each at a concentration of 125nM, were used in the same 
splice reaction. The combination ASO 3' - ASO 5' and ASO 3' - ASO br produced a 
modest pseudoexon exclusion from the mRNA, as demonstrated by the appearance of 
both mRNA spliced products LI-GHR6'1'-L2 (294 bases) and Ll-L2 mRNA (186 bases). 
Almost no pseudoexon skipping was seen for the combination ASO 5' - ASO br (Figure 
5.4). 
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Figure 5.4 Effect of ASOs, alone or in combination, on the mutant LI-GHR6'1'-L2 minigene 
splicing. The identity of each product is represented on the left. Splicing of Adml-par and the 
wild type and mutant mini genes Ll-GHR6tp-L2, in the absence of ASOs, is also shown. One 
representative example of three separate experiments is presented. The position of the spliced 
products with (294 bases) and without the pseudoexon (186 bases) are indicated by arrows. The 
position of a lariat (intermediate of reaction) is indicated by the asterisk. 
ASO 3' and 5', which had produced pseudoexon skipping, were further tested by 
titrating their concentrations from 250nM to lOnM. ASOs targeting the acceptor splice 
site (ASO 3') induced complete pseudoexon skipping from the mRNA at a concentration 
of250nM, 125nM and lOOnM. This effect was dose-dependent, with almost no effect at a 
concentration of 50nM and 10nM. ASOs targeting the donor splice site (ASO 5') 
produced a modest pseudoexon exclusion from the mRNA, with the maximum effect 
seen with concentrations of 250nM, 125nM and lOOnM and almost no effect seen at 
50nM andlO nM. (Figure 5.5). 
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Figure 5.5 Dose-response analysis with ASOs 3' and 5'. The identity of each product is 
schematically represented on the left. Splicing of Adml-par and of the wild type and mutant 
mini genes Ll-GHR6,¥-L2, in the absence of ASOs, is also presented. One representative example 
of three separate experiments is presented. The position of the spliced products with (294 bases) 
and without the pseudoexon (186 bases) are indicated by arrows. 
The ASO targeting the branch point (ASO br) did not cause exon skipping and 
reduced the efficacy of ASO 3' when used in combination. To test whether ASO br 
could act as an enhancer of pseudoexon inclusion, it was tested on the wild type 11-
GHR6,¥-L2 mini gene at concentrations ranging between 250nM and OnM. The addition 
of ASO br to the splice reaction had no effect on the wild type minigene splicing, as 
demonstrated by the absence of the 294 bases band corresponding to the L 1-GHR6,¥-L2 
mRNA and the appearance of the 186 bases band corresponding to L1-L2 mRNA (Figure 
5.6). 
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Figure 5.6 Effect of ASO targeting the branch point (ASO br) on the wild type LI-GHR6'P-
L2 minigene. The different ASO br concentrations tested are indicated above. One representative 
example of three separate experiments is presented. Splice products with (286 bases) and without 
(186 bases) the pseudoexon 6\{' are indicated by arrows. The position of an intermediate of 
reaction (lariat) is indicated by the asterisk. The identity of each product is schematically 
represented on the left. 
5.5.4 Correction of aberrant splicing caused by the IVS 6'1' mutation: effect of 
ASOs in HEK293 cells 
The three ASOs targeting the donor (ASO 5') and acceptor (ASO 3') splice sites 
and the branch point (ASO br) were transfected with the pcDNA3.1 Ll-GHR61'-L2 
mutant plasmid in HEK 293 cells. Two ASO concentrations (250nM and 125nM), which 
in vitro were effective in inducing pseudoexon skipping, were tested. Mock-transfected 
cells (no ASO) showed no skipping of the pseudoexon. ASO 3' induced a 91.8±11.6% 
and 100±O% pseudoexon exclusion at a concentration of 250nM and 125nM, 
respectively. The ASO directed against the donor splice site produced a modest 
pseudoexon skipping 31.8±10.3% and 46.2±19.0% at a concentration of 250nM and 
125nM, respectively. ASO br tested at a concentration of 250nM resulted in no 
pseudoexon skipping. Two ASOs, at 125nM concentration each, were then tested in the 
same splice reaction. The combination AS05'-AS03' resulted in a 49.1±37.3% 
pseudoexon exclusion, whereas the combination AS05'-ASO Br and AS03'-ASO Br 
resulted in 21.7±7.5% and 13.4±2.3% pseudoexon exclusion, respectively (Figure 5.7). 
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Figure 5.7 Effect of ASOs in HEK293 cells. A) HEK293 cells were transfected with plamid 
pcDNA3.1 Ll-GHR6\{'-L2 carrying the pseudoexon mutation ds-1 A to G and with one or more 
ASOs. One representative example of three separate experiments is presented. The position of the 
bands corresponding to the mRNA product with (294 bases) or without (186 bases) the 
pseudoexon is indicated. B) Quantitative data are presented as mean±standard deviation. 
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5.6 DISCUSSION 
The GHR pseudoexon mutation 6\{' A to G responsible for GHI has the unique 
characteristic of being associated with a wide range of phenotypes. Antisense 
oligonucleotides are effective in correcting aberrant gene splicing caused by this 
mutation, both in vitro and in a cell transfection system and represent a promising 
therapeutic tool for these patients. 
Phenotypic variability associated with the GHR pseudoexon defect 
The genetic study of GHI, the results of which are presented in Chapter 3 of this 
Thesis, demonstrated that the pseudoexon mutation was responsible for causing GHI in 
seven novel cases. Clinical data for these patients were pooled together with those of the 
initial 4 cases described in 2001, with the aim to identify the genotype-phenotype 
relationship of this mutation. Analysis of morphological features, as well as biochemical 
and auxological data, revealed the presence of a wide range of phenotypes associated 
with this mutation. Phenotypic variability in GHI patients with the same mutation has 
been described (Rosenbloom et aI., 1990, Rosenfeld et aI., 1994, Woods et aI., 1997), but 
was particularly striking in patients with the pseudoexon mutation. The 5 members of 
family A had normal facial features and a mild degree of GHI, with low but detectable 
IGF-I levels and heights ranging from -3.3 to -5.6 SDS. The remaining six patients have 
phenotypes varying between mild GHI with no typical Laron features (patient El and 2), 
to very severe GHI coupled with typical LS facial features (patient B 1), which is more 
severe than that originally reported (Metherell et aI., 2001) .. 
The variability in clinical phenotypes observed in patients carrying the pseudoexon 
mutation may be due to the presence of transcript heterogeneity. The presence of a splice 
mutation may result in competitive use of the normal and mutant splice sites and the 
production of different transcripts. Analysis of cDNA from patients carrying splice 
mutations has demonstrated that multiple abnormal splicing events can occur alongside 
the production of varying amounts of the normal splice product (Zhu et aI., 1997, 
Lemahieu et aI., 1999). It is, therefore, possible that mildly affected subjects in the 
pseudoexon cohort have a GHR transcript ratio in favour of the normal protein, while 
severely affected patients have a ratio in favour of the mutant GHR. 
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Alternative explanations for the clinical heterogeneity over and above that observed 
with typical missense and nonsense mutations of the GHR can be envisaged. The 
inclusion of the pseudoexon leads to impaired trafficking of the GHR (Maamra et aI., 
2006). Genetic variability in components of GHR processing and trafficking might, 
conceivably, have a greater influence on the mutant GHR than they do on the wild type. 
The same may be true for components of the receptor degradation pathways. 
Use of ASOs for correction of the aberrant splicing caused by the 6'1' GHR 
defect 
The presence of a wide range of phenotypes associated with the pseudoexon 
mutation leads one to speculate that there could be an even milder phenotype associated 
with it. The possibility arises that the pseudoexon mutation could be responsible for a 
small number of idiopathic short stature patients. The potential clinical involvement of 
this defect beyond GHI led to the search for a therapeutic tool to restore correct GHR 
splicing. The RNA antisense approach (ASOs) is currently used to correct aberrant 
splicing causmg neurodegenerative diseases and haematopoietic disorders, with 
promising results in vitro as well as in animal models (Dominski and Kole, 1993, 
Sierakowska et al., 1996, Vacek et al., 2003, van Deutekom and van Ommen, 2003, Hua 
et al., 2007). The present study is the first to adopt this technique to correct an endocrine 
disorder. The A to G base change at the 5' splice-site responsible for GHI in patients with 
the pseudoexon mutation, does not create a new donor splice-site, but increases the base-
pair match of the existing donor site with the VI snRNA. The simultaneous activation of 
a cryptic acceptor splice site leads to the recognition by the spliceosome of the 
pseudoexon sequence and its inclusion in the mature mRNA (Metherell et aI., 2001, 
Akker et al., 2007). 
This study tested the use of ASOs for blocking the aberrant splice site or other 
major splicing elements within the GHR pseudoexon, affecting the ability of the splicing 
machinery to recognise the pseudoexon sequence and, thus, restoring correct gene 
splicing. An ASO directed against the mutant donor splice site of the pseudoexon was 
tested alongside ASOs targeted against two additional major splicing regulatory 
elements: the acceptor splice site and the branch point. The efficiency and optimal 
conditions of the three ASOs were first tested using the in vitro splicing assay and then in 
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HEK293 cells transfected with the mutant plasmid. This cell transfection system was 
used because of the non-availability of cells from patients with the pseudoexon mutation. 
As expected, the effect of the ASOs was dose-dependent, with an optimal effect 
seen at concentrations between lOO-250nM. Surprisingly, the most effective ASO in 
restoring correct splicing, both in vitro and in the cell system, was the one against the 
acceptor splice site whereas the ASO against the donor splice site, where the pseudoexon 
mutation occurs, only showed a modest effect. Since very little is known about the 
precise mechanism of action of the ASOs, it is difficult to explain this finding. The 
presence of a different accessibility of the acceptor versus the donor splice sites in the 
two cell lines used in this study (HeLa cells for the in vitro splicing assay and HEK293 
cells for cell transfection studies) may justify the superior efficacy of the ASO targeting 
the 3' splice site compared to the ASO targeting the 5' splice site and testing of ASOs on 
additional cell lines would be advisable. 
Although some studies have suggested that targeting more than one splice element 
can be more effective than targeting a single one, this study demonstrated that 
simultaneous use of two ASOs is less effective and partially abolished the effect of 
individual ASOs, both in vitro and the cell system. This was particularly evident in the 
case of the ASO targeting the branch point (ASO br) which, used together with other 
ASOs, significantly blunted their effect. The mechanism responsible for this phenomenon 
remains unknown, but a promoting effect of the ASO br on GHR pseudexon inclusion 
appears unlikely. In fact, when tested in vitro on the wild type GHR minigene, the ASO 
br did not result in inclusion of the pseudoexon in the spliced mRNA. 
Limitations 
A limitation of this study is the lack of data on the effect of ASOs on the cells of 
GHI patients expressing the mutant GHR. Although the results of this study suggest a 
sequence-specific effect of the 3' ASO, the possibility cannot be excluded that this ASO 
can also block additional splice sites similar to the GHR 6'¥ pseudoexon, located in other 
pre-mRNAs. Assessment of the specific skipping of the GHR pseudoexon induced by the 
3' ASO in the cells of GHI patients is potential future work, as is the use of a scrambled 
3' ASO, which may provide further information on the ASO specific sequence effect. 
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Conclusion 
In conclusion, the GHR pseudoexon mutation is associated with a wide range of 
GHI phenotypes and should, therefore, be considered in all GHI patients in whom no 
mutation in the coding region of the GHR is found, regardless of the severity of their 
disease. Use of RNA antisense nucleotides for restoring aberrant splicing caused by the 
GHR pseudoexon mutation appears promising and results from this study could fonn the 
basis for gene therapy in patients with GHI caused by this defect. 
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CHAPTER 6 
GHR ALTERNATIVE EXONS AND PSEUDOEXONS 
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6.1 BACKGROUND 
The pre-mRNA of a gene can be spliced in different ways (Johnson et al., 2003). 
This process, called alternative splicing, is abundantly used in higher eukaryotes and is 
believed to playa fundamental role in producing multiple transcripts from the same pre-
mRNA, which differ in structure and function according to the type of tissue or 
developmental stage (Modrek et al., 2001, Stetefeld and Ruegg, 2005, Blencowe, 2006) 
(Figure 6.1). The reason why some exons are always included in the mature mRNA 
(constitutive exon), whereas others are only expressed in certain tissues or developmental 
stages (alternative exon) remains unknown. Possible explanations for this phenomenon 
include the presence (or absence) of tissue- or developmental-specific splicing factors in 
the gene-surrounding environment and the inefficient recognition of the alternative exon 
by the splicing machinery (Stamm et al., 1994, Stamm et al., 2000). 
Pre-mRNA mRNA 
Figure 6.1 Schematic representation of alternative splicing. Coding exons are presented in 
blue and the alternative exon in pink. 
The activation of an alternative exon can either maintain the open reading frame 
resulting in a novel translation product, or cause the appearance of a premature stop 
codon and potential degradation of the alternative protein variant. The latter often causes 
gene silencing and is a well recognised regulatory process of gene expression. 
Determination of gender in the Drosophila, which results from alternative gene splicing 
in embryonic life, is an example of this process. Inclusion of an alternative ex on in the 
sex-lethal protein pre-mRNA, in fact, results in the appearance of a premature stop codon 
leading to a truncated non-functional protein, which is responsible for male development 
(Gebauer et al., 1998). In addition to its regulatory role in physiological processes, 
alternative splicing is also thought to be involved in the pathogenesis of various diseases. 
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In particular, an association between neoplasia and expressIOn of alternative splice 
variants of proteins involved in cell adhesion and migration has been proposed (Gunthert 
et aI., 1991). 
DNA and RNA analysis has shown that, in addition to constitutive and alternative 
exons, introns are rich in sequences matching the consensus donor and acceptor splice 
sites. Such potential exons, are known as pseudoexons. Pseudoexons greatly outnumber 
real exons. Although their splice sites often match the consensus sequence better than real 
exons splice sites, they are not recognised by the spliceosome. It is thought that the 
presence or absence of additional splice elements, such as silencers and enhancers, as 
well as the exon surrounding environment, greatly influence the recognition of 
pseudoexons. However, subtle DNA changes in the pseudoexon sequences are at times 
sufficient to activate them. These events are generally associated with a disease (Akker et 
aI., 2007) and such an example is the intronic mutation identified in 2001 by our group in 
the GHR of four children with non-classical GHI (Metherell et aI., 2001). 
To date, no functional transcripts deriving from the expression of alternative exons 
located in the intronic regions between coding exons of the GHR have been described. 
The d3-GHR, a GHR protein that lacks 22 amino acids, in fact, derives from a gene 
variant, which lacks the genomic sequence coding for exon 3 (Pantel et aI., 2000). The 
only example of alternative splicing occurring in the GHR is the GHR variant arising 
from the utilisation of a splice site different to the natural splice site in ex on 9. This 
variant (GHR 1-279) encodes for a prematurely truncated receptor that lacks most of its 
intracellular domain. It is expressed in several tissues (Ballesteros et aI., 2000) and exerts 
a dominant negative effect on the wild type GHR (Ross et aI., 1997). While the 
physiological role of this transcript remains unclear, its discovery unveiled its therapeutic 
potential in the treatment ofGH/IGF-I disorders (Wilkinson et aI., 2007). 
The identification of alternative exons and pseudoexons relies on the study of 
mRNA from normal tissues and from patient samples, respectively. With this approach, 
however, transcripts present at a very low concentration or inducing mRNA nonsense 
mediated decay (NMD) may not be recognised unless specific probes targeting the novel 
exons are used. The currently available in silica ex on prediction programs are able to 
predict constitutive coding exons in uncharacterised genes. Programs, such as FEX have 
an internal exon prediction accuracy of 77%, with a specificity of 79% (Solovyev et aI., 
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1994b, Solovyev et aI., 1994a). Nevertheless, these programs rely on the recognition of 
exons, which would not interrupt the open reading frame (ORF) of a gene and, thus, 
automatically exclude exons that would cause a frameshift. Such exons may exist and 
prematurely truncated transcripts may have a regulatory role. 
The identification of alternative exons and regions rich in potential exons in the 
GHR may shed new light on the physiology of the GH/IGP-I axis and help the diagnostic 
screening of GHI patients with no mutations in the GHR coding region. 
162 
Chapter 6 GHR alternative exons and pseudoexons 
6.2 HYPOTHESIS AND AIMS 
The aim of the study was to: a) create an algorithm for identifYing potential 
alternative exons and pseudoexons in the GHR; b) compare these results to those 
obtained using an available in silica exon prediction program and ESTs; c) test the 
presence of potential novel exons in human cDNA; d) investigate the presence of newly 
identified exons in eDNA samples of GHI patients with no mutations in the GHR coding 
region. 
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6.3 COMPUTATIONAL APPROACH 
6.3.1 Criteria used for the construction of the algorithm 
The GHR sequence was obtained from www.ensembl.org. An arbitrary 1339 bases 
before the initial GHR Methionine and 48 bases after the last GHR coding triplet were 
used to select the 154,935 nucleotide sequence, which was analysed for the presence of 
alternative exons and pseudoexons. The Alex Dong Li's splice site finder 
(http://violin.genet.sickkids.on.ca/~ali/) was used to identify all potential donor and 
acceptor splice sites as well as branch points. This in silica program, which uses matrices 
described by Shapiro and Senapathy (Shapiro and Senapathy, 1987), was chosen over 
other available programs because it allows automatic matching of acceptor sites and 
branch points. 
The matrix for the algorithm was created with the help of Dr Dimopoulos, 
epidemiologist at Imperial College, using R version 2.6.2 (R Development Core Team, 
2008, R Foundation for Statistical Computing, Vienna, Austria). This is a freely available 
software language and environment for statistical computing and graphics (www.r-
project.org). R provides a wide variety of statistical (linear and nonlinear modelling, 
classical statistical tests, time-series analysis, classification, clustering) and graphical 
techniques, and is highly extensible. The R language is a well-developed, simple and 
effective programming language which includes conditionals, loops, user-defined 
recursive functions and input and output facilities. 
Bioconductor and its package seqinr were used for importing genomic data and 
translating triplets into amino acids or stop codons. Bioconductor is an open source and 
open development software project aimed at providing tools for the analysis and 
comprehension of genomic data (www.bioconductor.org). Bioconductor is based 
primarily on the R programming language. The majority of Bioconductor components are 
distributed as R packages, which are add-on modules for R. 
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The following criteria were used to identify potential GHR alternative exons and 
pseudoexons: 
a. the presence of a score 2: 65 for donor and acceptor splice sites. This threshold was 
arbitrary and corresponded to the lowest score among donors and acceptors sites of 
constitutive GHR exons (GHR donor splice site =65.3); 
b. the presence of at least one branch point sequence in the 60 bases upstream to the 
acceptor splice site, characterised by the consensus sequence CU(A/G)A(CIU) 
(Wu et aI., 1999, Smith and Valcarcel, 2000); 
c. an exon length between 50 and 200 bases. This range corresponds to the average 
length of an exon in humans (Lander et aI., 2001); 
d. the presence of a polypyrimidine tract, defined by a nucleotide ratio C+T/A+G 
2:0.5 in the 20 bases upstream of the acceptor splice site. This arbitrary cut-off 
corresponded to the lowest ratio identified upstream of constitutive exons in the 
GHR and met the requirement of a sequence significantly enriched in pyrimidines 
between the branch point and the acceptor splice site, especially next to the latter 
(Coolidge et al., 1997). 
The potential novel exonic sequences resulting from this first analysis were purged, 
discarding those a) sharing multiple donor or acceptor splice sites by choosing the best 
scoring consensus sequences, and b) having an acceptor score <80 as well as a branch 
point score <90. These criteria reflected what occurs naturally in the GHR as well as in 
other genes (Sironi et aI., 2004). 
The remaining potential exons were further purged using the following more 
stringent criteria: 1) a cut-off value 2: 74 for the acceptor splice site; 2) a cut-off value 
2:71 for the branch point. These new thresholds corresponded to the lowest scores for 
GHR constitutive exons (lowest acceptor score =74.7, lowest branch point score= 7l.6). 
Each of the remaining potential exons was inserted in the GHR mRNA according to 
its position relative to the constitutive exons and the resulting sequence was translated 
into an amino acid sequence. Stop codons were identified by the presence of TGA, TAG 
or TAA triplets. This criterion allowed subclassification of potential exons into those 
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potentially maintaining the ORF and those creating a premature stop codon in the novel 
GHR transcript. 
6.3.2 Bioinformatic tools 
The in silica exon prediction program FEX (http://linuxl.softbeny.com/berrv 
.phtml?topic=fex&group=help&subgroup=gfind) was used to identify novel potential 
exons in the GHR and its results were compared to those obtained with the novel 
algorithm created in this study. FEX was preferred over other in silica programs because 
it is free on the web, simple to use and widely adopted for the identification of coding 
exons. The reported accuracy of FEX in recognising exons, determined on a set of 210 
genes (with 761 internal exons), is 70%, with a specificity of 63%. The internal ex on 
prediction accuracy is 77%, with a specificity of 79%. The recognition quality computed 
at the level of individual nuc1eotides is 87% for exons sequences (Solovyev et aI., 1994b, 
Solovyev et aI., 1994a). 
Expressed sequence tags (ESTs) were retrieved from Ensembl (www.ensem1.org) 
and NCB I (www.ncbi.nlm.nih.gov) databases. 
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6.4 MATERIALS AND METHODS 
6.4.1 Primer design 
Forward and reverse primer pairs (sequences reported in Appendix 3, 10.3.7) 20-26 
bases long with a GC content of approximately 40% were designed to anneal within the 
potential novel exons. 
6.4.2 peR and sequencing 
The presence of the identified alternative exons was tested in liver cDNA, since this 
is the tissue in which GHR is expressed the most. The standard PCR technique was used 
to amplify liver cDNA (courtesy of Prof M. Korbonits), in a 12.5ft1 reaction with specific 
primer pairs (sequences reported in Appendix 3: 10.3.2 and 10.3 .7) and Taq polymerase 
(Sigma). To improve the specificity and sensitivity of the PCR technique, potential exons 
were amplified using a hemi-nested PCR technique. Briefly, 1 fll from the [rrst PCR 
reaction was used in a second 12.5fll PCR reaction and amplified with a second set of 
primers, one of which corresponded to the primer used in the [rrst PCR reaction, and the 
second primer annealed within the [rrst round PCR product. To identify the junction 
between a constitutive exon and the putative new exon, a forward primer was designed to 
bind within the GHR constitutive exon and the reverse primer within the novel exon. To 
identify the junction between the putative new exon and a constitutive exon, the forward 
primer was designed to bind within the novel exon and the reverse primers within the 
constitutive exons (Figure 6.2). PCR products were electrophoresed on an agarose gel. In 
the presence of multiple bands for the same PCR product, these were cut from the gel, 
purified and sequenced on the ABI 3700 Sequencer. 
.uI= ____ ~ ~ ~ I GHR ex+f- -~: Exon X ;.-1 -~1 GHR exon I 
. L C. :---:1--_: _ . 
Figure 6.2 Schematic diagram showing the design of primers for the identification of novel 
GHR exons. Primers used in hemi-nested PCRs are presented in green. Constitutive exons are 
presented as white boxes and the novel ex on as an orange box. 
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6.5 RESULTS 
6.5.1 Identification of GHR pseudoexon/alternative exons 
Analysis of the 154,935 nucleotide-long sequence of the GHR gene identified 3561 
acceptor splice sites with a score 2: 65 and a branch sequence in the upstream region and 
1639 donor splice sites with a score 2: 65. 5710 sequences with an acceptor, a donor 
splice site, a branch site and a length between 50 and 200 nucleotide were identified. 
After. purging for the presence of a polypyrimidine tract, 3093 potential exons were 
obtained. After excluding potential exons not fulfilling the criteria of having an acceptor 
score <80 as well as a branch point score <90, 2018 potential exons were obtained which 
included all constitutive GHR exons. 
To narrow down the number of potential exons, the 2018 exons were purged using 
more stringent criteria. After applying a cut-off score 2: 74 for the acceptor splice site and 
2: 71 for the branch point, 1441 potential exons and the 9 constitutive GHR exons were 
left. 
Almost all novel potential exons identified shared multiple donor or acceptor splice 
sites. After selecting the best-scoring consensus sequences, 687 potential exons remained, 
including the 9 constitutive GHR exons. Their predicted length corresponded to that 
reported in public databases, with the exception of exon 10, whose predicted length was 
189 bases instead of 972 bases. After purging for those before the beginning of ex on 2 
and after the beginning of exon 10, 460 exons remained. 
After excluding the 9 natural GHR exons, the remaining 451 potential exons where 
inserted in the GHR mRNA according to their genomic position. The majority of 
potential exons were located in IVS2 (197 exons), IVS3 (171 exons) and IVS 6 (38). 
310 potential exons were predicted to cause a frameshift and the appearance of a 
premature stop codon. 141 potential exons were predicted not to cause the appearance of 
a premature stop codon. Of these, 22 were also predicted not to cause a frameshift and 
among them was the pseudoexon 6'I' in IVS 6 (Table 6.1). 
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TABLE 6.1 POTENTIAL GHR EXONS AND PREDICTED CONSEQUENCES AT MRNA LEVEL. 
Potential exons Potential exons 
creating a stop codon not creating a stop codon 
not causing causing not causing causmg 
frameshift frameshift frame shift frame shift 
IVS 2 0 138 7 52 
IVS 3 0 114 13 44 
IVS 4 0 11 0 7 
IVS 5 0 7 1 4 
IVS 6 0 27 1 (641) 10 
IVS 7 0 4 0 0 
IVS 8 0 8 0 2 
IVS 9 0 1 0 0 
Total 0 310 22 119 
Intronic location and number of potential exons per intron (IVS) are indicated. 
6.5.2 ESTs results 
Four ESTs were annoted on Ensembl for the GHR gene: ENSESTT00000021994, 
ENSESTT00000021996, ENSESTT00000021988, ENSESTT00000021992. 
The ENSESTT00000021994 partly corresponded to the GHR intracellular domain 
(part of exon 8, exon 9 and part of exon 10). The ENSESTT00000021996 corresponded 
to the 3' UTR region. 
ENSESTT00000021988 and ENSESTT00000021992 were annotated as novel 
transcripts and their composition is depicted in Figure 6.3 
GHR 
ENSESTT 
00000021992 
ENSESTT 
00000021988 
~--------------~2 
2 
Figure 6.3 Schematic representation of two ESTs reported for the GHR. 
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ENSESTT00000021992 is composed of four exons (Figure 6.3). The first two 
exons constitute a 5'UTR and are followed by GHR exon 2 and by a novel exon, 
arbitrarily called Xl for the purpose of this Thesis. This exon is located in IVS2, 53,707 
bases downstream of the GHR exon 2 donor site and is 163 bases long. The predicted 
transcript for this EST is 608 bases long and translates into a 45 amino acid sequence. 
The A TG starting codon of this transcript is predicted to correspond to the wild type 
GHR starting codon in exon 2, whereas the stop codon is located within exon Xl. 
ENSESTT00000021988 is composed of 6 exons (Figure 6.3). The first exon is in 
the 5 'UTR and contains the A TG codon for the initial methionine. This exon is followed 
by the GHR exons 2 and 3 and by three novel exons located in intron 3, which, for the 
purpose of this Thesis, will be arbitrarily called exons X2, X3 and X4. The length of 
these novel exons is 32, 145 and 161 bases, respectively. The predicted transcript for this 
EST is 566 bases long and translates into a 69 amino acid sequence. The location of the 
ATG starting codon for this transcript is predicted 10 bases upstream of the start of GHR 
exon 2 whereas its stop codon is predicted within exon X3. 
6.5.3 Results from FEX IN SILleo exon prediction program 
The same 154,535 nucleotide-long GHR sequence was analysed for coding and 
alternative exons using the FEX in silica exon prediction program. A total of 161 
potential exons were identified. Of these, 159 were located after the triplet coding for the 
start of the GHR protein. Seven of 9 natural GHR exons and the pseudoexon 6\f' were 
included in these. GHR exons 8 and 9 were not recognised. FEX correctly identified the 
position and length of 5 (exons 3, 5, 6, 7, 10) out of the 7 identified constitutive GHR 
exons and those of the pseudoexon 6\f'. The beginning of exon 4, corresponding to its 
acceptor site was correctly identified, but the predicted exon length was shorter than that 
reported in public databases (87 versus 130 nucleotides). The beginning and end of exon 
2 were not correctly identified. Moreover, its predicted lenght was longer than that 
reported in public databases (122nt versus 81nt). Of the four potential exons (X1-X4) 
present in the GHR ESTs, only one corresponding to exon X2 was identified, even 
though predicted to be a first ex on of 31 bases. Neither exon Xl, X3, X4 were predicted 
byFEX. 
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6.5.4 Identification of alternative GHR variants 
Three out 4 exons (exons Xl-X3) described in the two ESTs were identified by the 
new algorithm. Their predicted length was: exon Xl= 64 bases, exon X2= 139 bases, 
exon X3= 145 bases. After insertion in the GHR mRNA, all three were predicted to 
create a frameshift and a premature stop codon. The presence of exon X4 was not 
predicted. 
Primers were designed to amplify the four exons Xl-X4 based on the ESTs and the 
algorithm predictions. Amplification of liver cDNA with a heminested PCR technique, 
using two sense primers in the GHR exon 2 (2FiGHRm and 2FfGHRm) and an antisense 
primer in exon Xl (exon XlR), produced three products (Figure 6.4), which were cut 
from the gel, purified and sequenced. The smaller product of approximately 110 bases 
revealed the presence of a sequence corresponding to 58 bases within ex on X 1. The other 
two fainter products did not sequence and their identity remains unknown. Amplification 
of liver cDNA using a sense primer in exon Xl (exon X 1 F) and two antisense primers in 
the GHR ex on 6 (6RGHRm) and 5 (5RGHRm), resulted in a product of approximately 
800 bases (Figure 6.4). This was cut from the gel, purified and sequenced, revealing a 
novel 613 base-long sequence, which spliced into the GHR exon 3 (Figure 6.5). This 
novel exon - exon Xa - is likely to continue into ex on Xl, and thus be more than 900 
bases long. Since the chromatogram did not show its remaining upstream 200 
nucleotides, exons Xl and Xa will be considered as two separate exollS. 
Amplification of GHR liver cDNA using primers annealing to sequences within 
exon X2 did not result in PCR products. 
Amplification of GHR liver cDNA with a heminested PCR technique, usmg 
primers annealing to sequences within exon X3 resulted in two products of approximately 
150 bases [sense primers in exon 2 (2FiGHRm and 2FfGHRm) and antisense primer in 
exon X3 (exon X3R)] and 400 bases [sense primer in exon X3 (exon X3F) and antisense 
primers in exon 6 (6RGHRm) and 5 (5RGHRm)] (Figure 6.4). These products revealed 
the presence of a sequence corresponding to exon X3, located between GHR exons 3 and 
4 (Figure 6.6). This novel exon is predicted to produce a frameshift and the appearance of 
a premature stop codon 96 residues after the first methionine when inserted in the wild 
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type GHR mRNA and after 57 residues when inserted in the d3-GHR mRNA (Figure 
6.7). 
Amplification of GHR liver cDNA using primers annealing to sequences within 
exon X4 did not result in any PCR product. 
bI) bI) bI) Q) Q) ~ ~ Q) bI) ~ If) If) 
M M Q) If) If) ~ ~ X X ~ ~ ~ Q) ~ 
~ ,........; 1-< ~ ,........; Q) Q) I I 1-< X X ,........; ,........; Q) ~ Q) ~ I 1-< I X X ~ I I ~ I I M Q) M 1-< 
('.l ('.l 1-< ('.l ('.l X ~ X ~ ro ~ ~ ro ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ 
Figure 6.4 RT -peR products from liver cDNA using primers against GHR exons Xl and 
X3. 
The presence of the newly identified altermative exons XI, Xa and X3 was 
investigated in GHI patients with no defects in the GHR coding region. cDNA from 
leukocytes was amplified using the above primers, but revealed the presence of multiple 
non-specific products. 
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Figure 6.5 Novel GHR transcript with an alternative exon in intron 2. Panel A: schematic 
representation of the GHR genomic sequence containing exons Xl and Xa. Primer location is also 
depicted. Exons for this region, identified by ESTs and cDNA analysis and predicted by FEX and 
the novel algorithm, are also presented overhead as blue rectangles and their length in bases is 
indicated. Panel B: exon Xa sequence resulting from liver cDNA amplification. The junctions 
between the alternative exon Xa and the GHR coding exons 3 and 4 are also indicated. 
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Figure 6.6 Novel GHR transcript with alternative exon X3 in intron 3. Panel A: schematic 
representation of the GHR genomic sequence containing exon X3 . Primer location is also 
indicated. Exons for this region, identified by ESTs and cDNA analysis and predicted by FEX 
and the novel algorithm are also presented overhead as blue rectangles and their length in bases is 
indicated. Panel B: partial sequence resulting from liver cDNA amplification. The junctions 
between the alternative exon X3 and the GHR coding exons 3 and 4 are also indicated. 
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GHR wt MDLWQLLLTL ALAGSSDAFS GSEATAAILS RAPWSLQSVN PGLKTNSSKE 
GHRX3 MDLWQLLLTL ALAGSSDAFS GSEATAAILS RAPWSLQSVN PGLKTRVLlIA 
GHR wt PKFTKCRSPE RETFSCHWTD EVHHGTKNLG PIQLFYTR 
GHR X3 SLMQSREAHQ LEGSMNEITR KSSLEKLTL* 
GHR d3 wt MDLWQLLLTL ALAGSSDAFS GSEDSSKEPK FTKCRSPERE 
GHR d3 X3 MDLWQLLLTL ALAGSSDAFS GSEGVLHASL MQSREAHQLE 
GHR d3 wt TFSCHWTDEV HHGTKNLGPI QLFYTR 
GHR d3 X3 GSMNEITRKS SLEKLTL* 
Figure 6.7 Amino acid sequences for the novel GHR transcript. Top: the amino acid sequence 
of the wild type GHR (GHR wt) is compared to the predicted amino acid sequence of the novel 
GHR transcript with alternative exon X3 (GHR X3). Bottom: amino acid sequence of the two 
transcripts in the absence of exon 3 (GHR d3 wt, and GHR d3 X3). Frameshift and the 
appearance of a novel amino acid sequence are indicated in blue. 
6.5.5 Comparison between FEX and the novel algorithm 
For the purpose of this Chapter, exons present in public databases or identified by 
cDNA analysis will be considered as true exons, as opposed to false exons not present in 
public databases or not identified by cDNA analysis. 
The novel algorithm correctly identified 9 out of 9 constitutive exons, the 
pseudoexon 6'I' and 3 out of 3 alternative exons (exon Xl, Xa and X3), thus resulting in 
the prediction of 13 out of 13 true exons. In particular, it predicted the presence of an 
exon of 184 bases for the region containing exon Xa and the presence of two exons of 64 
and 193 bases for the region containing exon Xl. An exon of 139 bases was predicted in 
the region between exon Xl and Xa (Figure 6.5). Moreover, the algorithm correctly 
predicted the position of the acceptor splice site of the 9 constitutive exons, the 
pseudoexon 6'I' and the alternative ex on X3 and correctly predicted the donor splice site 
of 8 out of 9 constitutive exons, the pseudoexon 6'I' and the alternative exon X3. The 
predicted donor splice site of exon 10 (last exon of the GHR) was 189 bases distal to the 
acceptor site compared to 972 bases annotated on public databases. The algorithm also 
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predicted the presence of 445 false exons, of which 21 would not cause a frameshift or 
the appearance of a premature stop codon if inserted in the mRNA. 
The in silica exon prediction program FEX identified 7 out of 9 constitutive exons, 
the pseudoexon 6\{' and exon Xa but did not predict exons Xl and X3, thus resulting in 
the prediction of 8 out l3 positive exons. Moreover, it correctly predicted the position of 
the acceptor splice site of 5 constitutive exons and the pseudoexon 6\{', and correctly 
predicted the donor splice site of 6 constitutive exons, the pseudoexon 6\{' and exon Xa. 
The algorithm also predicted the presence of 151 false exons, all of which would 
maintain the ORF, when inserted in the mRNA. 
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6.6 DISCUSSION 
In this study, a novel exon prediction algorithm was specifically designed to search 
for alternative exons in the GHR. Its results, combined with the analysis of ESTs 
annotated in public databases, identified the first two alternative transcripts for the GHR, 
both of which arose from the use of novel alternative exons located in intronic sequences 
between constitutively expressed GHR coding exons. 
Alternative splicing is abundantly used in higher eukaryotes and is thought to play 
a fundamental role in determining their functional diversity and complexity (Modrek et 
aI., 2001, Stetefeld and Ruegg, 2005, Blencowe, 2006). In 40-60% of human genes, the 
inclusion or exclusion of alternative exons within constitutive exons gives rise to 
structurally and functionally different transcripts from the same pre-mRNA, in different 
tissues and developmental stages (Johnson et aI., 2003). To date no GHR variants arising 
from the use of alternative exons, are known, with the exception of alternative first exons 
in the 5' untranslated region (Pekhletsky et aI., 1992, Edens and Talamantes, 1998). 
The identification of alternative exons relies on the alignment of genomic 
sequences to ESTs available from public databases and to cDNA deriving from different 
tissues and developmental stages (Gelfand et aI., 1999, Kan et aI., 2001, Modrek et aI., 
2001). In silica programs, such as the exon prediction program FEX, are important tools 
for the identification of coding exons from uncharacterised genes, but are of little help 
when looking for alternative exons or genomic areas containing pseudoexons. The 
identification of the latter is, generally, an incidental finding during analysis of patient 
mRNA. 
Comparison between the novel algorithm and the in silico prediction program. 
The algorithm presented in this study was constructed specifically for the 
systematic search of GHR alternative exons or pseudoexons located in intronic regions 
between constitutive exons. Like all exon prediction programs, the algorithm was based 
on the fundamentals of gene splicing, but the identification of promoters, translation 
initiating and terminating sites and poly(A)-signals was not included as its purpose was to 
search for internal exons. Compared to a largely used in silica ex on prediction program 
(FEX), the algorithm was better in recognising constitutive and alternative exons. In fact, 
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not only did it predict all constitutive GHR exons, but also predicted the pseudoexon 6'P 
and the three novel alternative exons identified by cDNA analysis in this study. 
Moreover, compared to FEX, it had a superior splice site recognition accuracy. This may 
be explained by the use of criteria, which take into consideration the characteristics of 
alternative exons. Identification of a potential exon did not, in fact, require the strict 
adherence of its splice elements to a consensus sequence, thus differentiating this 
algorithm from other available in silico prediction programs. Alternative exons are 
characterised by a reduced number of regulatory elements and by splice elements that 
deviate from the consensus sequences more than the splice sites of constitutive exons 
(Stamm et aI., 1994, Stamm et aI., 2000). The cut off value (score> 65) used in this study 
to identify splice sites, reflected a mere 65% adherence to the consensus sequences and 
was chosen based on the characteristics of the GHR exon splice sites. Thus, although the 
algorithm is potentially applicable to any gene, the cut-off values used were specific for 
the GHR. 
Another important difference between the algorithm developed in this study and 
other in silico exon prediction programs, was the omission of the requirement to maintain 
the ORF after insertion of the predicted exons in the mRNA. In silico programs are 
designed to identify constitutive coding exons and require potential regions to meet the 
fundamental criteria of protein coding, such as maintenance of the ORF. Nevertheless, 
the presence of alternative exons which, when included in the mRNA give rise to 
premature protein truncation have been described and alternative splicing leading to non-
functional proteins is a well recognised regulatory process (Gebauer et aI., 1998). 
Similarly to FEX, the algorithm identified numerous additional potential exons, 
confirming that introns are rich in sequences that resemble potential exons. To further 
improve the sensitivity of the algorithm, the presence of exonic hexamers corresponding 
to enhancers and silencers could have been taken into account. These splice elements are 
very important in determining exon expression and/or silencing, but their prediction is 
extremely difficult. Hexamers corresponding to exonic silencers are not well 
characterised and the hexameric sequences of exonic enhancers highly diverge from 
consensus sequences (Watakabe et aI., 1993, Liu et aI., 1998, Blencowe, 2000, Cartegni 
et aI., 2002). Despite these difficulties, introduction of these criteria in the algorithm is 
part of future work. 
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Identification of novel GHR transcripts 
Analysis of GHR intronic regions revealed that introns 2, 3 and 6 were the richest 
in sequences resembling potential exons. The GHR 6'¥ pseudoexon described in 2001 is, 
in fact, located in intron 6 and was among the predicted exons. Comparison of the results 
obtained from the novel algorithm and the GHR ESTs was performed for selecting 
intronic regions to be screened for the presence of alternative exons. This led to the 
identification of novel GHR transcripts arising from the expression of alternative exons. 
One of these exons was located in intron 3 and its sequence and length were correctly 
predicted by the algorithm, but not recognised by FEX. This alternative exon was present 
in one EST, but was predicted to be joined at its 5' splice site to additional alternative 
exons and not to splice into the GHR coding exons. The results of this study 
demonstrated, instead, that this novel alternative exon is inserted between the GHR 
coding exons 3 and 4. It does not have a polyadenylation signal (AAUAAA sequence) 
and is predicted to result in a frameshift and the appearance of a premature stop codon. 
The translation product of this novel GHR transcript lacks the amino acid sequence 
corresponding to the GH binding domain. Nevertheless, it remains to be clarified whether 
it has a regulatory effect on the wild type GHR. 
Screening of liver cDNA identified a second intronic region located in intron 2, 
which is recognised by the splice machinery. Although two novel exons (Xl and Xa) 
have been predicted to arise from this region, it is more likely that they are part of a 
single alternative exon, approximately 900 nUcleotides long, which splices into exon 3 of 
the GHR. The beginning of this alternative exon was correctly identified by the 
algorithm, although its length was predicted to be 68 nUcleotides long. This is not 
surprising, since one of the criteria for exon identification was a maximum length of 200 
nuc1eotides. 
These two novel transcripts may simply represent biological nOIse and, in this 
respect, analysis of GHR from other species may be of help. Conservation of an element 
among species is, in fact, highly suggestive of its functional significance. The possibility 
arises that these novel alternative transcripts may have a regulatory effect in specific 
tissues or developmental stages. Moreover, the presence of a SNP or a genetic defect 
within splice elements of these novel exons may increase the expression of the latter, 
resulting in the overexpression of the novel GHR variants over the wild type GHR, or 
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simply in silencing of the wild type GHR leading to GHI. The presence of these two 
novel alternative transcripts was investigated in GHI patients with no mutations in the 
GHR coding exons, but amplification of cDNA from leukocytes failed to produce 
specific products. This may be a consequence of the absence of GHR mRNA in these 
patients or may simply reflect the low amount of these transcripts in tissues other than 
liver. Nevertheless, the presence of activating mutations in these alternative exons cannot 
be excluded, since screening at genomic level was not performed in these patients. 
Conclusion 
The novel algorithm created in this study was superior to a largely used in silica 
exon prediction program in identifying GHR constitutive and alternative exons. The 
results obtained with this novel algorithm, in conjunction with EST analysis, allowed the 
identification of the first two GHR alternative transcripts known to date. The discovery of 
these novel coding regions prompts the screening of these DNA sequences in GHI 
patients with no mutations in the GHR constitutive coding exons. Moreover, increasing 
the expression of these regions with a target gene therapy may represent a potential novel 
approach to modulating GH sensitivity. 
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CHAPTER 7 
HETEROZYGOUS DEFECTS OF THE ACID-LABILE 
SUBUNIT GENE IN IDIOPATHIC SHORT STATURE 
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7.1 BACKGROUND 
Short stature is one of the most common cause of referral to paediatric 
endocrinologists. When no specific aetiology can be identified, a diagnosis of idiopathic 
short stature (ISS) is made. Into this category fall patients with heights 2 standard 
deviation scores (SDS) below the mean and normal birth size, in whom no endocrine or 
systemic diseases are found and no known genetic causes of short stature or other factors 
compromising growth are present (Wit et aI., 200Sa, Wit et aI., 200Sb). The biochemical 
profile and response to GH treatment of ISS patients is heterogeneous (Wit and Rekers-
Mombarg, 2002, Leschek et aI., 2004, Hintz, 2005) and could be influenced by the 
presence of multiple, as yet unidentified, pathological mechanisms contributing to short 
stature. Numerous genes in the GH-IGF-I axis are known to be involved in linear growth 
in childhood (Walenkamp and Wit, 2006, Weedon et aI., 200S) and molecular 
investigations have recently identified several functional mutations in genes coding for 
key proteins in patients previously labelled as having ISS (Ayling et aI., 1997, Metherell 
et aI., 2001) Single heterozygous defects in the GHR have been proposed as possible 
causes ofISS (Goddard et aI., 1995), but data are inconclusive as cosegregation of short 
stature and the heterozygous state is poor (Rosenbloom et aI., 1994a). Defects in the 
Short stature HOmeoboX (SHOX) gene have also been reported to be associated with 
isolated or familial ISS in up to 4% of cases (Rappold et aI., 2002). 
The clinical role of the acid-labile subunit (ALS), an S4-S6 kDa protein, which 
circulates in the serum and binds to IGF-I and IGFBP-3 to form the circulating ternary 
complex (Baxter, 1994), has come under scrutiny since the recent discovery of a 
homozygous inactivating mutation in the ALS gene (IGF ALS) in a patient with mild 
growth retardation (Domene et aI., 2004). The observation that heterozygous parents of 
patients with homozygous IGFALS defects (Hwa et aI., 2006, Domene et aI., 2007, 
Duyvenvoorde et aI., 200S, Heath et aI., 200S) are of short stature, was the basis for this 
project. 
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7.2 ORIGINAL HYPOTHESIS AND AIMS 
The aim of this study was to investigate the role of heterozygous IGFALS defects in 
the pathogenesis of mild short stature by direct sequencing of the IGF ALS in a cohort of 
prepubertal ISS patients. Moreover, the study aimed to analyse the auxological and 
biochemical profile of ISS patients with single heterozygous IGF ALS defect, and 
compare these data to those obtained from ISS children without IGFALS defects. The 
impact of single heterozygous IGF ALS defects on ternary complex formation was also 
assessed by means of size exclusion chromatography and the presence of the same defect 
in first degree family members of ISS children with heterozygous IGFALS defects was 
investigated. 
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7.3 STUDY POPULATION 
Patients of Caucasian origin followed at the Paediatric Endocrine Unit at the Royal 
London Hospital, London, UK were included in the study. Inclusion criteria were: 
prepubertal status, height SDS :::; -1.88 at ~ 3 years of age, birth weight and/or birth length 
SDS > -2.0 and exclusion of GH deficiency by peak GH level after glucagon provocation 
test ~10mU/I. Exclusion criteria were: chromosomal or genetic abnormalities, 
disproportionate short stature, chronic illnesses or endocrine disease. Parents and siblings 
of the ISS population were also enrolled in the study. Unrelated controls of normal 
stature and similar ethnic origin to the study population were also included and their 
IGFALS sequenced to derive the allele frequency of the newly identified mutations. All 
patients and parents gave written informed consent and the study was approved by the 
North East London Research Ethics Committee. 
Height and weight were measured using standard anthropometric techniques 
(Cameron, 2002) and were converted into SDS. Birth weight SDS was calculated 
according to the LMS method (Cole, 1990, Freeman et aI., 1995). Body mass index 
(BMI) was calculated as follows: Weight (Kilograms)/Height (meters) squared. BMI 
SDS was calculated according to the UK 1990 standards (Cole et aI., 1995). Pubertal 
status was assessed according to the criteria of Tanner (Marshall and Tanner, 1969, 
Marshall and Tanner, 1970). Boys were considered prepubertal if genitalia were stage 1 
and testicular volume was < 4ml (Zachmann et aI., 1974). Girls were prepubertal if 
breast development was stage 1 (Marshall and Tanner, 1969). DNA was available from 
52 of these ISS patients for IGFALS analysis and from 50 normal controls. 
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7.4 MATERIALS AND METHODS 
7.4.1 DNA extraction from blood samples and peR 
Genomic DNA was extracted from peripheral blood leucocytes. IGF ALS exons 1 
and 2 and their intronic boundaries were amplified by PCR using specific primers (primer 
sequences reported in Appendix 3: 10.3.3). Cycling conditions were 95°C for 2 min (1 
cycle); 95°C for 30 sec, 63°C for 30 sec and noc for 30 sec (35 cycles); and noc for 5 
min. PCR products were visualised on 1 % agarose gel and sequenced using the ABI 3700 
automated DNA sequencer. SNPs data were obtained from the Ensembl database 
(www.ensembl.org). 
7.4.2 Size exclusion chromatography 
Samples were fractioned on a HiPrep 16/60 Sephacryl S-200HR column as 
described in Materials and Methods 2.9.3. Briefly, serum samples (l00).!1) were incubated 
overnight at 22°C with 3.5xl06 counts per minute of 125I-labeled IGF-I and then cross-
linked with 5mM disuccinimidyl suberate. After 30 min, the cross-linking reaction was 
stopped by adding 1M Tris HCI. Five hundred ml were loaded into the column and 1ml 
fractions were collected and counted. Incorporation of 125I-labeled IGF-I in the ternary 
complex was calculated as: (sum of iodine count per minute in the ternary complex 1 total 
iodine count per minute) xl00. 
7.4.3 Biochemical assessment 
The biochemical assessment of all patients and the family members of those 
carrying the IGFALS mutations, was performed by assessing serum IGF-I, IGFBP-3 and 
ALS concentrations from venous blood samples. GH-dependent proteins levels were 
measured by Dr J Jones at the Diagnostic Systems Laboratories (DSL), GKT, School of 
Medicine King's Denmark Hill Campus, London, UK, using an enzyme-linked 
immunosorbent assay (ELISA kit; Diagnostic System Laboratories, Inc. Webster, TX, 
USA) as described in Chapter 3, section 3.4.5, of this Thesis. Normative values were 
obtained from DSL. 
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7.4.4 Statistical Analysis 
Statistical analyses were performed using R version 2.6.2 (R Development Core 
Team, 2008, R Foundation for Statistical Computing, Vienna, Austria). Numerical 
variables were expressed as median (range) and categorical variables as number 
(percent). Comparison between continuous variables was performed using Wilcoxon's 
rank sum test. Comparison between categorical variables was performed using Fisher's 
exact test. A two-sided p-value <0.05 was considered indicative of statistical significance. 
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7.5 RESULTS 
7.5.1 Auxological and biochemical characteristics of ISS subjects 
Fifty two prepubertal unrelated patients (14 female, 38 male) of Caucasian origin 
were included in the study. Median age was 7.9 yrs (range 3.0 to 14.5 yrs) and birth 
weight SDS was -0.54 (-1.92 to 0.80). Median height SDS was -2.48 (-3.60 to -1.91), 
weight SDS -2.43 (-4.24 to 0.43) and BMI SDS -0.69 (-3.24 to 1.33). Median IGF-I SOS 
was -0.42 (-3.50 to 2.74), IGFBP-3 SDS was -0.40 (-2.30 to 0.90) and ALS SOS was -
0.67 (-5.64 to 7.88). 
7.5.2 Genetic analysis 
Direct sequencing of the IGFALS identified 4 single heterozygous base changes. 
These were: C to T at position 65 (P22L), C to T at 860 (P287L), C to G at 1357 (L453V) 
and C to T at 1577 (P526L) (Figure 7.1). 
These four variants were not detected in 50 normal controls. The C to T base 
change at position 860 (P287L) has never been reported in the Caucasian population, but 
was found among the 38 Latino participants in the Multiethnic Cohort (MEC), with a 
reported T allele frequency of 0.014 (average Het.+/- std err 0.006 +/- 0.052) (refSNP 
ID: rs35706152, www.ensembl.org). Since no validation status or anthropometric data for 
this variant are available, the P287L was considered a potentially deleterious mutation. A 
fifth novel base change G to A at position 1478 (R493H) was also detected in 1 of 52 ISS 
patients. This variant was also present in 1 of 50 normal stature controls and was, 
therefore, considered a single nucleotide polymorphism. 
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Figure 7.1 Schematic representation of the IGFALS gene. Partial chromatograms of sequence 
analysis show the 4 single heterozygous mutations. Partial DNA and predicted amino acid 
sequence are also indicated. Arrows indicate point mutation locations. 
7.5.3 Auxological and biochemical data of the 5 ISS children with IGFALS 
defects 
IGFALS mutations were present in 5/52 ISS children (9.6%). The heights of the 5 ISS 
index cases with IGFALS defects were significantly lower (p=0.033) than those of subjects 
without IGFALS defects [median -3.24 SDS (range -3.39 to -2.33) versus -2.44 SDS (range 
-3.60 to -1.91)]. Weight SDS values in ISS patients with IGFALS defects were significantly 
lower (p=0.031) compared to those of subjects without IGFALS defects [-3.73 SDS (range -
4.24 to -2.64) versus -2.24 SDS (range -3.85 to -0.43)] . BMI SDS values were also 
significantly lower (p=0.025) in the ISS subjects with IGFALS defects [-2.14 SDS (range -
3.24 to -1.18) versus -0.57 SDS (range -2.87 to 1.33)] . There was no significant difference 
(p=0.60) in birth weight between subjects with and without IGFALS defects [-0.55 SDS 
(range -1.59 to 0.12) versus -0.53 SDS (range -1.92 to 0.65), Figure 7.2] . 
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Figure 7.2 Boxplots for height SDS, weight SDS, BMI SDS and birth weight SDS for 
prepubertal ISS patients with and without IGF ALS defects. Each boxplot depicts the median, 
the 25th and 75th percentiles. Whiskers depict minimum and maximum observed values. 
No significant differences were found between subjects with and without IGFALS 
variants in the following serum peptide SDS values [ISS with IGFALS defects versus ISS 
without IGFALS defects, median (range)]: IGF-I [-0.79 SDS (-2.35 to 0.54) versus -0.34 
(-3.50 to 2.74), p=0.15], IGFBP-3 [-0.30 SDS (-1.03 to 1.30) versus -0.40 SDS (-2.30 to 
0.90), p= 0.47] and ALS [-1.84 SDS (-2.54 to 1.92) versus -0.61 SDS (-5.64 to 7.88), p= 
0.47]. 
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7.5.4 Auxological and biochemical data of the family members of ISS children 
with IGFALS defects 
DNA samples from all 6 siblings and 7 of 10 parents of the index cases with 
IGFALS defects were available and were sequenced for IGFALS mutations (family trees 
for the patients with IGF ALS defects are shown in Figure 7.3). 
Family 1 (P22L) 
-2.16 sds 
44 yr 
-2.90 sds -2.56 sds -1.55 sds 
6.4 yrs 6.4 yrs 9 yrs 
Family 3 (P287L) 
-3.39 sds 
6.4 yrs 
-0.51 sds 
37 yr 
Family 4 (L453V) 
0.54SdS~ 
41" II 
-2.33 sds 
3.9 yrs 
Family 2 (P287L) 
0.64 sds 
41 yr 
-2.86 sds -3.24 sds -0.16 sds 
5.7yr 8.2yr 16yr 
Family 5 (P526L) 
n.a. 
-3.39 sds -2.52 sds -4.2 sds 
6.5 yrs 10.2 yrs 18 yrs 
Figure 7.3 Family trees for the 5 ISS index patients with single heterozygous mutations 
(P22L, P287L, L453V and P526L) in the IGF ALS. Height SDS and age are indicated. Affected 
family members are indicated in grey. Family members for whom DNA was not available are 
indicated with a cross. SDS, standard deviation score; n.a., not available; P, Proline; L, Leucine; 
V, Valine. 
Four of the SIX siblings, in Families 1, 2 and 5, were also carriers of the 
heterozygous defect. Three of these siblings were prepubertal (families 1, 2 and 5), 
showed similar growth retardation to the index cases and met the criteria of ISS. One 
sibling was pubertal (age 16 years, Family 2) and his height was -0.16 SDS. In Family 5, 
one sibling with no IGFALS defect had a height SDS of -4.2 at age 18 years. His birth 
weight SDS was -3.27 and he had a diagnosis of small for gestational age with no catch 
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up. The biochemical and auxological data of patients and family members are shown in 
Table 7.1. 
In three of the seven available parents, in Families 1, 2 and 3, the same single 
heterozygous IGFALS defect seen in the index case was found. All carriers had short 
stature, but less so than affected prepubertal subjects within the same families. Their 
height, weight and BMI SDS, as well as biochemical data are shown in Table 7.1. For 
Family 4, only one parent (mother) was available to study. Her height was normal (+0.50 
SDS) and no IGFALS defect was found. No DNA sample and auxological data were 
available for the patient's father. For Family 5, neither parent was available to study. 
TABLE 7.1 HEIGHT SDS AND BIOCHEMICAL DATA IN INDEX CASES AND AFFECTED 
FAMILY MEMBERS WITH SINGLE HETEROZYGOUS IGFALS DEFECTS. 
Family Mutation Patient Gender Age Height IGF-I IGBP3 ALS 
(yrs) (SDS) (SDS) (SDS) (SDS) 
1 P22L Index F 6.4 -2.90 -0.71 -0.61 -2.45 
Sibling F 6.4 -2.56 1.97 1.15 -2.54 
Parent M 41 -2.16 1.39 1.05 -0.96 
2 P287L Index M 8.2 -3.24 -2.46 -2.15 -1.09 
Sibling M 5.7 -2.86 -0.06 -0.47 -0.84 
Sibling M 16.4 -0.16 1.15 -0.21 1.96 
Parent F 41 -1.91 -0.18 -0.87 0.42 
3 P287L Index M 6.4 -3.39 -0.79 1.30 -1.84 
Parent M 38 -0.51 n.a. n.a. -1.26 
4 L453V Index M 3.9 -2.22 -2.40 -1.32 -2.37 
5 P526L Index M 6.5 -3.39 0.80 0.82 1.92 
Sibling M 10.2 -2.52 1.58 1.18 5.07 
DNA was not available for one parent in Family 4 and both parents in Family 5. No 
IGF ALS defect was detected in the parent from Family 4. n.a., not available. 
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7.5.5 Size exclusion chromatography 
Serum samples from patients carrying the four variants (P22L, P287L, L453V and 
P526L) were run on size exclusion chromatography. A reduction in the peak 
corresponding to the ternary complex was observed for serum samples from patients with 
defects P22L, P287L and L453V, whereas a modest increase was observed for the serum 
sample of a patient with the P526L variant. The amount of 1251 IGF-I incorporation in the 
ternary complex was calculated and compared to that obtained from a normal serum 
sample. This showed a reduction for mutations P22L, P287L and L453V, ranging from -
21.65% (mutation P287L) to -63.91 % (mutation L453V). Mutation P526L resulted in a 
27.20% increased incorporation of IGF-I in the ternary complex compared to normal 
(Figure 7.4). 
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Figure 7.4 Panel A: results of size exclusion chromatography. The position of the ternary 
complex (predicted molecular weight lS0kDa), binary complex (predicted molecular weight 40-
SOkDa) and unbound IGF-I (predicted molecular weight 7.SkDa) are indicated. Panel B: 
incorporation of 1251 IGF-I in the ternary complex and corresponding serum ALS SDS values. 1251 
IGF-I incorporation in the wild type ternary complex is expressed as mean±standard deviation 
(n=3). 
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7.6 DISCUSSION 
In this study, 9.6% of patients with ISS had a single heterozygous IGFALS defect. 
The study of relatives of index cases showed that the same defects were present in other 
family members who were also short. These defects were not found in any of the 50 
normal controls or in any SNP database. 
The identification of ISS aetiology is of great importance, since it can guide therapy 
in children with short stature. Linear growth is under the influence of many genetic, 
hormonal and metabolic factors and the GH-IGF-I axis plays a fundamental role. Hence 
its components are obvious candidates for genetic causes of growth failure (Walenkamp 
and Wit, 2006). 
Identification of acid-labile subunit defects in idiopathic short stature patients 
Most of the circulating IGF-I is bound to IGFBP-3 in a relatively unstable binary 
complex, which stabilises by binding to the ALS protein to form a ternary complex 
(Baxter, 1994, Boisclair et aI., 2001). The half-lives of the free IGF-I and of the binary 
complex IGF -II IGFBP-3 in the circulation are of minutes. However, when bound in a 
ternary complex, the half-life of circulating IGF-I is increased to 12-15 hours (GuIer et 
aI., 1989). ALS is, thus, believed to be an important regulator ofIGF -I bioavailability in 
the serum, increasing its half-life and regulating its clearance (Binoux and Hossenlopp, 
1988). The importance of ALS in influencing linear growth has recently been unveiled 
with the demonstration of absence of serum ALS and severe deficiencies of IGF-I and 
IGFBP-3 in patients with homozygous IGF ALS mutations who have mild growth failure 
(Domene et aI., 2004, Hwa et aI., 2006, Domene et aI., 2007, Duyvenvoorde et aI., 2008, 
Heath et aI., 2008). 
We wished to test the hypothesis that heterozygous IGFALS defects contributes 
towards the phenotype of patients with ISS. We analysed 52 unrelated ISS children and 
found single heterozygous IGFALS defects in 5. Moreover, the study of family members 
showed that relatives with heterozygous IGFALS defects were also short. Surprisingly, all 
defects found in this study were missense mutations involving a proline or leucine. Three 
out of four defects were, in fact, proline to leucine amino acid changes. Because of the 
chemical differences between these two amino acids, this defect is likely to induce a 
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change in the ALS secondary structure, possibly leading to a non-functional protein. 
Leucine has a hydrophobic aliphatic side chain that favours the formation of x-helices, 
whereas proline has a cyclic structure that does not. Moreover, proline induces a bend in 
the amino acids chain. 
The C to G base change at position 1438 (L453V) caused the most profound 
change in the ability of patient serum to form a ternary complex. It is of note that, the 
result of this mutation might be a splicing defect rather than an amino acid change as the 
C to G nucleotide change creates a strong enhancer for the SRp 55 protein in IGFALS 
exon 2 (score 3.3 versus 5.3; ESEfinder3.0), which may result in aberrant gene splicing 
and the creation of a profoundly altered ALS protein. 
Size exclusion chromatography showed that ternary complex formation was 
affected by all four mutations and results were in accordance with the impact of these 
mutations on the levels of ALS measured in the serum. Three mutations (P22L, P287L 
and L453V) resulted in a decrease in the formation of the ternary complex, as shown by 
the decreased IGF-I incorporation. The P287L and L453V mutations are localised in two 
of the predicted leucine-rich repeats and may affect ALS secondary structure. Mutation 
P22L is localised in the predicted ALS signal peptide. According to SignalP 3.0 
prediction program (Bendtsen et aI., 2004), this mutation is likely to affect the cleavage 
site and may thus hinder the processing and secretion of the ALS protein. The P526L 
mutation is localised in the C-terminal domain of the ALS protein. Its presence resulted 
in a modest increased peak corresponding to the ternary complex suggesting that it may 
increase the affinity of ALS for the binary complex and perhaps retard the release ofIGF-
I at the site of action. 
Reduced IGF-I, IGFBP-3 and ALS levels were present in most heterozygous 
IGFALS patients, although no significant differences were found between ISS children 
with and without IGF ALS defects. This is not surprising, since the latter cohort is a 
heterogeneous population with still unidentified genetic abnormalities. Reduction in GH 
dependent protein levels was also reported in the heterozygous parents of patients with 
ALS deficiency (Hwa et aI., 2006, Domene et aI., 2007, Duyvenvoorde et aI., 2008, 
Heath et aI., 2008), as well as in an IGF ALS heterozygous animal model. U eki et al (U eki 
et aI., 2000) demonstrated that mice with only one IGFALS allele have a 50% reduction 
in liver ALS mRNA and a 17% and 40% reduction of IGF-I and IGFBP-3 serum levels, 
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respectively. The ALS protein in the serum is in molar excess relative to IGFs and this is 
thought to be important in maintaining and promoting the affinity of ALS for the binary 
complex IGFIIGFBP (Holman and Baxter, 1996). A change in the ratio ALS/binary 
complex may be occurring in the heterozygous IGF ALS patients, explaining, at least in 
part, the phenotype. 
Prepubertal patients with IGFALS defects were significantly slimmer compared to 
ISS prepubertal children with no IGF ALS defects. Malnutrition, eating disorders or major 
illnesses were excluded in all cases. A different availability ofIGF-I resulting from single 
heterozygous IGFALS defects may have an effect on the metabolism of these patients. 
Postpubertal patients, however, did not exhibit low BMI values. 
Homozygous versus single heterozygous ALS defects: effects on stature 
In this study, the range of height SDS in patients with single heterozygous IGFALS 
defects was similar to that reported in patients with homozygous IGF ALS defects 
(Domene et a!., 2004, Hwa et a!., 2006, Domene et a!., 2007) suggesting that, despite the 
profound difference in the biochemical phenotype, the effect on growth is similar. The 
liver and local production ofIGF-I in patients with IGFALS defects appears to be normal 
and seems to be able to support linear growth, despite an alteration in the circulating lOF-
I levels. Unfortunately, measurement of free IGF-I is a difficult and sophisticated 
technique and free IGF-I levels are not routinely monitored. 
Identification of IGF ALS defects within family members of affected ISS 
children 
Analysis of family members of the affected patients showed that heterozygous 
IGF ALS defects were related to short stature. However, this relationship varied with 
pubertal status. Prepubertal heterozygous IGF ALS patients were significantly shorter than 
ISS patients without IGFALS defects, despite the fact that there was no significant 
difference in IGF-I, IGFBP-3 and ALS levels. Postpubertal heterozygous IGFALS 
patients had higher height SDS values compared to prepubertal IGF ALS patients in the 
corresponding families. It is possible that the near-normalisation in height SDS in the 
pubertal sibling from Family 2 reflects a pubertal growth spurt. Unfortunately, no 
prepubertal or follow-up data were available for this patient. A near-normal adult height 
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has been reported in homozygote and compound heterozygote IGF ALS patients and in 
their heterozygote parents (Hwa et aI., 2006, Domene et aI., 2007, Duyvenvoorde et a!., 
2008, Heath et aI., 2008), The broad range of adult height SDS in individuals with 
heterozygous and homozygous IGFALS defects may indicate that this genetic defect is 
not sufficient to determine the final height and is only one of many contributors to a 
complex genetic and environmental scenario. 
Limitation 
A limitation of this study is the relatively small number of ISS patients included. 
The analysis of a larger population is required to confirm the frequency and contribution 
of single heterozygous IGFALS defects to short stature. Further prospective studies are 
also needed to clarify whether the discrepancy in height observed between prepubertal 
and postpubertal patients is a real phenomenon or simply reflects the fact that IGFALS 
defects only affect final height in the presence of a genetic defect or polymorphism in one 
or more genes. Moreover, in vitro characterisation of the detected mutations was not 
performed as this requires the establishment of a cell expression system for ALS mutant 
proteins and the analysis of their interaction with IGF-I/ IGFBP-3. However, the amino 
acid changes induced by these mutations are likely to affect the ALS secondary structure 
and have a deleterious effect on protein function. 
Conclusion 
In conclusion, a single heterozygous defect in the IGFALS was found in 9.6% of 
ISS children and in their relatives with short stature. Prepubertal children with IGF ALS 
defects were significantly shorter than ISS children without IGFALS defects, but did not 
have significantly lower GH-dependent protein levels. The study of a larger population is 
required to accurately define the prevalence of this genetic finding in the ISS population. 
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8.1 SUMMARY OF FINDINGS 
Short stature is a common reason for referral to paediatric endocrinologists. It can 
be due to several causes, among which resistance to the action of GH due to genetic 
defects, namely growth hormone insensitivity. Nevertheless, it has been estimated that in 
approximately 80% of referred children no aetiology can be identified and they are 
classified as ISS (Wit et aI., 2008b). Significant effort is made to understand the causes of 
short stature. Identification of novel genes, as well as characterisation of novel defects in 
known genes responsible for growth failure, can shed new light of the physiology of 
longitudinal growth and guide therapy in children with short stature. 
The overall aim of this thesis was to identify and characterise the molecular 
mechanism of GHI and ISS. The GH-IGF-I axis plays a fundamental role in promoting 
longitudinal growth and all its elements are strong candidates when searching for 
molecular defects causing growth failure. A large, ethnically heterogeneous, population 
of patients with primary GHI was genetically characterised. All subjects had severe GH 
resistance as demonstrated by the high GH levels and low or undetectable GH dependent 
proteins levels, not increasing after administration of exogenous GH. Nevertheless, 
despite a similar biochemical profile, different degrees of growth failure were present. 
The initial genetic screening of these patients started with the analysis of the GHR. 
GH exerts its biological actions through the binding to its receptor and any mutation 
leading to the absence or to a non-functional GHR, results in GHI. GHR mutations 
represent the most common cause of primary GHI and were present in the majority of 
patients in this study. During the course of the project several novel defects in the GHR 
were identified. Among these was a novel single heterozygous mutation hypothesised to 
exert a dominant negative effect similarly to the two single heterozygous GHR defects 
identified by Ayling et al. and Iida et al. (Ayling et aI., 1997, Iida et aI., 1998). Although 
all three mutations occur in the genomic region coding for the GHR intracellular domain 
and share the same pathogenetic mechanism, they produce different phenotypes. The 
child studied during the course of this project and her two affected family members, 
presented with non-classical GHI, characterised by mild short stature and normal facial 
features. This finding is in agreement with the cases reported by Ayling et aI., but 
dissimilar to the cases described by Iida et aI. The three patients described by Iida et aI. 
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had, in fact, classical Laron facial features: prominent forehead and saddle nose. 
Different phenotypes in patients with the same mutation are known to occur when the 
defect causes aberrant gene splicing. This phenomenon was documented in the 
Equadorian GHI population carrying the E180 splice mutation (Rosenbloom et aI., 1999) 
and has is maximum expression in patients with the GHR pseudoexon 6\f mutation, as 
described in Chapter 5 of this Thesis. 
The GHR pseudoexon 6\f was identified in our laboratories in 2001. DNA is rich in 
intronic sequences resembling coding exons, which are not normally included in the 
mature mRNA and are known as pseudoexons. The GHR pseudoexon 6\f defect is an 
example of how a subtle DNA change can lead to the recognition of these intronic 
sequences by the splicing machinery and lead to their inclusion in the mRNA. When the 
pseudoexon 6\f mutation was identified, it was believed to represent a rare GHI-causing 
defect. The four children, in whom it was reported, had normal facial features and mild 
GHI. The genetic characterisation of a large heterogeneous GHI cohort performed during 
the course of this study identified several new cases of GHI due to the pseudoexon 6\f 
defect. Although genotype analysis suggests a common ancestor for these patients, the 
pseudoexon defect still appears to be a more common cause of GHI than initially thought 
and should be looked for in GHI patients with no GHR mutations. 
Analysis of the 11 patients with the pseudoexon mutation identified so far, showed 
a wide range of phenotypes arising from this defect. Patients presented with normal or 
classical Laron facial features and GHI severity ranged from mild to severe with a wide 
range of biochemical profiles. This variability in phenotypes is likely to arise from the 
presence of low amounts of wild type GHR. Because of the complexity of mRNA 
splicing, a defect may not always be completely efficient in causing aberrant splicing. In 
patients with the pseudoexon 6\f mutation, low quantities of the wild type GHR 
transcript were demonstrated to occur alongside the mutant GHR. Individual factors may 
playa role in determining the efficiency of aberrant splicing and therefore the presence of 
a different ratio of mutant to wild type transcript in patients with the same genetic defect. 
The presence of the wild type GHR, even at low levels, may also account for the 
significant milder phenotype observed in patients with GHI due to single heterozygous 
defects with a dominant negative effect, albeit in these patients, the functional wild type 
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GHR dimer can be present alongside the non-functional mutant homozygous dimer and 
the non-functional mutant heterozygous dimer. 
Among the novel GHR defects identified during this study was a homozygous 
mutation in the polypyrimidine tract. Defects in this splice element are extremely rare and 
this is the first of its kind to be identified in the GHR. The majority of splice mutations 
identified so far in the GHR and in other genes, disrupt the invariant dinucleotide 
sequences at their splice sites and their effect on mRNA splicing are easily predicted. 
Nevertheless, in recent years an increasing number of mutations outside the splice sites 
has been identified. These defects are intronic or exonic and can disrupt splice elements 
such as enhancers, silencers, branch points or polypyrimidine tracts. The lack of a 
comprehensive understanding of these splice regulatory elements in combination with 
their scarce adherence to consensus sequences, makes it extremely difficult to predict the 
consequences at a mRNA level of a base change occurring in these elements. For this 
reason, analysis of RNA extracted from patient leucocytes or fibroblasts is mandatory for 
establishing the diagnosis. Obtaining tissue samples can, however, be difficult especially 
from infants and children, particularly those with reduced body size, as are those with 
GHI. 
One of the aims of this thesis was to establish the diagnostic value of an in vitro 
splicing assay as an alternative technique for assessing the consequences of genetic 
defects on mRNA splicing. The assay was based on a three-exon minigene system spliced 
in HeLa nuclear extracts and was employed to assess the effect of GHR mutations 
identified in the GHI population. The in vitro splicing assay is widely used to study the 
physiology of splicing and of its regulatory elements, but had not been employed to study 
the consequences of naturally occurring mutations. If validated, this could represent a 
quicker and straightforward alternative to RNA analysis from patient samples or from 
transfected cells. Although the splicing assay was used in 2001 to study the consequences 
of the GHR pseudoexon 6'I' defect (Metherell et aI., 2001), data on its accuracy in 
predicting the effect of other splice mutations were not available. Moreover, a reliable 
protocol for the creation of three-exon minigenes was lacking. Considerable effort was, 
therefore, made to establish the latter during the course of this project. Having achieved 
this, several mutant and the corresponding wild type minigenes were produced, allowing 
the study of GHR mutations. As a collateral project to this Thesis, I also used the in vitro 
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splicing assay to assess seven different defects identified in a gene responsible for 
familial glucocorticoid deficiency, namely the melanocortin receptor accessory protein 
(MRAP) gene. Because of its non-pertinence to the main theme of this Thesis, the results 
of the in vitro splicing assay on MRAP mutations, published in 2005 in Nature Genetics 
(Metherell et aI., 2005), are not included. 
The results of the in vitro splicing assay on GHR defects, presented in Chapter 4, 
support the validity of this assay in identifying nucleotide changes resulting in aberrant 
gene splicing. The comparison between in silica and in vitro results demonstrated that the 
splicing assay was particularly helpful in case of defects occurring outside the invariant 
nucleotides of the splice sites, for which the in silica prediction programs gave 
ambiguous results. Since only a small number of mutations were studied and very few in 
vivo data were available, more data are required to further validate this system, as 
discussed in the "Future Prospects" section. 
The discovery of the GHR pseudoexon 6'£1 mutation was the basis for another part 
of this project. The obvious interest of our group in this mutation and the finding that it is 
not such a rare cause of GHI, as initially thought, led to the search for a therapeutic tool 
aimed at correcting aberrant GHR splicing caused by this defect. The RNA antisense 
approach is a promising tool in gene therapy. It has been tested for correcting aberrant 
splicing which causes neurodegenerative diseases and haematopoietic disorders, with 
promising results both in vitro and in animal models. The results presented in Chapter 5 
of this Thesis are the first to demonstrate the efficiency of this tool in correcting an 
endocrine disorder. Three ASOs directed against the three major splicing elements - the 
donor and acceptor splice sites and the branch point - were designed and tested using the 
in vitro splicing assay and a cell transfection system. Near-complete restoration of correct 
GHR splicing was seen with the ASO targeting the acceptor splice site. Although this 
result requires confirmation with in vivo studies on patient cells and the specific activity 
of this ASO needs further testing, ASOs appear to be a valid option for gene therapy in 
GHI patients with the pseudoexon 6'£1 defect. Interestingly, the most effective ASO was 
the one targeting the acceptor splice site, whereas the ASO targeting the donor splice site 
where the pseudoexon defect is localised, only had a modest effect. This could be 
explained by cell specific differences in accessibility of the donor versus the acceptor 
splice site. Additional studies to confirm these findings are required. 
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Genetic characterisation of a large GHI population in this Thesis, allowed the 
identification of novel defects in the GHR, but also in other genes, such as STAT5b and 
IGFALS. The second ever reported case ofGHI due to a STAT5b mutation was identified 
during the course of this project, in collaboration with Dr Rosenfeld's group at the 
Department of Paediatrics, Oregon, US and reported in 2005 (Hwa et aI., 2005). Direct 
sequencing of the GHR and analysis of GHR SNPs in the two patients and their parents 
allowed exclusion of the involvement of the GHR and the search for other candidate 
genes. The involvement of the STAT5b was investigated based on the co-existance, in 
these children, of GHI and immunological disorders, as previously described by Kofoed 
et aI. (Kofoed et aI., 2003). 
At the time this project started, very little was known on the relationship between 
ALS deficiency due to IGFALS defects and GHI. The description of the first case of ALS 
deficiency (Domene et aI., 2004) prompted consideration of the role of IGFALS as a 
cause of GHI in children with no evidence of GHR defects. Three children, homozygous 
for novel defects and one child, compound heterozygous for two novel IGF ALS defects, 
were identified during the course of this project. These patients belonged to four of the 
nine families known worldwide with IGF ALS defects. Although two of these patients 
were simultaneously studied elsewhere and the genetic data published by other authors 
(Hwa et aI., 2006, van Duyvenvoorde et aI., 2008), the four children reported in this 
project represent the largest series of unrelated subjects with IGFALS defects studied in 
one single centre. When data from GHI patients with IGFALS defects were compared to 
those of GHI patients with nonsense or missense GHR defects, no significant difference 
in IGF-I levels between the two groups was found, despite the significant difference in 
height SDS. This confirms the milder degree of growth failure observed in GHI due to 
ALS deficiency, which is similar to that observed in GHI due to GHR dominant negative 
mutations and to the GHR pseudoexon mutation. 
No pubertal delay was present in at least two out of the four patients described in 
this Thesis, which is in disagreement with other ALS deficient patients (Domene et aI., 
2004, Domene et aI., 2007) and suggests that a delayed puberty may be due to the 
individual genetic background rather than to IGF ALS defects. 
Data analysis from ALS deficient patients and their affected family members led to 
the interesting observation that parents of ALS deficient patients, obligate single 
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heterozygous carriers of IGF ALS mutations, also had short stature, albeit to a lesser 
degree than their homozygote children. This observation suggested that single 
heterozygous IGF ALS defects may be sufficient to affect final height. Data available on 
the single IGFALS null allele mouse model confirmed this observation (Ueki et aI., 
2000). This led us to speculate that single heterozygous IGFALS defects may be 
implicated in the pathogenesis ofISS. To test this hypothesis the IGFALS was studied in 
a large cohort of ethnically homogenous prepubertal ISS children. In 9.6% of ISS 
patients, a single heterozygous IGF ALS defect was identified. ISS children with 
heterozygous IGF ALS defects were significantly shorter than ISS patients without 
IGFALS defects, despite no significant difference in IGF-I, IGFBP-3 and ALS levels. 
Although all mutations are predicted to cause a major change in the ALS secondary 
structure, serum samples from ISS children with IGFALS defects tested by means of size 
exclusion chromatography showed a modest alteration in ternary complex formation 
compared to a normal control. The ALS protein is in molar excess relative to IGF-I and II 
in the serum and this is thought to be important in maintaining and promoting the affinity 
of ALS for the binary complex IGF/IGFBP (Holman and Baxter, 1996). The occurrence 
of single heterozygous defects may induce a change in the ratio ALS to binary complex 
and a change in the affinity and availability ofIGF-I at tissue level explaining, at least in 
part, the phenotype. 
IGF ALS defects were also found in short stature family members of affected index 
cases. Interestingly, postpubertal subjects with single heterozygous IGFALS defects had 
higher height SDS values compared to prepubertal affected patients in the corresponding 
families. Although this so far remains an observation it has to be noted that the height 
discrepancy between pre and post pubertal status can also be observed in patients with 
homozygous IGF ALS defects and ALS deficiency. 
8.2 FUTURE PROSPECTS 
8.2.1 The GHR polypyrimidine tract mutation 
The base change localised in the polypyrimidine tract of GHR exon 8 resulted in 
clear exon skipping when assessed by the in vitro splicing assay. Nevertheless, the three-
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exon minigene system spliced in nuclear extract is an in vitro system, and tissue-specific 
differences may occur. Study of patient mRNA is particularly advisable in the case of the 
polypyrimidine tract mutation. Obtaining patient leukocytes or fibroblasts was sought 
during the course of this project, but was not possible. As an alternative, confirmation of 
the effect of this mutation may be obtained by transfecting cells, such as HEK293 or 
CHO, with a mutant minigene. Moreover, it may be of interest to demonstrate that the T 
to C base change affects the binding of spliceosome elements such as U2AF or hnRNP to 
the polypyrimidine tract, thus inhibiting the first steps of GHR mRNA splicing (Figure 
8.1). 
A 
PremRNA 
B 
PremRNA 
Figure 8.1 Effect of the polypyrimidine tract mutation on GHR splicing. Apposition of the 
U2AF splice element takes place in the wild type GHR mRNA (Panel A), but is prevented in the 
mutant GHR mRNA (Panel B). 
8.2.2 Identification of novel GHR defects 
In several GHI patients, no mutations in the GHR coding region could be identified. 
The presence of undetectable or very low serum GHBP levels in these patients suggests 
the presence of a defective GHR. Study of the GHR promoter region and patient RNA 
could lead to the identification of a promoter defect or a intronic mutation activating a 
novel pseudoexon. 
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8.2.3 Validation of the in vitro splicing assay 
This thesis provides evidence of the validity of the in vitro splicing assay for 
demonstrating the occurrence of aberrant mRNA splicing caused by mutations localised 
at the splice sites or in other regulatory elements. Nevertheless, few data on the in vivo 
effect of the GHR mutations studied were available and are required in order to validate 
the results obtained with the in vitro assay. This can be achieved by analysing patients' 
RNA or RNA extracted by cells transfected with minigenes. Moreover, the study of 
additional mutations, especially outside the invariant splice site sequences in the GHR 
and in other genes, and the corresponding in vivo analysis, is advisable to further assess 
the accuracy of this system. 
8.2.4 Modulation of GH sensitivity by increasing the expression of GHR 
alternative transcripts 
At least two novel alternative GHR exons were identified during the course of this 
project. If inserted in the mature mRNA, both exons would cause a frameshift and the 
appearance of a stop codon a few amino acids after the signal peptide. The novel 
alternative GHR transcripts arising from these exons are predicted to be prematurely 
truncated and lack GH binding domains. Although a possible functional role for these 
transcripts cannot be excluded, they are likely to represent biological noise and be 
susceptible to nonsense mediated decay. It could, therefore, be hypothesised that 
increasing the expression of these exons could lead to silencing of the GHR and 
modulation of GH sensitivity at specific tissues. This could potentially be achieved by 
targeting exonic silencers in these exons with specific ASOs, or by designing a 
bifunctional ASO. The latter consists of an RNA sequence complementary to the target 
pre-mRNA to which a non-complementary tail, mimicking an exonic enhancer motif or a 
small peptide resembling the SR protein RS domain enhancer, is attached. 
8.2.5 The role of IGF ALS defects in ISS 
ALS traps IGF-I and II in the circulation limiting their transendothelial passage and 
can thus be considered one of the principal regulators ofIGFs bioavailability. Very little 
is, however, known on ALS physiology and its role outside the circulation. Although the 
relation between growth failure and ALS deficiency arising from homozygous JGF ALS 
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defects has been demonstrated, the relation between growth failure and single 
heterozygous IGFALS mutations suggested in this study requires further confirmation. 
Screening of a larger population of ISS patients is required, but, more importantly, 
assessment of the frequency of IGFALS defects in the normal population is mandatory. 
The defects identified in this study are likely to cause a profound alteration in the 
ALS secondary structure, according to in silica prediction programs and based on the 
nature of the base changes. Nevertheless, size exclusion chromatography only detected a 
modest change in ternary complex formation. Expression of the wild type and mutant 
ALS proteins in a cell system, such as REK293 or CRO cells, as well as reconstitution 
and in vitro study of ternary complex formation, is advisable. 
8.3 CONCLUDING REMARKS 
This thesis focused on identifying and characterising the molecular defects 
underlying ORI and ISS. The genetic analysis of a large genetically heterogeneous 
population identified several novel defects in three genes in the OR/IOF-I axis: GHR, 
STAT5b and IGFALS. Moreover, the study of the clinical and genetic data of this large 
cohort combined with published data from another large heterogenous ORI cohort and 
from two studies on GHR mutations with a dominant negative effect identified a 
genotype/phenotype relationship between GHR defects and ORI severity. 
The genetic characterisation of a large ORI population revealed that the GHR 
pseudoexon 61.£1 defect is more frequent than initially thought. The results of this Thesis 
suggest that the ASOs approach is a potentially effective gene therapy for restoration of 
correct mRNA splicing in these patients. 
Identification and analysis of patients with ALS deficiency caused by IGF ALS 
defects and the observation of short stature in their heterozygote parents, led to 
hypothesise the involvement of IGFALS in the pathogenesis of ISS. Data gathered in this 
thesis supported this hypothesis. 
In several ORI patients, no genetic diagnosis was obtained during the course of this 
project. Undetectable ORBP serum levels suggested the presence of a defective GHR. An 
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algorithm for the identification of intronic DNA sequences in the GHR, which could 
represent alternative exons or pseudoexons, was created. Several potential regions were 
identified, two of which were expressed in liver cDNA. This finding could be the basis 
for future studies aiming at modulating GH response in specific tissues. 
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10.1 APPENDIX 1: LABORATORY EQUIPMENT 
Equipment 
Pipettes 
Pipettes P2, P20, PI 00, P200, PI 000 
Balances 
Can 28 automatic electrovalence 
Mettler PM 300 
Centrifuges 
Sorvall OTD-55B Ultracentrifuge 
Sorvall RT 6000B 
Beckman J-6B 
Falcon 6/300 
Microcentaur microcentrifuge 
Water tank 
Grant JB 1 and SE 10 
Electrophoresis Tanks 
Electrophoresis Tank 
Power supply units 
LKB Bromma 2197 
Gibco BRL 400L 
Spectrophotometer 
ND-I000 UV Nis 
pH meter 
EDT GP 353 
Thermocyclers 
GeneAmp PCR system 9700 
GeneAmp PCR system 2400 
Hybaid Omnigene thermal cycler 
Ultraviolet transilluminator 
UVP20 
DNA sequencer 
ABI Prism 377 DNA sequencer 
Manufacturer 
Gilson, Inc, USA 
WT A very Ltd, Midlands, UK 
Gallenkamp, London, UK 
Du Pont (UK) Ltd. Stevenage, Herts, UK 
Du Pont (UK) Ltd. Stevenage, Herts, UK 
Beckman Instruments, CA, USA 
Sanyo Gallenkamp PLC, Leicester, UK 
MSC, UK 
Chemlab Instruments, Hornchurch, Essex, UK 
BRL, Pisley, UK 
LKB Instruments Ltd, Croyden, Sussex, UK 
Life Technologies Ltd, Paisley, UK 
NanoDrop Technologies, USA 
Pentacourt Ltd, Haltead, Essex, UK 
PE Applied Biosystem, Cheshire, UK 
PE Applied Biosystem, Cheshire, UK 
Hybaid Life Science Int., UK 
Genetic Research Instruments, Herts, UK 
Perkin Elmer Corporation, Foster City, Ca, 
USA 
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Iodine counter 
NE 1600 
Fraction collector 
2070 Ultrorac 
Pump tubes 
PVC flowmeasured Orange/green 
Phosphor Screen 
Phosphor Screen 
Gel dryer 
Gel dryer Model 583 
Liquid nitrogen storage 
Cryostat 
Cryolab 
Laminar flow cabinet 
Envair MSC 11 
Temperature controlled incubators 
LEECMK 11 
Orbital incubator Innova 4300 
C02 incubators 
LEEC C02 incubators 
Water purification system 
MilliQ 
Camera 
Kodak ID and ID image analysis software 
Appendices 
Nuclear enterprises, UK 
LKB Bromma, USA 
Pulse Instrumentation LTD, USA 
Amersham Biosciences, GE Healthcare, USA 
Biorad, Hemel Hempstead, Hertfordshire, UK 
J encons, Bedfordshire, UK 
Stateboume Cryogenics, Tyne and Wear, UK 
Envair Ltd, Rossendale, Lane, UK 
Luckams, Sussex, UK 
New Brunswick Scientific, UK 
LEEC Ltd, Nottingham, UK 
Waters Millipore, Harrow, UK 
Kodak Ltd, Hemel Hempstead, Herts, UK 
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10.2 APPENDIX 2: SOLUTIONS, BUFFERS AND MEDIA 
10.2.1 ASOs dilution 
ASOs were dispatched dried and were diluted with TE to obtain a 100mM stock 
using the following protocol: 
a) 5 volumes of TE were added per x nmol of ASO (e.g. add 421.251l1 of TE to 
84.25nmol of ASO); 
b) ASOs absorbance at 260nm was assessed using a spectrophotometer; 
c) ASOs concentration in IlM was calcultated as follows: 
ASOs IlM = (absorbance at 260nm/extension coefficient) xl.OOO.OOO 
d) XIlI of TE were added to dilute the ASOs to obtain a 100mM concentration. 
10.2.2 DEPC treated H20 (0.1 %) 
Dissolve 1ml of Diethyl Pyrocarbonate (DEPC) in 1L of dH20, stir overnight and 
autoclave. 
10.2.3 Soc medium 
Prepare the following solutions: 
• 250mM KCI solution: dissolve 1.86g of 2.5mM KCI in 100ml of deionized water; 
• 1M solution of MgCh : dissolve 20.33g of 10mM MgCb in 100ml deionized water, 
and autoclave. 
• 2M solution of glucose: weigh out 36g of 20mM glucose and dissolve in a final 
volume of 100ml deionized water. Filter sterile this solution. 
For 1 litre of Soc medium: dissolve 20g of 2% Tryptone, 5g 0.5% Yeast extract, 
0.5g NaCI (0.05%) in 950ml of water. Add 10ml of the stock KCI and then adjust pH to 
7.0 with 5M NaOH. Bring the volume to 980ml with deionised water and autoclave. Let 
the solution cool to 55°C and then add 10ml of the filter-sterilised 2M glucose and 10ml 
of 1M MgCh. Store at room temperature. 
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10.2.4 RNA dye mixture (FormamideIEDTA/XC/BPB gel-loading buffer) 
Dissolve 10ml of Formamide 10ml, 10mg of Xylene cyanol FF 10mg and 10mg of 
Bromophenol blue in O.S EDTA (pH 8.0) 200).!!, 
10.2.510% SDS 
Dissolve 109 of SDS in 80ml of dH20 and heat to 68°C to dissolve. Adjust to a 
final volume of 100ml with dH20. 
10.2.6 LB Agar 
Dissolve 8g of Agar and 9g of LB Broth in 400ml of dH20 and autoclave. 
10.2.7 LB broth 
Dissolve 109 of LB broth in 400ml of dH20 and autoclave. 
10.2.8 3M Sodium Acetate 
Dissolve 40.8g of sodium acetate in 80ml of dH20. Adjust to pH 7.6 with glacial 
acetic acid, make up to a final volume of 100ml and autoclave. 
10.2.9 Buffer A 
Dissolve O.OSM NaH2P04 and O.1SM NaCl in lL of dH20 and adjust to pH 7.2. 
Filter and degas the solution. 
10.2.10 TAE 
Dissolve 40mM Tris, 20mM acetic acid and lmM EDTA and adjust to pH 8.S. 
10.2.11 TBE 
Dissolve 4SmM tris, 4SmM borate and 1mM EDTA and adjust to pH 8. 
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10.3 APPENDIX 3: OLIGONUCLEOTIDE SEQUENCES 
10.3.1 Sequences of oligonucleotides used for GHR amplification: 
Ex2 F 
Ex2R 
Ex 3 F 
Ex3 R 
Ex4F 
Ex4R 
Ex 5 F 
Ex5 R 
Ex6F 
Ex6R 
Ex 7 F 
Ex 7R 
Ex 8 F 
Ex 8R 
Ex 9F 
Ex 9R 
Ex 10 F1 
Ex 10 R2 
Ex 10 F2 
Ex 10 R1 
Int 6F 
Int 6R 
5' TAC AAC CTG CTG TTT GAG TTC 3' 
5' ACT GAC TAC TGC ATT CCT CC 3' 
5' GTT GGT TTG GGA AGC TGA GG 3' 
5' GGA TAG TAG CTT AAT TAC AC 3' 
5' TCA CAT ATG ACT CAC CTG 3' 
5' AGG TAC ATC CAT GGA GAG 3' 
5' ACT TAA GCT ACA ACA TGA 3' 
5' GCT TCC CCA TTT ATT TAG TC 3' 
5' TTG GTC TTC TGA GAA GAA TGC C 3' 
5' ATA GAA AGA AAA GTC AAA GTG TAA G 3' 
5' GAA TAC CTG TAG TGT TCA TTG C 3' 
5' GCT CAA GGT CTC TCA TCC TG 3' 
5' AAA CTG TGC TTC AAC TAT TCG 3' 
5' GGA GAT AAA AGT GTA CTA GG 3' 
5' GCT ATA ATT GAG AAT ATG TAG C 3' 
5' CAT ATG ACA GGA GTC TTC AGG TG 3' 
5' GAG TTT CTT TTC ATA GAT CTT C 3' 
5' GCTGGTGTAATGTCGCTCA3' 
5' TGA AGG AGC TGA GTC AAC TC 3' 
5' CTT TGC TAT TAA ATA CGT AGC 3' 
5' TTG TGA TCC AGT CAA CAG TGA CT 3' 
5' TCT TGT TTG ACT TAG CAT CCA AT 3' 
10.3.2 Sequences of oligonucleotides used for GHR mRNA RT-PCR 
2FiGHRm 
2FfGHRm 
5FGHRm 
5RGHRm 
6RGHRm 
7FGHRm 
8FGHRm 
5' ATG GAT CTC TGG CAG CTG CTG TTG 3' 
5' GGA TCA AGT GAT GCT TTT TCT GGA AGT G 3' 
5' ACC CAT ACA GCT GTT CTA TAC CAG AAG G 3' 
3' GGC ATT CTT TCC ATT CTT GAG TCC ATT C 5' 
3' ATT CAA CCC AAG AGT CAT CAC TGT GG 5' 
5' CGA AAC TCT GGA AAT TAT GGC GAG TTC AGT GAG GT 3' 
5' GGG CTA ACA GTG ATG CTA 3' 
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9RGHRm 
lOr3GHRm 
GAPDHF 
GAPDHR 
3' CCA CGC AAT GCA GAT ATT CAG AAA GG 5' 
3' ACC AAC TGA ACA AAA TCA TGC CTT AG 5' 
5' TCC CAT CAC CAT CTT CCA 3' 
3' AGC AAC AGG GTG GTG GAC 5' 
10.3.3 Sequences of oligonucleotides used for IGF ALS amplification 
IfALS GGCACGAGGGGGTTAACAGA 
lrALS AAATGCGGCTGCTGGGGTT 
2fALS GCTTCCGGCTGTGCTGGTAT 
2rALS CAGAAACTCTACCTGGACCG 
3fALS GCAGCCTCTGGGACCTCAA 
3rALS ACCTTCACCGGCCTCTCG 
4fALS CTCTGGGAACTGTCTCCGGAA 
4rALS GAAGGCATGGCGGCCC 
10.3.4 Sequences of oligonucleotides used for minigenes construction: 
T7-Ll 5' TAA TAC GAC TCA CTA TAG GGA GAC CGG CAG ATC AGC TT 3' 
Admlpar-int51 AS 5' TTATTAACCCTCACTAAAG 3' 
Admlpar-int51 S 5' GCA GTA GTC AAG GGT TTC C 3' 
L2A 5' ATC CAA GAG TAC TGG AAA GAC CG 3' 
Exon2spi F 5' CTC ACT AAA GAT AAT GGT CTG CTT TTA ATT GCT 3' 
Exon2spi R 5' ATT TCC ACC CTC AGT GTT GCA GTA GTC A 3' 
Exon4 spi F 5' CTC ACT AAA GGA TCA CAT ATG ACT CAC CTG ATT 3' 
Exon4 spi R 5' TGA CTA CTG CCC ATG GAG AGG AAA ATC AGA A 3' 
Exon8 spi F 5' CTC ACT AAA GGC ATT GAG TTG TTG ACT CTT TGG 3' 
Exon8 spi R 5' TTC TTT GGT ATT TTG TAC GCA GTA GTC A3' 
Ps spi F 5' TTA GCA GTA GTG AAG GGT TTC CTT GAA GCT TTC GT 3' 
Ps spi R 5' ACG AAA GCT TCA AGG AAA CCC TTG ACT ACT GCT AA 3' 
10.3.5 Sequences of oligonucleotides used for site-directed mutagenesis: 
Exon2sdm IF 
Exon2sdm lR 
Exon2sdm 2F 
Exon2sdm 2R 
Exon4sdm S 
5' CTG GAA GTG AGG GTG GGT TCT GCT TTT CCA TTT CC 3' 
5' GGA AAT GGA AAA GCA GAA CCC ACC CTC ACT TCC AG 3' 
5' GGA AAT GGA AAA GCA GAA CGC ACC CTC ACT TCC AG 3' 
5' CTG GAA GTG AGG GTG CGT TCT GCT TTT CCA TTT CC 3' 
5' AGT GCC GTT CAC CTG AGT GAG AGA CTT TTT CAT GC 3' 
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Exon4sdmAS 
Exon8sdm S 
Exon8sdmAS 
Exon8sdm S 
Exon8sdmAS 
Ps sdm F 
Ps sdmR 
Appendices 
5' GCA TGA AAA AGT CTC TCA CTC AGG TGA ACG GCA CT 3' 
5' CTG GAA ATT ATG GTG AGT TCA GTG AGG 3' 
5' CCT CAC TGA ACT CAC CAT AAT TTC CAG 3' 
5' ATTTTA TATGTTTTCAACGATTAAAATGCTGAT TC3' 
5' GAA TCA GCA TTT TAA TCG TTG AAA ACA TAT AAA AT 3' 
5' TGA GAC ACC AGG ACA TTC GGT GAG CCA CTG AAA AAG 3' 
5' CTT TTT CAG TGG CTC ACC GAA TGT CCT GGT GTC TCA 3' 
10.3.6 Sequences of antisense oligonucleotides (ASOs) 
ASO branch 
ASO 3' splice 
ASO 5' splice 
Mu.mU.mA.mG.mA.mA.mU.mU.mA.mG.mU.mU.mA.mU.mA.mU.mU.mG 
mU.mG.mU.mG.mG.mC.mU.mG.mU.mG.mG.mU.mU.mA.mG.mA.mC.mA 
mU.mU.mC.mA.mG.mU.mG.mG.mC.mU.mC.mA.mC.mC.mG.mA.mA.mU 
10.3.7 Sequences of oligonucleotides used for identification of alternative 
GHR exons: 
EXONXIF 
EXONXIR 
EXONX2F 
EXONX2R 
EXONX3F 
EXONX3R 
EXONX4F 
EXONX4R 
5' CCTACTTCCAAGAGAACGAAAT 3' 
3' GCTCCTGCCACTCTGTGTCT5' 
5'GGTCCATGCTCACATATCAA3' 
3'CTTGATATGTGAGCATGGACCCC5' 
5' GCCTAATGCAGAGTAGAGAAGC3' 
3'CCTTCAAGTTGGTGAGCTTCTC5' 
5' GCAAGTTGCACAGCTGGGATTC3' 
3'CCCAGCTGTGCAACTTGCTAGT5' 
10.3.8 Sequences of oligonucleotides used for genotyping: 
D5s2021 F 5' TTC TAC GGA TTC CAA TCA C 3' 
D5s2021 R 3' CAA AAG CAA CTT AAC CAC G 5' 
D5s2022 F 5' CTT CAT TGC ACT CCA GC 3' 
D5s2022 R 3' GGC CAA TAA GTT TAT ATC GG 3' 
D5s 430 F 5' TCT GCC CAG CAA TTC CAT AG 3' 
D5s430 R 3' GGC AAG CAA TTT TCA CAG TTT T 5' 
D5s 2082 F 5' ACC CCT AAG CCC TAG CA 3' 
D5s 2082 R 3' CCC TAC CCT GTG AAA CCT 5' 
D5s2087 F 5' TAG CAC CTA GCC AGT GCC TAG C 3' 
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D5s2087 R 
D5s474 F 
D5s474 R 
3' CCA AAA GTC ATT TAG GAG CAG GTC 5' 
5'CTGAGGTAGCCTACACCT3' 
3'AGAACGAATAGGACAAATGC5' 
Appendices 
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lOA APPENDIX 6: GHR FRAMEWORKS 
GHR frameworks in 35 healthy controls. Location of polymorphic sites in intron 9. 
From Amselem S. et aI. (Amselem et aI., 1989). 
Chr. 
Frame IVS ntl12 IVS nt124 IVS nt168 VS nt199 IVS nt212 IVS nt213 studied 
(n=70) 
I A G C T T T 37 
II A G C C - - 14 
III G G C T - - 12 
IV A G C T - - 5 
V A A C T - - 1 
VI A G T T T T I 
10.5 APPENDIX 7: ADML-PAR GENOMIC SEQUENCE 
GGGAGACCGGCAGATCAGCTTGGCCGCGTCCATCTGGTCATCTAGGATCTGATATCA 
TCGATGAATTCGAGCTCGGTACCCCGTTCGTCCTCACTCTCTTCCGCATCGCTGTCTG 
CGAGGGCCAGCTGTTGGGgtgagtactccctctcaaaagcgggcatgacttctgccctcgagttattaaccctcactaaagc 
agtagtcaagggtttccttgaagctttcgtgctgaccctgtcccttttttttccacAGCTGCAGGTCGACGTTGAGGACAA 
ACTCTTCGCGGTCTTTCCAGTACTCTTGGAT 
Exon L1 and L2 sequences are indicated in capital letters. 
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10.6 APPENDIX 8: ALGORITHM FOR THE IDENTIFICATION OF NOVEL 
GHREXONS 
dat <- read.table("E:/AAA RESEARCH/alessia/R code ale/splice.csv", 
header=TRUE, sep=",", na.strings="", dec=".", strip.white=TRUE) 
datacc=data.frame(dat[dat$accdon=="a",]) 
datdon=dat[dat$accdon=="d",] 
pseud=c () 
yy=O 
for(ii in 1: length(rownames(datacc))) { 
ack=datacc$base[ii]+14 
lenk=(datdon$base+l)-ack+l 
lenkl=lenk[lenk<202] 
lenkl=lenkl[lenkl>51] 
2 
[yy]] 
lenk2=lenkl 
if(length(lenk2»O) { 
for(tt in 1:length(lenk2)) { 
yy=yy+l 
pseud$acc[yy]=datacc$base[ii]+14 
pseud$length[yy]=lenk2[tt] 
pseud$don [yy] =pseud$acc [yy] +pseud$length [yy]-l 
pseud$accorigin [yy]=datacc$base [ii] 
pseud$donorig [yy] =pseud$acc [yy] +pseud$length [yy]-
pseud$scoreacc [yy] =datacc$probabil [ii] 
pseud$scorebr [yy] =datacc$scorebr [ii] 
pseud$scoredon [yy] =datdon$probabil [datdon$base==pseud$ donorig 
} } 
print(c(ii,lenk2)) 
} 
pseud=as.data.frame(pseud) 
intron <- read. table ("E:/AAA RESEARCH/alessia/R code ale/full 
GHRgene.txt", header=FALSE, sep=",", na.strings="NA", dec=".", 
strip.white=TRUE) 
intron2=as.character(intron[1,1]) 
intron3=strsplit (intron2, "") [[1]] 
intron4=c () 
intron4$intr=as. character (intron3) 
intron4=as.data.frame(intron4) 
intron4[1:10,1] 
pseud3=pseud 
yy=O 
for(uy in 1:length(pseud3$acc)) { 
numbasi=20 
if (pseud3$acc[uy]<=numbasi) next 
ales=intron4[ (pseud3$acc[uy]-numbasi): (pseud3$acc[uy]-1),] 
cbases=grep("c", ales) 
tbases=grep("t", ales) 
pseud3$accb [uy] =pseud3$acc [uy] 
pseud3$c[uy]=length(cbases) 
pseud3$t [uy]=length (tbases) 
totalct=length (cbases) +length (tbases) 
totalag=numbasi-totalct 
pseud3$ratio[uy]=round(totalct/numbasi, 3) 
pseud3$ct [uy]=length (cbases) +length (tbases) 
} 
pseud4=pseud3[pseud3$ratio>O.5,] 
pseud6=pseud4 
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pseud6$include=ifelse (pseud6$scoreacc<80,ifelse (pseud6 $scorebr>90, 
"y", tin") ("ylf) 
pseud7=pseud6[pseud6$include=="y",] 
pseud8=pseud7 
pseud8$include=ifelse (pseud8$scoreacc>=74,ifelse (pseud 8$scorebr>=71 
I "y", "nIT), "nIT) 
pseud9=pseud8[pseud8$include=="y",] 
rownarnes(pseud9)=seq(1:nrow(pseud9)) 
pseud9$bestk=NA 
for(uu in 1:nrow(pseud9)) { 
if(is.na(pseud9$bestk[uu])==FALSE) next 
acck=pseud9$acc[uu] 
whk=as.nurneric(rownarnes(pseud9) [pseud9$acc==acck]) 
rnk=rnax(pseud9$scoredon[whk]) 
whrnax=whk[rnatch(rnk , pseud9$scoredon[whk])] 
pseud9$bestk[whk]="no" 
pseud9$bestk[whrnax]="yes" 
) 
pseudlO=pseud9[pseud9$bestk=="yes",] 
pseudlO$prdop=ifelse(pseudlO$acc<1329, "elirn", 
ifelse(pseudlO$acc>153916, "elirn", "keep")) 
pseudll=pseudl0[pseudl0$prdop=="keep",] 
rnrn <- read.table("E:/AAA RESEARCH/alessia/R code ale/rnRNA 
GHR.txt", header=FALSE, sep="", na.strings="NA", dec=".", 
strip.white=TRUE) 
rnrn2=as.character(rnrn[I,I]) 
rnrn3=strsplit (rnrn2, "") [[1]] 
rnrn4=c () 
rnrn4$intr=as. character (rnrn3) 
rnrn4=as.data.frarne(rnrn4) 
coffpos=c(I,33,114,180,310,483,662,828,919,989) 
coff=c(1340,1409, 64502,64567, 124353,124482, 130380, 
130552, 135287, 135465, 146670, 146835, 
148892, 148982, 153515, 153584, 153916) 
cofend=c(1409, 64567, 124482, 130552, 135465, 146835, 148982, 
153584, 154862) 
costart=c(1340, 64502, 124353, 130380, 135287, 146670, 148892, 
153515, 153916) 
exl=costart[l] :cofend[l] 
ex2=costart[2] :cofend[2] 
ex3=costart[3] :cofend[3] 
ex4=costart[4] :cofend[4] 
ex5=costart[5] :cofend[5] 
ex6=costart[6] :cofend[6] 
ex7=costart[7] :cofend[7] 
ex8=costart[8] :cofend[8] 
ex9=costart[9] :cofend[9] 
rnrnanorrn=intron4[c(exl,ex2,ex3,ex4,ex5,ex6,ex7,ex8,ex9),1] 
exs=c () 
exs [ [1] ] =exl 
exs [[2]] =ex2 
exs[[3]]=ex3 
exs [ [4] ] =ex4 
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exs [ [5] ] =ex5 
exs [[6]]=ex6 
exs[[7]]=ex7 
exs [ [B]] =exB 
exs[[9]]=ex9 
exs1=exs 
library (seqinr) 
pseud12=pseudll 
pseud12$stop=NA 
for(rt in 1:length(pseud12$acc)) { 
exs=exs1 
difk=pseud12$acc[rt]-cofend 
difk1=difk[difk>0] 
if (length (difkl)==O) next 
difkl=min(difk1) 
endnum=match(difk1, difk) 
if( (pseud12$acc[rt]-costart[endnum+1]»0) 
pseud12$stop[rt]="nk" 
next 
if((pseud12$don[rt]-costart[endnum+1]»0) 
pseud12$stop[rt]="nk" 
next 
if(length(difk1)==0) 
pseud12$stop[rt]="nk" 
next 
exs [ [endnum]] =c (exs [ [endnum]] , 
pseud12$acc[rt] :pseud12$don[rt]) 
mrnanew=as.character(intron4[c(exs[[1]],exs[[2]],exs[[3]],exs 
[ [4]] , exs [ [5]] , exs [ [6]] , exs [ [7]] , exs [ [B]] , exs [ [9]] ) ,1] ) 
aak=getTrans(mrnanew) 
stopk=grep("[*]", aak) 
if (length (stopk) >0) { 
pseud12$stop[rt]="y" 
) ) 
pseud12$stop[is.na(pseud12$stop)==TRUE]="no stop" 
summary(as.factor(pseud12$stop)) 
pseud13=pseud12[pseud12$stop=="no stop",] 
pseud13=as.data.frame(pseud13) 
nrow (pseud13) 
pseud13$bestkacc=NA 
for(uu in 1:nrow(pseud13)) { 
if(is.na(pseud13$bestkacc[uu])==FALSE) next 
donk=pseud9$don[uu] 
whk=as.numeric(rownames(pseud13) [pseud9$don==donk]) 
mk=max(pseud13$scoreacc[whk]) 
whmax=whk[match(mk, pseud13$scoreacc[whk])] 
pseud13$bestkacc[whk]="no" 
pseud13$bestkacc [whmax] ="yes" 
) 
pseud14=pseud13[pseud13$bestk=="yes",] 
pseud14$mult3=ife1se((pseud14$length/3) !=round(pseud14$length, 0), 
"not mu3", "mu3") 
pseud15=pseud14[pseud14$mu1t3=="mu3",] 
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